fulvestrant has been researched along with Breast Neoplasms in 1196 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 92 (7.69) | 18.2507 |
| 2000's | 380 (31.77) | 29.6817 |
| 2010's | 464 (38.80) | 24.3611 |
| 2020's | 260 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Bryant, HU; Cullinan, GJ; Glasebrook, AL; Hauser, KL; Muehl, BS; Palkowitz, AD; Pell, TR; Phillips, DL; Sato, M; Shetler, PK; Short, LL; Thrasher, KJ | 1 |
| Bélanger, A; Caron, B; Cloutier, J; Dory, YL; Favre, A; Gauthier, S; Labrie, C; Labrie, F; Larouche, D; Leblanc, G; Mailhot, J; Martel, C; Mérand, Y; Ouellet, C; Schwerdtfeger, A; Simard, J | 1 |
| Liebl, R; von Angerer, E; Walter, G | 1 |
| Dong, J; Filardo, EJ; Pang, Y; Thomas, P | 1 |
| Birzin, ET; Blizzard, TA; Chan, W; Chen, HY; DaSilva, CA; DiNinno, F; Hammond, ML; Hayes, EC; Kim, S; Pai, LY; Rohrer, SP; Schaeffer, JM; Wu, JY; Yang, YT | 1 |
| Bermont, L; Boubekeur, K; Cleeren, A; Jacquot, Y; Laïos, I; Laurent, G; Leclercq, G; Nonclercq, D; Refouvelet, B; Xicluna, A | 1 |
| Abraham, DJ; Lin, HR; Safo, MK | 1 |
| Agouridas, V; Blazejewski, JC; Cleeren, A; Laïos, I; Laurent, G; Leclercq, G; Magnier, E; Nonclercq, D | 1 |
| Abdel-Razik, AF; Alexi, X; Alexis, MN; Ioannou, E; Roussis, V; Vagias, C | 1 |
| Carlson, KE; Katzenellenbogen, BS; Katzenellenbogen, JA; Kieser, KJ; Kim, DW | 1 |
| Bhatnagar, D; Boue, SM; Burow, ME; Collins-Burow, BM; Driver, J; Elliott, S; Jiang, Q; McLachlan, JA; Payton-Stewart, F; Rhodes, LV; Sridhar, J; Stevens, C; Wang, G; Wiese, TE; Zhang, Q; Zheng, S | 1 |
| Bearss, NR; Bhatnagar, D; Boue, SM; Burow, ME; Cleveland, TE; Erhardt, PW; Khupse, RS; Reese, MD; Sarver, JG; Trendel, JA; Wiese, TE | 1 |
| Jiang, XR; Smith, CL; Wang, P; Zhu, BT | 1 |
| Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Grillot, K; Hager, JH; Heyman, R; Joseph, JD; Julien, J; Kahraman, M; Kaufman, J; Lai, A; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
| Andrews, DM; Ballard, P; Bradbury, RH; Buttar, D; Callis, RJ; Currie, GS; Curwen, JO; Davies, CD; de Almeida, C; De Savi, C; Donald, CS; Feron, LJ; Gingell, H; Glossop, SC; Hayter, BR; Hussain, S; Karoutchi, G; Lamont, SG; MacFaul, P; Moss, TA; Norman, RA; Pearson, SE; Rabow, AA; Tonge, M; Walker, GE; Weir, HM; Wilson, Z | 1 |
| Aparicio, AM; Bonnefous, C; Darimont, BD; Douglas, KL; Govek, SP; Grillot, KL; Hager, JH; Joseph, JD; Kahraman, M; Kaufman, JA; Lai, AG; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, JY; Prudente, RY; Rix, PJ; Sensintaffar, J; Smith, ND | 1 |
| Akerstrom, VL; Bratton, MR; Guo, S; Liu, J; Ma, P; Ma, Y; Miele, L; Pannuti, A; Skripnikova, EV; Wang, G; Wiese, TE; Yuan, C; Zhang, C; Zhang, Q; Zheng, S; Zhong, Q | 1 |
| Gutgesell, LM; Karumudi, B; Lee, S; Lu, Y; Thatcher, GR; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
| Abrams, T; Baird, J; Burks, HE; Fekete, A; Hamann, LG; Kim, S; Kirby, CA; Lombardo, F; Loo, A; Lubicka, D; Macchi, K; McDonnell, DP; Mishina, Y; Norris, JD; Nunez, J; Peukert, S; Saran, C; Sun, Y; Thomsen, NM; Wang, C; Wang, J | 1 |
| Carlson, KE; Gong, P; Guillen, VS; Katzenellenbogen, BS; Katzenellenbogen, JA; Kim, SH; Mayne, CG; Min, J; Nettles, KW; Sharma, A; Srinivasan, S; Zhao, Y; Ziegler, Y | 1 |
| Abrams, T; Baird, J; Burks, HE; Firestone, B; Gaither, LA; Hamann, LG; He, G; Kim, S; Kirby, CA; Lombardo, F; Macchi, KJ; McDonnell, DP; Mishina, Y; Norris, JD; Nunez, J; Peukert, S; Springer, C; Sun, Y; Thomsen, NM; Tiong-Yip, CL; Tria, GS; Wang, C; Wang, J; Yu, B | 1 |
| Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Hager, JH; Heyman, R; Joseph, JD; Kahraman, M; Kaufman, J; Lai, A; Lee, K; Lu, N; Maheu, K; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
| Bailey, A; Buttar, D; Carbajo, RJ; Curwen, J; Davey, PRJ; Davies, RDM; Degorce, SL; Donald, C; Gangl, E; Greenwood, R; Groombridge, SD; Johnson, T; Lamont, S; Lawson, M; Lister, A; Morrow, CJ; Moss, TA; Pink, JH; Polanski, R; Scott, JS | 1 |
| Chen, H; Dubrovyskyii, O; Dye, K; Gordon-Blake, J; Gutgesell, LM; He, D; Hollas, M; Huang, F; Lasek, AW; Lee, S; Li, Y; Lu, Y; Rosales, CI; Shen, Z; Thatcher, GRJ; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
| Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J | 1 |
| Balazs, A; Barlaam, B; Breed, J; Carbajo, RJ; Chiarparin, E; Davey, PRJ; Delpuech, O; Fawell, S; Fisher, DI; Gagrica, S; Gangl, ET; Grebe, T; Greenwood, RD; Hande, S; Hatoum-Mokdad, H; Herlihy, K; Hughes, S; Hunt, TA; Huynh, H; Janbon, SLM; Johnson, T; Kavanagh, S; Klinowska, T; Lawson, M; Lister, AS; Marden, S; McGinnity, DF; Morrow, CJ; Moss, TA; Nissink, JWM; O'Donovan, DH; Peng, B; Polanski, R; Scott, JS; Stead, DS; Stokes, S; Thakur, K; Throner, SR; Tucker, MJ; Varnes, J; Wang, H; Wilson, DM; Wu, D; Wu, Y; Yang, B; Yang, W | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Arnautova, YA; Arora, S; Chan, B; Clark, MA; Cuozzo, JW; Disch, JS; Duffy, JM; Gikunju, D; Huguet, C; Keefe, AD; Kohlmann, A; Kozhushnyan, A; Lau, AC; Lee, ECY; Levin, B; Liu, Y; McRiner, AJ; Monteiro, MI; Mullins, PB; Talcott, SA; von Rechenberg, M; Westlund, NE; Yu, Y; Zhang, J; Zhang, Y; Zhou, F | 1 |
| Bai, C; Luo, G; Ren, S; Wu, S; Xiang, H; Zhu, M | 1 |
| Lin, X; Luo, G; Ma, L; Ren, S; Wang, X; Wu, S; Xiang, H | 1 |
| Boudreau, MW; Fan, TM; Hergenrother, PJ; Mulligan, MP; Shapiro, DJ | 1 |
| Cao, Y; Guo, B; Kong, D; Lu, Z; Meng, X; Yang, Y; Zhang, D | 1 |
| Chan, CC; Chen, S; Ding, CZ; Dong, J; Gong, T; Gu, Q; He, H; Hu, G; Hu, L; Huang, Y; Li, J; Li, X; Liu, K; Liu, Z; Lu, J; Shen, L; Sun, D; Tang, W; Wang, T; Xia, Y; Zeng, X; Zhu, X; Zhu, Y | 1 |
| Chen, JZ; Khan, MZI; Nazli, A; Uzair, M | 1 |
| Cook, RS; Elion, DL; Stauffer, KM; Stricker, T | 1 |
| Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil-Gil, M; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-de Dueñas, E; Pérez-García, JM; Ruíz-Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P | 1 |
| Amiri-Kordestani, L; Beaver, JA; Bloomquist, E; Cheng, J; Gao, JJ; Ison, G; Krol, D; Osgood, C; Pazdur, R; Prowell, TM; Royce, M; Sridhara, R; Tang, S; Wedam, SB | 1 |
| Asakawa, H; Baba, N; Nakamura, A; Park, K; Shigekawa, T | 1 |
| Cheng, MY; Gao, HF; Ji, F; Li, JQ; Niu, G; Wang, K; Yang, CQ; Yang, M; Zhang, JS; Zhang, LL; Zhang, QZ; Zhu, T | 1 |
| Chen, YC; De Bruyn, T; Gelzleichter, T; Malhi, V; Metcalfe, C; Perez-Moreno, PD; Wang, X; Yu, J | 1 |
| Cheng, J; Feng, J; Hu, X; Li, W; Liu, Q; Liu, Y; Ouyang, Q; Pan, Y; Shi, Y; Sun, T; Teng, Y; Tong, Z; Wang, X; Wang, Y; Wu, F; Wu, X; Xie, W; Xu, B; Yan, M; Yan, P; Yan, X; Yin, Y; Zhang, P; Zhang, Q; Zhu, X; Zou, J | 1 |
| Lagampan, C; Parinyanitikul, N; Poovorawan, N | 1 |
| Barbazán-Vázquez, FJ; Galeazzi-Martínez, V; Pampín-Sánchez, R; Pelaez-Fernández, I; Reguero-Cuervo, V; Sampedro-Gimeno, T | 1 |
| Balcueva, E; Barlow, WE; Conlin, AK; Dy, PA; Gralow, JR; Hayes, DF; Hicks, JB; Hortobagyi, GN; Kuhn, P; Lew, DL; Moore, HCF; Pusztai, L; Schott, AF; Somlo, G; Tripathy, D; Welter, L; Yeon, CH | 1 |
| Ala-Hongisto, H; Bertula, K; Elo, LL; Euro, L; Heikkilä, P; Hollmann, B; Hukkinen, K; Ikkala, O; Joensuu, H; Junttila, MR; Kivento, M; Klefström, J; Kovanen, P; Leidenius, M; Martikainen, L; Mattson, J; Meretoja, T; Metcalfe, C; Monni, O; Munne, PM; Mutka, M; Nevalaita, L; Patrikainen, L; Peura, A; Pokki, J; Pouwels, J; Räty, I; Ruuska, J; Sahu, B; Salmela, M; Suomi, T; Väänänen, J; Yavuz, K | 1 |
| Alarcón, J; Albanell, J; Antón, A; Bezares, S; Casas, M; de la Cruz-Merino, L; de la Haba-Rodríguez, J; Fernández, I; González-Cortijo, L; Margelí, M; Martínez, MT; Martínez-Jañez, N; Moreno, F; O'Connor, M; Ramos, M; Rojo, F; Sánchez-Muñoz, A; Sánchez-Rovira, P; Santaballa, A; Virizuela, JA | 1 |
| Lippman, ME; Rae, JM | 1 |
| Argueta, C; Li, S; Liu, L; Lyu, R; Shen, Y; Tan, L; Xiong, L; Zhu, X | 1 |
| Ahn, SH; Bang, WS; Cho, Y; Choi, YH; Gong, G; Heo, SH; Jung, SW; Kim, HJ; Kim, YA; Lee, H; Lee, HJ; Park, HS; Seo, JH; Song, IH | 1 |
| Alonso-Romero, JL; Antón, A; Carrasco, E; Chen, J; Cubedo, R; Ferrer, N; Galinsky, K; García-Sáenz, JÁ; González-Santiago, S; Jerez, Y; Lahuerta, A; Leonard, EJ; Martínez-Jáñez, N; Neuwirth, R; Ramos, M; Slamon, D; Vincent, S | 1 |
| Aoyama, Y; Fukada, I; Hara, F; Hosonaga, M; Inagaki, L; Kawai, S; Kobayashi, K; Kobayashi, T; Kurata, M; Maeda, T; Masuda, J; Miyake, S; Ohno, S; Ozaki, Y; Saeki, S; Shibayama, T; Takano, T; Ueno, T; Yoshida, K | 1 |
| Board, RE; Flynn, M; Guppy, AE; Hanna, D; Jayaweera, HK; Keshwani, K; King, J; Konstantis, A; Lerner, A; Murphy, R; Okines, A; Raja, F; Rehman, F; Roylance, R; Sanderson, B; Sharkey, E; Spurrell, E; Takeuchi, E; Westbury, C | 1 |
| Beck, JT; Chan, A; Chandiwana, D; De Laurentiis, M; Delea, TE; Fasching, PA; Im, SA; Jerusalem, G; Lanoue, B; Lonshteyn, A; Martin, M; Neven, P; Nusch, A | 1 |
| Anderson, J; Bose, R; Bryce, R; Bucheit, L; Carey, LA; Cobleigh, M; Ellis, MJ; Freedman, RA; Gao, F; Goetz, MP; Haas, B; Jones, JM; Kimmick, G; Lalani, AS; Lin, NU; Lu, J; Luo, J; Ma, CX; Marcom, PK; Nangia, JR; Pegram, MD; Pluard, TJ; Thomas, S; Valdez-Albini, F; Winer, EP | 1 |
| Ashizawa, N; Hosomura, N; Ichikawa, D; Inoue, S; Kawaguchi, Y; Kimura, A; Kono, H; Maruyama, T; Nakada, H; Nakayama, Y; Omori, M | 1 |
| Grischke, EM; Jansen, VM; Litchfield, LM; Llombart-Cussac, A; Neven, P; Sledge, GW; Sohn, J; Soliman, H; Toi, M; Tolaney, SM; Wang, H; Wijayawardana, S | 1 |
| Abdulkareem, NM; Bae, L; Bhat, R; Cataldo, ML; De Angelis, C; Fu, X; Nanda, S; Schiff, R; Thangavel, H; Trivedi, MV; Vasaikar, S; Zhang, B | 1 |
| Ballestrero, A; Benelli, M; Bergqvist, M; Bernardo, A; Bliss, JM; Bonetti, A; Cameron, D; Colleoni, M; Davies, DM; De Swert, H; Duhoux, FP; Fumagalli, D; Gebhart, G; Henry, S; Hilbers, FS; Ignatiadis, M; Jerusalem, G; Kammler, R; Loi, S; MacPherson, IR; Maibach, R; Malorni, L; McCartney, A; Migliaccio, I; Neven, P; Papadimitriou, K; Piccart, M; Regan, MM; Ruepp, B; Seles, E; Thomson, A; Tyekucheva, S; Zoppoli, G | 1 |
| Alves da Costa, F; Bernardo, C; Brito, C; Cardoso Borges, F; Ferreira, AR; Furtado, C; Lourenço, A; Martins-Branco, D; Mayer-da-Silva, A; Miranda, A; Ramos, A; Ramos, C | 1 |
| André, F; Arnould, L; Bachelot, T; Berger, F; Bidard, FC; Bièche, I; Canon, JL; Clatot, F; De La Motte Rouge, T; Delaloge, S; Hardy-Bessard, AC; Lemonnier, J; Marce, M; Marques, S; Pradines, A | 1 |
| Bianchini, G; Daniele, T; Dugo, M; Galbardi, B; Gianni, L; Győrffy, B; Locatelli, A; Macchini, M; Sica, L; Tacchetti, C; Tosi, D; Ulisse, A; Viganò, L; Zambelli, S; Zambetti, M | 1 |
| Aranda, E; Chien, C; Drnevich, J; Imir, OB; Katzenellenbogen, BS; Kulkoyluoglu-Cotul, E; Liu, YJ; Madak Erdogan, Z; Mogol, AN; O'Neill, JD; Park, BH; Park, NH; Raghavendra, AS; Santaliz Casiano, A; Shapiro, DJ; Tripathy, D; Ziegler, Y; Zuo, Q | 1 |
| Anan, K; Aogi, K; Fujisawa, T; Hasegawa, Y; Hattori, M; Ito, Y; Kawaguchi, H; Masuda, N; Morita, S; Nakamura, S; Nakayama, T; Ohno, S; Ohtani, S; Saji, S; Sato, N; Takano, T; Toi, M; Tokunaga, E; Yamaguchi, M; Yamamoto, Y; Yamashita, H; Yamashita, T; Yotsumoto, D | 3 |
| Iwata, H; Laurent, T; Muramatsu, Y; Sawaki, M; Togo, K | 1 |
| Fu, F; Guindy, M; Kano, J; Ma, J | 1 |
| Jacobson, A | 2 |
| Andrikopoulou, A; Chatzinikolaou, S; Dimopoulos, MA; Kaparelou, M; Liontos, M; Panourgias, E; Zagouri, F | 1 |
| Alba, E; Alonso-Romero, JL; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, MI; Ciruelos, EM; Corsaro, M; Csöszi, T; de la Haba-Rodríguez, J; Gil-Gil, M; Huang, X; Kahan, Z; Margelí, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Ruiz-Borrego, M; Sánchez-Rovira, P; Santaballa, A; Thallinger, C; Turner, N; Zielinski, C | 1 |
| Armgardt, E; Miller, J; Svoboda, A | 1 |
| Adam, V; Bedard, PL; Carrasco, E; Criscitiello, C; Di Leo, A; Pérez-Fidalgo, JA; Regan, MM; Ribi, K | 1 |
| Çelik, H; Çil, T; Duman, BB; Erçolak, V; Eser, K; İnal, A; Kesen, O; Köşeci, T; Önder, AH; Öztürk, B; Sezer, E | 1 |
| Dixit, J; Gupta, D; Gupta, N; Gupta, S; Jyani, G; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Prinja, S; Rajsekhar, K; Roy, PS; Singh, A | 1 |
| André, F; Bananis, E; Bondarenko, I; Colleoni, M; Cristofanilli, M; DeMichele, A; Harbeck, N; Huang, X; Im, SA; Iwata, H; Kim, S; Lechuga Frean, MJ; Liu, Y; Loi, S; Loibl, S; Masuda, N; O'Leary, B; Rugo, HS; Slamon, DJ; Turner, NC | 1 |
| Atkinson, C; Hart, K; Milligan, G; Mitra, D; Mycock, K; Taylor-Stokes, G; Zhan, L | 1 |
| Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M | 1 |
| Armstrong, A; Bardia, A; Bertelli, G; Bowen, R; Boyle, F; Chang, CW; Decker, T; Desai, R; Fernando, TM; Flechais, A; Gupta, K; Jerzak, KJ; Lindeman, GJ; McCune, S; Shannon, C; Song, X; Wilson, TR | 1 |
| Eisner, JR; Lerner, LM; Michmerhuizen, AR; Pesch, AM; Pierce, LJ; Rae, JM; Schwartz, R; Speers, CW; Ward, C; Wilder-Romans, K; Zhang, A | 1 |
| Adam, JP; Chabot, I; David, MÈ; Lessard-Hurtubise, R; Marineau, A; St-Pierre, C | 1 |
| Aithal, KB; Albacker, LA; Banka, D; Bolduc, DM; Furman, C; Hao, MH; Irwin, S; Kim, A; Korpal, M; Larsen, N; Montesion, M; Moriarty, AD; Murugesan, K; Nguyen, TV; Prajapati, S; Puyang, X; Rimkunas, V; Sahmoud, T; Vaillancourt, FH; Wick, MJ; Wu, ZJ; Yao, S; Zeng, H; Zhang, X; Zhang, Z; Zheng, GZ; Zhu, P | 1 |
| Attwood, K; Edge, S; Hamilton, D; Knudsen, ES; Levine, E; O'Connor, T; Schultz, E; Witkiewicz, AK | 1 |
| Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; de Bruin, EC; Foxley, A; Howell, SJ; Ingarfield, K; Jones, RH; Meissner, M; Moon, S; Morgan, S; Schiavon, G; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Parichatikanond, W; Pinthong, D; Reabroi, S; Tohkayomatee, R; Tungmunnithum, D | 1 |
| Harao, M; Hayashi, K; Kitayama, J; Nishida, S; Ogihara, K; Sakuragi, M; Sasaki, Y; Sata, N; Shiba, S | 1 |
| Bardia, A; Bauchet, AL; Bouaboula, M; Campone, M; Cartot-Cotton, S; Celanovic, M; Chandarlapaty, S; Cohen, P; Doroumian, S; Gosselin, A; Lee, JS; Linden, HM; Ming, JE; Paux, G; Pelekanou, V; Ternès, N; Ulaner, GA | 1 |
| Li, X; Li, Z; Lin, X; Lu, X; Luo, G; Xiang, H | 1 |
| Alluri, PG; Chiang, CM; Chinnaiyan, AM; Geboers, S; Gupta, GP; Hofstad, M; Jagsi, R; Kumar, S; Larios, JM; Liu, Y; Malladi, S; Malladi, VS; Mani, RS; Park, BH; Parra, K; Posner, BA; Raj, GV; Sharma, JK; Udden, SN; Wang, Q; Wei, S; Wicha, MS; Williams, NS; Wu, SY | 1 |
| Basilico, V; Destro, A; Fernandes, B; Gaudioso, G; Giordano, L; Masci, G; Mazzara, S; Rudini, N; Salvini, P; Santoro, A; Torrisi, R; Vaira, V | 1 |
| Abrate, P; Carretta, MT; Costantini, A; Fulgenzio, C; La Malfa, A; Lasala, R; Musicco, F; Pasquantonio, M; Petragnani, N; Proli, EM; Romagnoli, A; Sansone, M; Santoleri, F; Vici, P; Vita, F; Zeuli, M | 1 |
| Adamczyk-Grochala, J; Błoniarz, D; Lewińska, A; Wnuk, M; Wołowiec, S; Wróbel, K | 1 |
| Gan, C; Huang, Y; Li, Y; Orahoske, CM; Su, B; Urmetz, SM; Zhang, W | 1 |
| Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Garcia-Fructuoso, I; Gomez-Bravo, R; Schettini, F | 1 |
| Bajgiran, KR; Dorman, JA; Khan, AH; Lassiter, HR; Martin, EC; Melvin, AT; Moe, M; Ortega Quesada, BA; Pojman, JA; Zhou, SP | 1 |
| Choong, GM; Ferre, RAL; Giridhar, KV; Goetz, MP; Haddad, TC; Hobday, TJ; Liddell, S; Liu, MC; O'Sullivan, CC; Peethambaram, PP; Ruddy, KJ | 1 |
| Sharma, A; Wang, L | 1 |
| Agrawal, KU; Barke, MR; Shields, CL | 1 |
| Lauchle, JO; Metcalfe, C | 1 |
| Aimi, J; Bacarro, N; Bellet, M; Chang, CW; Daemen, A; Eng-Wong, J; Gates, MR; Giltnane, J; Hafner, M; Ingalla, ER; Liang, J; Liang, Y; Metcalfe, C; Moore, HM; Roose-Girma, M; Tai, L; Tam, L; Wang, BE; Yao, X | 1 |
| Haddad, N; Huang, CS; Im, YH; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; van Hal, G; Zhang, W | 1 |
| André, F; Arnould, L; Bachelot, T; Berger, F; Bidard, FC; Bièche, I; Callens, C; Canon, JL; Chakiba, C; Clatot, F; D'Hondt, V; Dalenc, F; de la Motte Rouge, T; Delaloge, S; Derbel, O; Dubot, C; Ferrero, JM; Frenel, JS; Garnier-Tixidre, C; Grenier, J; Hardy-Bessard, AC; Ladoire, S; Lemonnier, J; Levy, C; Lortholary, A; Mouret-Reynier, MA; Pierga, JY; Pistilli, B; Plaza, JE; Pradines, A; Sabatier, R; Stefani, L; Teixeira, L; Vegas, H | 1 |
| Atake, Y; Bun, A; Fujimoto, Y; Fukui, R; Hattori, A; Higuchi, T; Imamura, M; Kanaoka, H; Miyoshi, Y; Murase, K; Nagahashi, M; Natori, K; Ozawa, H; Takatsuka, Y | 1 |
| Abdel-Razeq, H; Abdel-Razeq, N; Abu Rous, F; Abuhijla, F; Edaily, S | 1 |
| Tang, SC; Wang, Y | 1 |
| Acconcia, F | 1 |
| Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Carañana, V; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil Gil, MJ; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-De Dueñas, E; Mina, L; Pérez-García, JM; Ruiz Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P | 1 |
| Bailleux, C; Grellety, T; Hajjaji, N; Petit, T | 1 |
| Fisher, V; Graf, RP; Lee, JK; Madison, RW; Oxnard, GR; Raskina, K; Rugo, HS; Schrock, AB; Sivakumar, S; Sokol, ES; Tukachinsky, H | 1 |
| Lüftner, D | 1 |
| Burnette, SE; Force, J; Lee, HJ; Moore, HN; Poehlein, E; Westbrook, K | 1 |
| Aksoy, S; Aktepe, OH; Çakır, İY; Dizdar, Ö; Erul, E; Güven, DC; Kertmen, N; Şahin, TK; Yıldırım, HÇ | 1 |
| Atkinson, C; Hanson, KA; Law, EH; Milligan, G; Mitra, D; Mycock, K; Preciado, S; Taylor-Stokes, G | 1 |
| Bouvier, M; Diennet, M; El Ezzy, M; Haidar, S; Mader, S; Vallet, A | 1 |
| Bananis, E; Diéras, V; Finn, RS; Huang, X; Im, SA; Joy, AA; Kim, S; Loi, S; Mahtani, R; Rugo, HS; Shparyk, Y; Sleckman, B; Theall, KP; Walshe, JM | 1 |
| Akla, S; Bailleux, C; Bello Roufai, D; Benderra, MA; Bertho, M; Bertucci, A; Bidard, FC; Blonz, C; Cottu, P; De La Motte Rouge, T; Delaloge, S; Desmoulins, I; Gligorov, J; Gonçalves, A; Grenier, J; Lerebours, F; Loirat, D; Pierga, JY; Renaud, E; Renouf, B; Robert, L; Saghatchian, M; Simon, H; Tharin, Z | 1 |
| Kaderbhaï, CG; Royer, B; Schmitt, A | 1 |
| Abdel-Aziz, N; Abdel-Razeq, H; Abulkhair, O; Al Foheidi, M; Al Ghamdi, M; Al Zahwahry, H; Alsaleh, K; Arafah, M; Ayari, J; Bahadoor, M; Bensalem, A; Bounedjar, A; Boussen, H; Bouzid, K; Dabouz, F; Errihani, H; Filali, T; Ghosn, M; Haddaoui, A; Kandil, A; Kullab, S; Larbaoui, B; Mahfouf, H; Mezlini, A; Nabholtz, JM; Oukkal, M; Rasool, H; Saadeddine, A | 1 |
| Ademuyiwa, FO; Clifton, K; Dai, C; Davis, AA; Dong, X; Du, P; Frith, A; Haas, B; Hernandez-Aya, LF; Jia, S; King, BL; Krishnamurthy, J; Luo, J; Luo, SJ; Ma, CX; Peterson, LL; Rearden, TP; Rigden, C; Summa, T; Suresh, R; Tan, L; Tandra, PK; Thomas, S; Wang, X; Weilbaecher, K; Zheng, T; Zhou, K | 1 |
| Acar, Ö; Akagündüz, B; Aksoy, S; Alkan, A; Almuradova, E; Altınbaş, M; Artaç, M; Aslan, F; Avşar, E; Aydıner, A; Bayoğlu, İV; Bayram, E; Baytemür, NK; Celayir, ÖM; Çelebi, A; Çetin, B; Çiçin, İ; Dede, İ; Demir, H; Demir, N; Demirci, A; Demirel, BÇ; Doğan, M; Ebinç, S; Er, Ö; Erdem, D; Erdoğan, AP; Eren, T; Ergün, Y; Ertürk, İ; Erul, E; Geredeli, Ç; Gökmen, E; Gökmen, İ; Göksu, SS; Gülbağcı, BB; Gümüş, M; Hacıbekiroğlu, İ; İmamoğlu, Gİ; Işık, D; Kahraman, S; Kalender, ME; Kalkan, Z; Kanıtez, M; Karaboyun, K; Karacin, C; Karadağ, İ; Karadurmuş, N; Karakaya, S; Kayıkçıoğlu, E; Keskinkılıç, M; Korkmaz, T; Kut, E; Kuzu, ÖF; Menekşe, S; Mocan, EE; Nayır, E; Oksuzoglu, B; Oktay, E; Öktem, İN; Okutur, K; Oyman, A; Özdemir, Ö; Öztosun, B; Paksoy, N; Paydaş, S; Şahin, E; Şakalar, T; Sakin, A; Salim, DK; Selçukbiricik, F; Selvi, O; Şendur, MAN; Seyyar, M; Sönmez, Ö; Tanrıverdi, Ö; Teker, F; Türker, S; Uğraklı, M; Uluç, BO; Ünal, OÜ; Yaren, A; Yavuzşen, T; Yıldırım, N; Yılmaz, F; Yılmaz, H | 1 |
| Alexis, MN; Chatziioannou, A; Ganou, V; Gkotsi, EF; Meligova, AK; Mitsiou, DJ; Papadodima, O; Pilalis, E; Siakouli, D; Stasinopoulou, S; Xenopoulou, DS; Zoumpouli, M | 1 |
| Chen, JW; Cortés, J; De Laurentiis, M; Dent, S; Diéras, V; Harbeck, N; Hutchinson, KE; Im, YH; Jacot, W; Krop, IE; Savage, HM; Schimmoller, F; Stout, TJ; Wilson, TR | 1 |
| Carter, JM; Clark, AS; D'Assoro, AB; Giridhar, KV; Goetz, MP; Haddad, TC; Hobday, TJ; Ingle, JN; Isaacs, CJ; Karuturi, MS; Keyomarsi, K; Leon-Ferre, RA; Liu, MC; Marcom, PK; Mayer, EL; Mayer, IA; McMenomy, BP; Morikawa, A; O'Sullivan, CC; Oh, SY; Peethambaram, PP; Santo, K; Suman, VJ | 1 |
| Cai, L; Chen, Q; Cui, S; Feng, J; Li, H; Liao, N; Ouyang, Q; Song, Y; Sun, Q; Sun, T; Teng, Y; Tong, Z; Wang, J; Wang, X; Xu, B; Yin, Y | 1 |
| Behrendt, CE; Ge, X; Lavasani, S; Mortimer, J; Patel, N; Samoa, R; Sedrak, M; Stewart, D; Waisman, J; Yost, SE; Yuan, Y | 1 |
| Coutinho, A; Cui, ZL; Karuturi, M; Lokhandwala, T; Lunacsek, O; Ring, A; Rybowski, S; Sapunar, F; Sheffield, KM; Smyth, EN; Willey, J | 1 |
| Ishiguro, H; Iwakuma, N; Iwamoto, T; Kikawa, Y; Kobayashi, K; Masuda, N; Niikura, N; Oba, M; Okuno, T; Ozaki, S; Saji, S; Tada, H; Takeshita, T; Toh, U; Tsuneizumi, M; Watanabe, K; Yamamoto, Y | 1 |
| Berg, T; Garly, R; Glavicic, V; Jensen, MB; Khan, H; Knoop, A; Kümler, I; Olsen, J; Poulsen, PB; Volmer, L | 1 |
| Chen, JW; Cortés, J; Dent, S; Harbeck, N; Hutchinson, KE; Jacot, W; Krop, I; Savage, HM; Schimmoller, F; Sivakumar, S; Sokol, ES; Stout, TJ; Trabucco, SE; Wilson, TR | 1 |
| Alves, CL; Bak, M; Ditzel, HJ; Ehmsen, S; Johansen, LE; Karimi, L; Lim, E; Portman, N; Terp, MG; Tuttolomondo, M | 1 |
| Cameron, C; Law, EH | 1 |
| Hamilton, E; Shastry, M | 1 |
| Dai, Z; Ju, J; Kang, Y; Ma, F; Wang, J; Wang, X; Xu, B; Yuan, P; Yue, J; Zhang, P | 1 |
| Bianchini, G; Corti, C; Criscitiello, C; Curigliano, G; De Angelis, C; Giuliano, M; Hamilton, E; Jeselsohn, R; Jhaveri, K; Malorni, L | 1 |
| Borgonovo, K; Di Menna, G; Dottorini, L; Ghidini, A; Ghilardi, M; Luciani, A; Parati, MC; Petrelli, F; Rea, CG | 1 |
| Decker, T; Degenhardt, T; Fasching, PA; Harbeck, N; Hoffmann, O; Kates, RE; Kümmel, S; Lüftner, D; Marschner, N; Müller, V; Otremba, B; Schem, C; Schinköthe, T; Schmidt, M; Schumacher, J; Tesch, H; Thomssen, C; Uleer, C; Warm, M; Witzel, I; Wuerstlein, R; Zaiss, M | 1 |
| Fakhouri, W; Faris, LH; Haro, JM; Kawaguchi, T; Novick, D; Nozawa, K; Onishi, M; Ozaki, Y; Takano, T; Tanizawa, Y; Terada, M; Tsurutani, J | 1 |
| Beaufort, CM; Bos, MK; Boven, E; de Jonge, E; Helmijr, JCA; Jager, A; Jansen, MPHM; Lam, SW; Martens, JWM; Motta, G; Sleijfer, S | 1 |
| Cortes, J; Dalenc, F; de Bruin, EC; Foxley, A; Gomez Moreno, HL; Grinsted, L; Howell, SJ; Hu, X; Jhaveri, K; Krivorotko, P; Loibl, S; Morales Murillo, S; Okera, M; Oliveira, M; Park, YH; Rugo, HS; Schiavon, G; Sohn, J; Toi, M; Tokunaga, E; Turner, NC; Yousef, S; Zhukova, L | 1 |
| Aftimos, P; Arlt, H; Bardia, A; Bidard, FC; Bihani, T; Binaschi, M; Burr, R; Chirn, B; Cortés, J; Dubash, TD; Fiascarelli, A; Habboubi, N; Haber, DA; Iafrate, AJ; Kaklamani, VG; LiCausi, JA; Maheswaran, S; Patel, H; Rai, S; Reeves, BA; Scartoni, S; Toner, M; Wittner, BS | 1 |
| Bazgier, V; Berka, K; Holcakova, J; Hrstka, R; Kolarova, T; Kudova, E; Kvasnica, M; Oklestkova, J; Rarova, L; Strnad, M; Tichy, V; Vonka, P | 1 |
| Ren, T; Sun, X; Wang, Y; Xie, D; Ye, X; Zhang, T; Zhao, Q | 1 |
| Anurag, M; Asirvatham, JR; Bikorimana, E; Chang, EC; Chen, A; Chica-Parrado, MDR; Dou, Y; Ellis, MJ; Fandino, D; Hanker, AB; Hilsenbeck, SG; Holt, MV; Kennedy, H; Kim, BJ; Lei, JT; Lim, B; Miles, G; Mohamed, N; Peng, J; Singh, P; Sreekumar, A; Wang, Y; Ye, D; Zhang, B; Zheng, ZY | 1 |
| Anan, K; Aogi, K; Fujisawa, T; Hasegawa, Y; Hattori, M; Kawaguchi, H; Masuda, N; Masuyama, M; Morita, S; Nakamura, S; Nakayama, T; Ohno, S; Ohtani, S; Saji, S; Sato, N; Takano, T; Toi, M; Tokunaga, E; Yamaguchi, M; Yamamoto, Y; Yamashita, T; Yotsumoto, D | 1 |
| Alzahrani, FM; Fasseas, K; Giannopoulou, E; Kalofonos, HP; Karamouzis, MV; Manou, D; Raftopoulou, S; Sarantis, P; Siatis, KE; Theocharis, AD | 1 |
| Arnedos, M; Arteaga, CL; Bell, JSK; Bhave, M; Bidard, FC; Bose, R; Brufsky, A; Burkard, ME; Chia, S; Crown, J; de Miguel, MJ; DiPrimeo, D; Eli, LD; Frazier, A; Gal-Yam, EN; Gambardella, V; Garcia-Saenz, JÁ; Goldman, JW; Guerrero-Zotano, A; Hanker, AB; Hurvitz, SA; Jhaveri, K; Loi, S; Ma, C; Park, H; Peterson, L; Piha-Paul, SA; Prat, A; Rapael, A; Reid, S; Saura, C; Solit, DB; Spanggaard, I; Stemmer, SM; Suga, JM; Unni, N; Vinayak, S; Waisman, J; Wildiers, H; Wong, A; Yang, ES; Ye, D | 1 |
| Arakawa, I; Hatakeyama, S; Inoue, T; Kaneko, M; Ogura, J; Sawada, H; Shida, T; Yamaguchi, H | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gersch, CL; Gralow, JR; Hayes, DF; Henderson, NC; Henry, NL; Hertz, DL; Hortobagyi, GN; Kidwell, KM; Medley, S; Mehta, RS; Pusztai, L; Rae, JM; Rutherford, DV; Tirumali, NR; Vandenberg, TA | 1 |
| Chen, S; Fan, Y; Ji, D; Lan, B; Luo, Y; Ma, F; Wang, J; Xu, B | 1 |
| Beck, JT; Bianchi, GV; Chakravartty, A; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Fasching, PA; Im, SA; Jerusalem, G; Martín, M; Neven, P; Nusch, A; Petrakova, K; Slamon, DJ; Sonke, GS; Wang, C; Wang, Y; Zarate, JP | 1 |
| Cai, J; Chen, L; Chen, Y; Ji, Z; Li, Z; Lin, W; Liu, Y; Wu, J; Zheng, D; Zheng, J; Zou, J | 1 |
| André, F; Appiah, AK; Chen, Y; Goel, S; Huynh, T; Tolaney, SM | 1 |
| Bahnassy, S; Balachandran, M; Beckman, RA; Jin, L; McCoy, MD; Mobin, D; Podar, M; Riggins, RB; Stires, H; Tam, S | 1 |
| Cheng, YC; Cohen, G; Guarducci, C; Jeselsohn, R; Liu, W; Ma, W; McDonald, TO; Michor, F; Nardone, A; Stein, S | 1 |
| Cai, J; Hu, C; Lin, H; Liu, J; Sun, H; Wei, X; Wu, W | 1 |
| Melegari, E; Palleschi, M; Rocca, A | 1 |
| Bananis, E; Castrellon, A; Cristofanilli, M; DeMichele, AM; Finn, RS; Gelmon, KA; Huang, X; Joy, AA; Lu, DR; Mori, A; Rugo, HS; Slamon, DJ; Sleckman, B; Theall, KP | 1 |
| Raj, GV; Soleja, M; Unni, N | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Agarwal, S; Chang, DW | 1 |
| Olufade, T; Schwartzberg, LS; Skinner, KE; Walker, MS | 1 |
| Mahtani, RL | 1 |
| Rugo, HS | 1 |
| Andreano, KJ; Bae, Y; Blitzer, JT; Chao, CA; Desautels, TK; Heetderks, KA; McDonnell, DP; Norris, JD; Wardell, SE; Yllanes, AP | 1 |
| Barriga, S; Burdaeva, O; Conte, P; Frenzel, M; Grischke, EM; Hurt, K; Inoue, K; Johnston, S; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M | 1 |
| Bun, A; Fujimoto, Y; Fukui, R; Higuchi, T; Imamura, M; Miyagawa, Y; Miyoshi, Y; Ozawa, H; Sata, A | 1 |
| Stirrups, R | 2 |
| Hua, YM | 1 |
| Akika, R; Awada, Z; Cahais, V; Cuenin, C; Ghantous, A; Herceg, Z; Nasr, R; Zgheib, NK; Zhivagui, M | 1 |
| Killock, D | 1 |
| Huizing, MT; Najim, O; Papadimitriou, K; Seghers, S; Sergoynne, L; Tjalma, W; Trinh, XB; Van Gaver, H; Wouters, K | 1 |
| Balslev, E; Bogovic, J; Buhl, ASK; Buhl, IK; Christensen, IJ; Christensen, TD; Danø, H; Ejlertsen, B; Glavicic, V; Hansen, A; Jakobsen, EH; Jensen, PB; Knoop, AS; Knudsen, S; Langkjer, ST; Linnet, S; Luczak, A; Nielsen, D; Rasmussen, A | 1 |
| Tamura, K | 2 |
| Berger, M; Billard, H; Bougaret, L; Bourgne, C; Caldefie-Chezet, F; Cholet, J; Decombat, C; Delort, L; Dumontet, C; Vermerie, M | 1 |
| Dittmer, A; Dittmer, J; Lange, T; Leyh, B | 1 |
| Arnedos, M; Arteaga, CL; Baselga, J; Bidard, FC; Boni, V; Brufksy, AM; Bryce, R; Cai, Y; Cervantes, A; Chandarlapaty, S; de la Fuente, MI; Dujka, M; Eli, LD; Gavrila, EI; Gonzàlez-Farré, X; Gorelick, AN; Hyman, DM; Jhaveri, K; Juric, D; Lalani, AS; Lanman, RB; Loi, S; Lu, J; Mann, G; Mau-Sørensen, M; Mayer, IA; Melcer, M; Meric-Bernstam, F; Moreno, V; Nagy, RJ; Piha-Paul, SA; Samoila, A; Saura, C; Scaltriti, M; Schram, AM; Schwartzberg, LS; Selcuklu, SD; Shapiro, GI; Smyth, LM; Sohn, J; Solit, DB; Spanggaard, I; Taylor, BS; Ulaner, GA; Won, HH; Xu, F; Zimel, C | 1 |
| Beck, JT; Bianchi, GV; Chakravartty, A; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Esteva, FJ; Fasching, PA; Im, SA; Jerusalem, G; Martín, M; Neven, P; Nusch, A; Petrakova, K; Pivot, X; Rodriguez-Lorenc, K; Slamon, DJ; Sondhi, M; Sonke, GS; Taran, T; Wang, Y | 1 |
| Chasen, BA; Damodaran, S; Fujii, T; Gao, H; Hortobagyi, GN; Ibrahim, NK; Iwase, T; Lim, B; Liu, DD; Lucci, A; Reuben, JM; Saigal, B; Shen, Y; Tahara, RK; Tripathy, D; Ueno, NT | 1 |
| Bai, L; Huang, J; Li, Q; Liao, W; Wen, F; Wu, Q; Zhang, N; Zhou, K | 1 |
| Chiang, C; Faulkner, D; Francis, PA; Jennens, R; Samuel, E | 2 |
| Alberini, JL; Becette, V; Boughdad, S; Champion, L; Cherel, P; Fourme, E; Lemonnier, J; Lerebours, F | 1 |
| Duan, S; He, Y; Li, M; Liao, C; Wei, Y; Xiong, Y; Yi, F; Zhang, W | 1 |
| Brufsky, AM; Nasrazadani, A | 1 |
| Alchami, F; Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; Cox, C; Foxley, A; Howell, SJ; Joffe, J; Jones, RH; Madden, TA; Moon, S; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Benoist, C; Bidard, FC; Bièche, I; Cabel, L; Darrigues, L; El Ayachy, R; Epaillard, N; Jeannot, E; Melaabi, S; Michel, M; Noret, A; Pierga, JY; Proudhon, C; Rampanou, A; Stern, MH; Vincent-Salomon, A | 1 |
| Chen, CS; Chen, XS; Cheng, Y; Ding, BN; Guan, YD; Guo, W; Li, LY; Ren, XC; Sun, XY; Tao, YG; Wang, HY; Wang, KS; Yang, JM; Ye, YC; Yin, MZ; Yu, P; Zhang, Y | 1 |
| Andre, V; Carter, GC; Grischke, EM; Kaufman, PA; Neven, P; Price, GL; Shekarriz, S; Sledge, GW; Sohn, J; Stoffregen, C; Toi, M | 1 |
| Adler, B; Bass, IR; Gallagher, EJ; Ryncarz, A; Tiersten, A; Trlica, K | 1 |
| Buisseret, L; de Azambuja, E; Eiger, D; Nogueira, MS; Pondé, NF; Wagner, M | 1 |
| Chen, PH; Ho, CL; Huang, TC; Kang, YN; Lee, CH; Lin, C; Wu, YY | 1 |
| Carroll, D; Cheung, KL; Dixon, JM; Evans, A; Fasching, PA; Harbeck, N; Henschen, S; Jahan, A; Kenny, LM; Kirwan, CC; Klinowska, T; Kothari, A; Lindemann, JPO; MacDonald, A; Mather, R; Maudsley, R; Mohamed, O; Moschetta, M; Nikolaou, M; Robertson, JFR; Roudier, MP; Sarvotham, T; Schiavon, G; Schmid, P; Wuerstlein, R; Zhou, D; Zhou, L | 1 |
| Jiang, YZ; Liu, XY; Shao, ZM; Wang, H | 1 |
| Huang, J; Jin, XY; Shen, LS; Tou, LZ; Wang, XM | 1 |
| Di, G; He, M; Liu, C; Liu, G; Liu, Y; Shao, Z; Shi, Q; Sun, Y; Wang, Z; Xu, X; Yang, Z; Yuan, H; Zhang, Y | 1 |
| Altelaar, M; Bhamra, A; Dowsett, M; Fitzpatrick, M; Gao, Q; Johnston, SR; Leal, MF; Marangoni, E; Martin, LA; Montaudon, E; Morisset, L; Nikitorowicz-Buniak, J; Pancholi, S; Ressa, A; Ribas, R; Schuster, E; Simigdala, N; Sourd, L; Thornhill, A | 1 |
| Antunes, F; Bincoletto, C; Guarache, GC; Muler, ML; Oliveira, RB; Pereira, GJDS; Smaili, SS; Ureshino, RP | 1 |
| Amaral, C; Fernandes, PA; Ferreira Almeida, C; João Ramos, M; Oliveira, A; Teixeira, N | 1 |
| Guan, X; Li, C; Li, H; Li, L; Liu, B; Ma, F; Qian, H; Rong, G; Sun, X; Wang, W; Xu, B; Yi, Z; Zhai, J | 1 |
| André, F; Catron, K; Chan, A; Chapman, SC; Gainford, MC; Goel, S; Hilton, JF; Im, SA; Johnston, SR; Kim, SB; Price, GL; Ricci, F; Tolaney, SM; Troso-Sandoval, TA; Wardley, AM; Yang, Z; Zambelli, S | 1 |
| Battisti, NML; Ring, A | 1 |
| Li, DQ; Liu, HY; Shao, ZM; Xie, HY; Yang, F; Yang, LF; Zhang, FL; Zhang, L | 1 |
| André, F; Campone, M; Cerda, H; Ciruelos, EM; Conte, P; Gaudenzi, F; Iwata, H; Jurado, JC; Juric, D; Loibl, S; Lteif, A; Mayer, I; Miller, M; Mills, D; Rugo, HS; Stemmer, SM; Toledano, I; Wilke, C; Yamashita, T | 1 |
| Goloubeva, O; Kazi, A; Sabnis, GJ; Schech, A; Yu, S | 1 |
| Briceño-Casado, MDP; Fénix-Caballero, S; Gil-Sierra, MD | 1 |
| Kim, DH; Sun, R; Wei, LJ | 1 |
| Frenzel, M; Sledge, GW | 1 |
| Hindié, E | 1 |
| Jerusalem, G; Slamon, DJ | 1 |
| Copur, MS | 1 |
| He, J; Hu, T; Huang, H; Liao, Y; Liu, B; Liu, N; Liu, X; Shao, Z; Xia, X; Xu, Q; Yu, C | 1 |
| Firenze, A; Gebbia, V; Valerio, MR; Vigneri, P | 1 |
| Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J | 1 |
| Hu, CT; Long, H; Prijatelj, V; Weng, CF | 1 |
| Higham, C; Howell, SJ; Keevil, B; Monaghan, PJ; Owen, LJ | 1 |
| Arrighi, A; Ballestrero, A; Becherini, P; Brandhorst, S; Caffa, I; Cea, M; Cilli, M; Clevers, H; Cortellino, S; Cremonini, AL; De Braud, F; Driehuis, E; Ferrando, L; Gradaschi, R; Longo, VD; Mantero, C; Mastracci, L; Monacelli, F; Nencioni, A; Odetti, P; Passalacqua, M; Piacente, F; Piazza, S; Provenzani, A; Salvadori, G; Spagnolo, V; Sukkar, SG; Tagliafico, A; Valdemarin, F; Vellone, VG; Vernieri, C; Wei, M; Zoppoli, G; Zucal, C | 1 |
| Cao, WM; Chen, JQ; Chen, ZH; Huang, J; Huang, P; Huang, Y; Lei, L; Lou, CJ; Shao, XY; Sun, Y; Wang, XJ; Ye, WW; Zheng, YB | 1 |
| Ameye, L; Awada, A; Azambuja, E; Brandão, M; Caparica, R; De Angelis, C; Desmedt, C; Di Cosimo, S; Eiger, D; Franzoi, MA; Kotecki, N; Lambertini, M; Piccart, M; Ponde, N | 1 |
| Hu, Y; Lee, S; Li, L; Lin, L; Schiff, R; Tan, Y; Veeraraghavan, J; Wang, X; Wang, XS | 1 |
| Alexandrou, S; Caldon, CE; Chia, KM; Coulson, R; Fernandez, KJ; Halilovic, E; Haupt, S; Haupt, Y; Lim, E; Milioli, HH; Parker, A; Portman, N; Segara, D; Swarbrick, A; Tilley, WD; Yong, A | 1 |
| Cao, Y; Ding, J; Fu, W; Guo, Y; Jiang, X; Li, K | 1 |
| Burdaeva, O; Gradishar, WJ; Hegg, R; Im, SA; Iwata, H; Izquierdo, MA; Johnston, SRD; Kenny, S; Kurteva, G; Park, IH; Press, MF; Sarp, S; Simon, SD; Tjulandin, S; Williams, LS | 1 |
| Baumann, WT; Conde, IP; Demas, DM; He, W; Shajahan-Haq, AN | 1 |
| Brandão, M; de Azambuja, E; Debiasi, M; Ferreira, A; Lambertini, M; Martel, S; Maurer, C; Piccart, M; Pondé, NF; Ziegelmann, PK | 1 |
| Abrahamsson, A; Dabrosin, C; Rodriguez, GV | 1 |
| Gigantino, V; Giurato, G; Nassa, G; Nyman, TA; Palumbo, D; Rizzo, F; Salvati, A; Strianese, O; Tarallo, R; Weisz, A | 1 |
| Huang, P; Huang, X; Lin, S; Liu, Y; Luo, S; Ming, WK; Wang, H; Weng, X | 1 |
| Abdelhady, AM; Bachelot, T; Calvo, E; Fasolo, A; Forero-Torres, A; Hamilton, E; Im, YH; Lee, SC; Lu, YS; Maur, M; Nardi, L; Ruan, S; Stammberger, U; Tiedt, R; Tolaney, SM | 1 |
| Abraham, J; Baird, RD; Bliss, JM; Braybrooke, JP; Bye, H; Cameron, D; Cutts, R; Gevensleben, H; Hubank, M; Kernaghan, S; Kilburn, LS; Kingston, B; Macpherson, IR; Martin, S; Moretti, L; Oikonomidou, O; Randle, K; Rea, D; Ring, A; Roylance, R; Shaaban, A; Snowdon, C; Stephens, P; Turner, NC; Tuthill, M; Wardley, AM; Wilkinson, K; Winter, MC | 1 |
| Bergqvist, M; Bethune, A; Bidard, FC; Brain, E; Cabel, L; Cottu, P; Donnadieu, A; Kiavue, N; Lerebours, F; Loirat, D; Pierga, JY; Rodrigues, M; Rosenblum, D; Tanguy, ML | 1 |
| André, F; Bartlett, CH; Cristofanilli, M; Cutts, RJ; Garcia-Murillas, I; Hrebien, S; Huang, X; Liu, Y; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Andre, VAM; Barriga, S; Cox, J; García-Sáenz, JA; Goetz, M; Huober, J; Masuda, N; Rugo, HS; Sohn, JH | 1 |
| Baird, RD; Batra, AS; Brindle, KM; Bruna, A; Caldas, C; Couturier, DL; D'Santos, P; de Boo, LW; Georgopoulou, D; Hesketh, RL; Hu, DE; Lerda, G; Lewis, DY; Linn, SC; Lubling, Y; Mannion, E; Martin, A; Oliveira, M; Pelossof, R; Razavi, P; Ros, S; Rueda, OM; Scaltriti, M; Wright, AJ | 1 |
| Corbaux, P; Sabatier, R | 1 |
| Cavadias, I; Héquet, D; Lerebours, F; Rouzier, R | 1 |
| Cao, J; Gong, C; Hu, X; Li, Y; Tao, Z; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhao, Y | 1 |
| Beck, JT; Bianchi, GV; Chan, A; Chandiwana, D; De Laurentiis, M; Esteva, FJ; Fasching, PA; Jerusalem, G; Lanoue, B; Martin, M; Neven, P; Nusch, A; Pivot, X; Ridolfi, A; Rodriguez Lorenc, K; Wang, Y | 1 |
| Atlas, E; Cuyàs, E; Espinoza, I; Lupu, R; Mehmi, I; Menendez, JA; Papadimitropoulou, A; Vander Steen, T; Vellon, L; Verdura, S | 1 |
| Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mukai, H; Muramatsu, Y; Ohno, S; Ohtani, S; Rai, Y; Shimizu, C; Toi, M; Umeyama, Y | 1 |
| Jerusalem, G; Neven, P; Sonke, GS | 1 |
| Liu, W; Lu, Y | 1 |
| Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Chatterjee, DK; Chen, W; Chen, X; Fan, J; Fernandes, LL; Gao, JJ; Geiser, G; Ghosh, S; Goldberg, KB; Gong, Y; Jiang, X; King-Kallimanis, BL; Kluetz, PG; Li, E; Narayan, P; Pathak, A; Pazdur, R; Philip, R; Prowell, TM; Qiu, J; Reyes Turcu, F; Rhieu, SY; Ricks, TK; Seidman, J; Song, P; Tang, S; Theoret, MR; Wang, X; Windsor, K; Yu, J; Zhang, X | 1 |
| Arnesen, S; Christenson, JL; Elias, A; Gertz, J; Goodspeed, A; Hanamura, T; Jacobsen, BM; Li, Z; O'Neill, KI; Oesterreich, S; Reese, J; Richer, JK; Riggins, RB; Rosas, E; Sams, SB; Spoelstra, NS; Torkko, KC; Williams, MM | 1 |
| Cortés, J; Cui, N; De Laurentiis, M; Dent, S; Diéras, V; Drullinsky, P; Harbeck, N; He, J; Hsu, JY; Im, YH; Jacot, W; Krop, IE; Schimmoller, F; Sousa, S; Wilson, TR | 1 |
| Bach Hamba, S; Bellesoeur, A; Brain, E; Carton, M; Cottu, P; Haroun, L; Kirova, Y; Lerebours, F; Loirat, D; Porte, B | 1 |
| Lu, Q; Ouyang, Q; Pang, D; Peng, R; Shi, Y; Wang, S; Xia, W; Xu, F; Yuan, Z; Zheng, Q | 1 |
| André, F; Campone, M; Ciruelos, EM; Conte, PF; Ghaznawi, F; Inoue, K; Iwata, H; Juric, D; Kaper, M; Kaufman, B; Loibl, S; Lu, YS; Mayer, IA; Miller, M; Mills, D; Pápai, Z; Rubovszky, G; Rugo, HS; Takahashi, M; Yamashita, T | 1 |
| Bachelot, T; Cassier, PA; Vanacker, H | 1 |
| Asano, M; France, D; Funahashi, Y; Nakagawa, T; Niwa, Y; Semba, T | 1 |
| Fujii, M; Fujimoto, Y; Haeno, H; Hakozaki, Y; Kashima, Y; Kobayashi, SS; Morita, TY; Mukohara, T; Ohashi, A | 1 |
| Foukakis, T; Matikas, A | 1 |
| Aja, J; Brantley, E; Campbell, P; Davis, MB; Loaiza-Perez, A; Mavingire, N; Wooten, J | 1 |
| Ortmann, O; Riedmeier, M; Schüler-Toprak, S; Skrzypczak, M; Treeck, O | 1 |
| André, VAM; Campone, M; Chouaki, N; Goetz, MP; Grischke, EM; Manso, L; Okera, M; San Antonio, B; Sledge, GW; Toi, M; Wildiers, H | 1 |
| Alhusban, A; Alkhalifa, AE; Ayoub, NM; Ibrahim, DR | 1 |
| Akiyama, Y; Doi, S; Hagihara, K; Matsushita, K; Motoki, Y; Nakaguchi, K; Sakisaka, H | 1 |
| Beachler, DC; de Luise, C; Freston, JW; Jamal-Allial, A; Lanes, S; Lewis, JH; Suzuki, A; Taylor, DH; Yin, R | 1 |
| Akrap, N; Alves, CL; Beumers, L; Borg, Å; Borgquist, S; Bosch, A; Ditzel, HJ; Ebbesson, A; Ehinger, A; Ehmsen, S; Harbst, K; Hedenfalk, I; Honeth, G; Kaminska, K; Pérez-Fidalgo, A; Staaf, J; Veerla, S | 1 |
| Baena-Cañada, JM; Bayo, JL; Blancas, I; Carabantes, F; Conde, V; Cruz, J; Herrero, C; Olier, C; Ruiz-Borrego, M; Zarcos-Pedrinaci, I | 1 |
| Balasubramanian, S; Broome, R; Carroll, JS; Chernukhin, I; D'Santos, C; Farcas, AM; Groen, AJ; Jamieson, S; Kishore, K; Mahtey, A; Mao, SQ; Papachristou, EK; Siersbæk, R; Tejedo, CG; Theodorou, V | 1 |
| Bruinsma, ES; Emch, MJ; Goetz, MP; Hawse, JR; Ingle, JN; Jones, CJ; Subramaniam, M | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| Bernard-Tessier, A; Bidard, FC; Bièche, I; Cabel, L; Cottu, P; Darrigues, L; Dubot, C; Geiss, R; Loirat, D; Michel, M; Pierga, JY; Proudhon, C; Ricci, F; Silveira, AB; Vincent-Salomon, A | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Alarid, ET; Almodovar, J; Álvarez-García, YR; Domenech, M; Reyes-Ramos, AM; Solodin, N; Torres-Garcia, W | 1 |
| Arce, C; Bachelot, T; Chia, S; Ciruelos, E; Drullinsky, P; Hsu, WC; Juric, D; Kanakamedala, H; Lerebours, F; Neven, P; Park, YH; Prat, A; Rugo, HS; Ruiz-Borrego, M; Shen, YM; Sophos, N; Turner, N; Turner, S; Zarate, JP | 1 |
| Brunton, VG; Faulds, K; Findlay Paterson, KA; Graham, D; Kapara, A; Zagnoni, M | 1 |
| Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L | 1 |
| Isaacs, C; O'Regan, R; O'Shaughnessy, JA | 1 |
| Chandiwana, D; Chia, S; Hsu, WC; Kanakamedala, H; Park, J; Ridolfi, A; Rugo, HS; Turner, S; Yu, CL; Zarate, JP | 1 |
| Duco, MR; Murdock, JL; Reeves, DJ; Sharma, SC | 1 |
| Borg, Å; Brueffer, C; Chen, Y; Dahlgren, M; Ehinger, A; George, AM; Gladchuk, S; Gruvberger-Saal, SK; Häkkinen, J; Hegardt, C; Larsson, C; Loman, N; Malmberg, M; Rydén, L; Saal, LH; Vallon-Christersson, J | 1 |
| Kudo, S; Makino, T; Tanaka, T; Umetsu, R | 1 |
| Chang, YF; Fanning, SW; Green, B; Greene, GL; Greene, ME; Komm, B; Kurleto, JD; Lainé, M; Phung, L | 1 |
| Gallagher, P; Haynes, HR; Mohan, V; Mozayani, B | 1 |
| Abe, M; Chiba, R; Ishiguro, A; Ito, K; Kato, H; Kubota, R; Matsunami, O; Narita, Y; Ohigashi, A; Tanimoto, A | 1 |
| Bièche, I; Chateau-Joubert, S; Dahmani, A; De Plater, L; El Botty, R; Jacquemetton, J; Kassem, L; Le Romancer, M; Marangoni, E; Montaudon, E; Morisset, L; Poulard, C; Sourd, L; Trédan, O; Treilleux, I; Vacher, S | 1 |
| Bananis, E; Brufsky, A; Cristofanilli, M; DeMichele, A; Harbeck, N; Huang, X; Iwata, H; Loibl, S; McRoy, L; Park, YH; Rugo, HS; Theall, KP; Turner, NC | 1 |
| Beck, JT; Chakravartty, A; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Deore, U; Fasching, PA; Im, S; Jerusalem, G; Ji, Y; Martín, M; Neven, P; Nusch, A; Petrakova, K; Slamon, DJ; Sonke, GS; Taran, T; Valeria Bianchi, G; Wang, C; Zarate, JP | 1 |
| Chandiwana, D; Delea, TE; Park, J; Stellato, D; Thabane, ME | 1 |
| Garre, E; Gustafsson, A; Landberg, G; Leiva, MC; Salerno, S; Ståhlberg, A | 1 |
| Bergh, J; Couch, F; de la Haba, J; Dickler, MN; Ellis, MJ; Goetz, MP; Loibl, S; Martin, M; Polley, MC; Roberston, J; Sinnwell, J; Tenner, K | 1 |
| Buechlein, A; Burks, HE; Burow, ME; Chrisey, D; Collins-Burow, BM; Elliott, S; Matossian, MD; Miller, DFB; Nephew, KP; Phamduy, T; Rhodes, LV; Rusch, DB | 1 |
| Jeselsohn, RM | 1 |
| Albert, R; Alcon, C; Baselga, J; Gómez Tejeda Zañudo, J; Johnson, GN; Kowalski, K; Letai, A; Mao, P; Montero, J; Scaltriti, M; Wagle, N; Xu, G | 1 |
| Albert, R; Alcon, C; Gómez Tejeda Zañudo, J; Letai, A; Montero, J; Samitier, J; Scaltriti, M; Wagle, N | 1 |
| Burdaeva, O; Conte, P; Grischke, EM; Haddad, N; Hurt, KC; Inoue, K; Johnston, SRD; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Goetz, MP; Haddad, N; Hurt, KC; Iwata, H; Kaufman, PA; Lu, Y; Neven, P; Rugo, HS; Sledge, GW; Toi, M; Tolaney, SM | 1 |
| Alves, CL; Bak, M; Bosch, A; Ditzel, HJ; Ehmsen, S; Gammelgaard, OL; Honeth, G; Hundebøl, MF; Johansen, LE; Kaminska, K; Lim, E; Portman, N; Terp, MG; Tuttolomondo, M | 1 |
| Bianchi, GV; Cazzaniga, ME; Cortesi, L; De Sanctis, R; Fabi, A; Gambaro, AR; Gueli, R; Leonardi, V; Palumbo, R; Pizzuti, L; Santoro, A; Tagliaferri, B; Torrisi, R; Valerio, MR; Vici, P | 1 |
| Duan, D; Ganesh, AN; McLaughlin, CK; Shoichet, BK; Shoichet, MS | 1 |
| Li, XY; Lin, WZ; Wang, HB; Xu, QN | 1 |
| Cappelletti, MR; Corona, SP; Cretella, D; Dester, M; Generali, D; Gobbi, A; Petronini, PG; Ravelli, A; Zanotti, L | 1 |
| Anan, K; Aogi, K; Fujisawa, T; Hasegawa, Y; Hattori, M; Ito, Y; Kawaguchi, H; Masuda, N; Morita, S; Nakamura, S; Nakayama, T; Ohno, S; Ohtani, S; Saji, S; Sato, N; Toi, M; Tokunaga, E; Yamaguchi, M; Yamamoto, Y; Yamashita, T | 1 |
| Brown, M; De Angelis, C; Jeselsohn, R; Schiff, R | 1 |
| Caramia, F; Joshi, S; Loi, S; Moodie, K; Savas, P; Van Geelen, C; Wein, L | 1 |
| Fan, M; Hu, X; Huang, W | 1 |
| Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
| Kim, ES; Scott, LJ | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P | 1 |
| Griggs, JJ; Wolff, AC | 1 |
| Barriga, S; Bourayou, N; Burdaeva, O; Frenzel, M; Grischke, EM; Inoue, K; Kaufman, PA; Koh, H; Lin, Y; Llombart-Cussac, A; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Smith, IC; Sohn, J; Toi, M | 1 |
| Bargonetti, J; Brekman, A; Gao, C; Kim, JY; Kundu, N; Xiao, G | 1 |
| Byun, YS; Choi, KC; Go, RE; Hwang, KA; Kim, CW; Nam, KH | 1 |
| André, F; Bartlett, CH; Cristofanilli, M; Dowsett, M; Folkerd, E; Harbeck, N; Hoffman, J; Im, SA; Iwata, H; Loi, S; Loibl, S; Masuda, N; Puyana Theall, K; Ro, J; Turner, NC; Verma, S; Zhang, K | 1 |
| Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B | 1 |
| Ding, H; Fang, L; Huang, P; Tong, Y; Xin, W; Zhou, Q | 1 |
| Chen, S; Huang, TT; Liu, CY; Petrossian, K; Tseng, LM; Wu, CY | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Chen, S; Kwon, E; Munster, PN; Park, J; Pawlowska, N; Piper, M; Sbitany, H; Terranova Barberio, M; Thomas, S | 1 |
| Adjei, AA; Ames, MM; Black, J; Buhrow, SA; Chalmers, ZR; Collins, JM; Dockter, T; Doroshow, JH; Erlichman, C; Frampton, G; Goetz, MP; Haddad, T; Hawse, JR; Ingle, JN; Kipp, BR; Kuffel, M; Liu, MC; Mahr, MA; McGovern, RM; Northfelt, DW; Ralya, AT; Reid, JM; Safgren, SL; Streicher, H; Suman, VJ; Visscher, D | 1 |
| Messina, C; Messina, M; Zanardi, E | 1 |
| Adachi, K; Enomoto, K; Fujisaki, S; Hara, Y; Hirano, T; Kubota, H; Makishima, M; Saga, R; Sakurai, K; Suzuki, S; Tomita, R | 1 |
| Abenhardt, W; Beckmann, MW; Belleville, E; Brucker, SY; Ettl, J; Fasching, PA; Fehm, TN; Fersis, N; Geberth, M; Häberle, L; Hadji, P; Hartkopf, AD; Hielscher, C; Huober, J; Janni, W; Kolberg, HC; Kurbacher, C; Lüftner, D; Lux, MP; Müller, V; Nabieva, N; Overkamp, F; Schneeweiss, A; Schwitulla, J; Taran, FA; Tesch, H; Thomssen, C; Untch, M; Volz, B; Wallwiener, D; Wallwiener, M; Wimberger, P; Wuerstlein, R | 1 |
| Freedman, RA; Tolaney, SM | 1 |
| Kim, ES | 1 |
| Baena-Cañada, JM; Bayo, JL; Blancas, I; Bofill, JS; Carabantes, F; Conde, V; Cruz, J; Esquerdo, G; Fontanillas, M; García-Palomo, A; Gordon, MM; Illarramendi, JJ; Jaen, A; Jáñez, NM; Lao, J; Martínez, E; Mendiola, C; Pérez-Ruiz, E; Ruiz-Borrego, M; Sotelo, MJ | 1 |
| Ali, S; Bhamra, A; Buluwela, L; Carroll, J; Dowsett, M; Fribbens, C; Gao, Q; Garcia-Murillas, I; Gellert, P; Harrod, A; Hills, M; Li, Z; Martin, LA; Martins, V; Nikitorowicz-Buniak, J; Oesterreich, S; Pancholi, S; Patani, N; Poulogiannis, G; Ribas, R; Schuster, E; Sikora, MJ; Simigdala, N; Tenev, T; Thornhill, A; Turgeon, MO; Turner, N; Zwart, W | 1 |
| Bachelot, T; Blau, S; Bordonaro, R; Ciruelos, E; Csőszi, T; Decker, T; Dharan, B; Di Leo, A; Egle, D; El-Hashimy, M; Janni, W; Johnston, S; Kalev, D; Lee, KS; Lønning, PE; Mouret-Reynier, MA; O'Regan, R; Schirone, A; Sellami, D; Tjan-Heijnen, VCG; Weber, D | 1 |
| Augereau, P; Campion, L; Campone, M; Caroline, F; du Rusquec, P; Dumas, L; Frenel, JS; Gourmelon, C; Palpacuer, C; Patsouris, A; Robert, M | 1 |
| Deeks, ED | 1 |
| D'Assoro, A; Goetz, MP; Haddad, TC; Ingle, JN; Liu, MC; Opyrchal, M; Peethambaram, P; Suman, V | 1 |
| Benet, LZ; Krings, G; Munster, PN; Park, J; Pawlowska, N; Terranova-Barberio, M; Thomas, S; Wolfe, AR; Zhong, AY | 1 |
| Di Leo, A; Jerusalem, G; Lichfield, J; Malorni, L; Martin, M; Pendergrass, K; Torres, R; Verhoeven, D | 1 |
| Cox, DG; Pivot, X | 1 |
| Bisagni, G; Colleoni, M; De Fato, R; Del Mastro, L; Frassoldati, A; Gianni, L; Mansutti, M; Valagussa, P; Viale, G; Zamagni, C; Zambetti, M | 1 |
| Liu, C; Liu, Y; Peng, Z; Sun, L; Yin, G; Zeng, B | 1 |
| Ciccarese, M; Cinieri, S; Fedele, P; Surico, G | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Diéras, V; Ettl, J; Finn, RS; Gelmon, KA; Giorgetti, C; Im, SA; Iyer, S; Lipatov, O; Lu, DR; Martin, M; Mori, A; Moulder, S; Turner, NC | 1 |
| Cook, RS; Duvall, C; Elion, D; Elledge, R; Estrada, MV; Hicks, DJ; Joly, MMM; Lee, L; Massarweh, S; McKernan, C; Rahman, B; Sanchez, V; Werfel, T; Williams, MM | 1 |
| Adachi, K; Enomoto, K; Fujisaki, S; Hara, Y; Hirano, T; Kubota, H; Sakurai, K; Suzuki, S; Tomita, R | 1 |
| Cheng, J; Jia, X; Liu, G; Shao, Z; Shen, Z | 1 |
| Ellis, MJ; Fazal, M; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J | 1 |
| Akiyoshi, S; Ijichi, H; Ishida, M; Koga, C; Koi, Y; Masuda, T; Nakamura, Y; Ohno, S; Tokunaga, E | 1 |
| Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Huang, X; Koehler, M; Liu, Y; Morden, JP; O'Leary, B; Turner, NC | 1 |
| Kotake, T; Toi, M | 1 |
| Fang, Q; Lin, J; Liu, L; Ruan, Y; Shen, W; Zhao, H; Zhu, Z | 1 |
| Ahn, JS; Heo, MH; Im, YH; Kim, HK; Kim, JY; Lee, H; Park, YH | 1 |
| Sidaway, P | 3 |
| Guo, J; Long, X; Shi, Y; Ye, P; Zeng, H; Zhou, Q | 1 |
| Cheung, KL; Degboe, A; Ellis, MJ; Fazal, M; Lichfield, J; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J | 1 |
| Telford, C | 1 |
| Brufsky, A; Burnette, B; Cheema, P; Goldstein, LJ; Haley, B; Klein, P; Kornblum, N; Makower, DF; Manola, J; Miller, KD; Ramaswamy, B; Soori, GS; Sparano, JA; Stella, PJ; Telli, M; Truica, CI; Wassenaar, TR; Wolff, AC; Zhao, F | 1 |
| Chaiyakunapruk, N; Imanaka, Y; Kunisawa, S; Lertjanyakun, V | 1 |
| Gonçalves, A | 1 |
| Blackburn, SA; Cheung, KL; Parks, RM | 1 |
| Chen, L; Ding, W; Li, Z; Ruan, G; Tu, C; Wang, C | 1 |
| Lindman, H; Valachis, A; Zewenghiel, L | 1 |
| Choi, S; Kang, KS; Kim, SH; Lee, D; Park, S | 1 |
| Ellis, MJ; Shafaee, MN | 1 |
| Hanif, R; Ismail, M; Jabeen, I; Khalid, S; Mansoor, Q | 1 |
| Abdel-Razeq, H | 1 |
| Beck, JT; Bianchi, GV; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Esteva, FJ; Fasching, PA; Im, SA; Jerusalem, G; Martín, M; Miller, M; Neven, P; Nusch, A; Petrakova, K; Pivot, X; Rodriguez Lorenc, K; Slamon, DJ; Sonke, GS; Taran, T; Vidam, G; Wang, Y | 1 |
| Avogadri-Connors, F; Cutler, RE; Dowsett, M; Guest, SK; Johnston, SR; Lalani, AS; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Rani, A; Ribas, R; Schuster, E; Simigdala, N; Thornhill, A | 1 |
| Liu, C; Wang, H; Wang, R; Xia, D; Xu, J | 1 |
| Alves, CL; Bak, M; Ditzel, HJ; Elias, D; Lyng, MB | 1 |
| O'Leary, KA; Schuler, LA; Shea, MP; Vezina, CM; Wegner, KA | 1 |
| Kase, AM; Menke, D; Tan, W | 1 |
| Chen, X; Wang, J; Wang, W; Xu, B; Zhai, X | 1 |
| Iguchi, E; Kawamura, Y; Kawasaki, S; Morita, M; Nakatsukasa, K; Nishida, M; Oouchi, Y; Sakaguchi, K; Sakuramachi, A; Soshi, M; Taguchi, T; Watanebe, A | 1 |
| Colleoni, M; Cristofanilli, M; Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Huang Bartlett, C; Loi, S; Lu, DR; Mori, A; Rugo, HS; Schnell, P; Slamon, DJ; Turner, NC | 1 |
| Bartlett, CH; Finn, RS; Harbeck, N; Huang, X; Im, SA; Iyer, S; Johnston, S; Joy, AA; Kim, S; Masuda, N; Rugo, HS; Schnell, P; Sun, W; Turner, NC; Verma, S | 1 |
| Carpenter, E; Farfus, A; Filkowski, J; Kovalchuk, O; Li, D; Lykkesfeldt, AE; Malach, M; Rodriguez-Juarez, R; Storozynsky, Q; Wang, B | 1 |
| Augereau, P; Campone, M; Chassain, K; Guillemois, S; Le Corre, Y; Patsouris, A; Peyraga, G | 1 |
| Blackwell, KL; Kornblum, NS; Sammons, S | 1 |
| Acconcia, F; Bianchi, F; Busonero, C; Leone, S | 1 |
| Arteaga, C; Floris, G; Hoste, G; Jongen, L; Matton, T; Menten, J; Neven, P; Punie, K; Slembrouck, L; Vanden Bempt, I; Vander Borght, S; Wildiers, H | 1 |
| Audemard, E; Dumeaux, V; El Ezzy, M; Mader, S; Traboulsi, T | 1 |
| Band, J; Darden, C; Davis, K; Iyer, S; McSorley, D; Mitra, D | 1 |
| Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J | 1 |
| Chanchan, G; Fangfang, S; Xiangyu, S; Xiaoyi, G; Yan, C | 1 |
| Nakatsukasa, K; Taguchi, T; Tomida, S | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Bourdeau, L; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; El-Hashimy, M; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Le Mouhaër, S; Masuda, N; Pistilli, B; Sankaran, B; Sellami, D; Tseng, LM | 1 |
| Gong, C; Li, Y; Liu, C; Wang, B; Wu, B; Xie, Y; Yang, Z; Zhang, Y; Zhao, Y | 1 |
| Baulande, S; Becette, V; Benoist, C; Boulai, A; Bouvet, LV; Briaux, A; Callens, C; Chemlali, W; De La Motte Rouge, T; Lemonnier, J; Lerebours, F; Liang, X; Mouret-Reynier, MA; Rivera, S; Schnitzler, A | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Giorgetti, C; Huang, X; Im, SA; Liu, Y; Loi, S; Masuda, N; Slamon, DJ; Theall, KP; Turner, NC; Verma, S | 1 |
| Cooper, K; Gaisford, W; Harris, P; Kalita, N; Onyimadu, O; Picot, J | 1 |
| André, F; Bondarenko, I; Colleoni, M; Cristofanilli, M; DeMichele, A; Giorgetti, C; Harbeck, N; Huang Bartlett, C; Huang, X; Im, SA; Iwata, H; Loi, S; Loibl, S; Masuda, N; Puyana Theall, K; Ro, J; Slamon, DJ; Turner, NC; Verma, S | 1 |
| Jeselsohn, R; Schiff, R | 1 |
| Gibson, K; Iyer, S; Milligan, G; Mitra, D; Taylor-Stokes, G; Waller, J | 1 |
| Hara, F; Hashigaki, S; Huang, X; Inoue, K; Iwata, H; Masuda, N; Mori, Y; Mukai, H; Muramatsu, Y; Nagasawa, T; Nakamura, R; Ohno, S; Rai, Y; Umeyama, Y | 1 |
| Duraki, D; Helferich, WG; Huang, R; Kim, JE; Mao, C; Nelson, ER; Park, BH; Shapiro, DJ; Wang, L; Yu, L | 1 |
| Jager, A; Konings, IR; Sonke, GS; Uyl-de Groot, CA; van der Noort, V; van Ommen-Nijhof, A; van Zeijl, CJJ | 1 |
| Brown, M; Cohen, O; Ding, L; Egri, SB; Fassl, A; Gimelbrant, AA; Hinohara, K; Igarashi, KJ; Jadhav, A; Jaffe, JD; Jeselsohn, R; Kales, SC; Lal-Nag, M; Madsen, T; Maloney, DJ; McDonald, TO; Meissner, A; Michor, F; Papanastasiou, M; Peluffo, G; Polyak, K; Rai, G; Sicinski, P; Simeonov, A; Vigneau, S; Wagle, N; Wu, HJ; Yamamoto, KN | 1 |
| Brown, M; Buchwalter, G; Carlson, KE; Chandarlapaty, S; Dharmarajan, V; Fanning, SW; Fowler, CE; Greene, GL; Griffin, PR; Han, R; Hosfield, DJ; Houtman, R; Jeselsohn, R; Karimi, M; Katzenellenbogen, JA; Lainé, M; Martin, TA; Mayne, CG; Nettles, KW; Nowak, J; Nwachukwu, JC; Shen, Y; Tajkhorshid, E; Toy, W | 1 |
| Basak, P; Bhat, V; Chatterjee, S; Hu, P; Jin, H; Lee-Wing, V; Liu, Q; Murphy, LC; Raouf, A; Su, A | 1 |
| Cohen, O; Cuoco, MS; Freeman, S; Helvie, K; Kapstad, C; Lin, NU; Ma, CX; Marini, L; Nayar, U; Oliver, N; Painter, C; Persky, NS; Regev, A; Rozenblatt-Rosen, O; Wagle, N; Waks, AG; Wander, SA; Winer, EP | 1 |
| Baselga, J; Blumenstein, L; Bootle, D; Burris, HA; Demanse, D; Gil-Martin, M; Huang, A; Janku, F; Juric, D; Mayer, IA; Middleton, MR; Quadt, C; Rodón, J; Rugo, HS; Schuler, M; Schumacher, K; Seggewiss-Bernhardt, R | 1 |
| Brown, H; Cataldo, ML; Chamness, GC; De Angelis, C; Delpuech, O; Fu, X; Hilsenbeck, SG; Jeselsohn, R; Mitchell, T; Nagi, C; Nardone, A; Osborne, CK; Pilling, M; Rimawi, MF; Schiff, R; Shea, MJ; Trivedi, M; Veeraraghavan, J; Weir, H | 1 |
| Armstrong, DK; Button, B; Christenson, ES; Chu, D; Cravero, K; Croessmann, S; Dalton, WB; Dennison, L; Donaldson, J; Hunter, T; Karthikeyan, S; Kyker-Snowman, K; May, B; Park, BH; Petry, D; Ramin, C; Roden, R; Rosen, DM; Visvanathan, K; Waters, I; Zabransky, DJ | 1 |
| Asmar, N; Barriere, J; Rey, JF; Sattonnet, C | 1 |
| Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN | 1 |
| Hayashi, SI; Hirakawa, H; Ito, T; Niwa, T; Sato, N; Tsuboi, K; Uchiumi, K; Yamaguchi, Y | 1 |
| He, Q; Hu, ZY; Li, J; Liu, J; Ouyang, Q; Wang, H; Wang, Y; Xia, X | 1 |
| Anderson, D; Bagu, E; Dai, C; Davies, G; Goel, R; Lukong, KE; Miah, S; Ogunbolude, Y; Vizeacoumar, FJ; Vizeacoumar, FS; Ward, A | 1 |
| Armstrong, A; Higham, C; Howell, S; Keevil, BG; Monaghan, PJ; Owen, LJ; Salih, Z | 1 |
| Agrapart, V; Andre, F; Bachelot, T; Bossard, CJ; Campone, M; Dubois, F; Guigal-Stephan, N; Lockhart, B; Pallis, A; Penault-Llorca, F; Pierrat, MJ; Poirot, C; Xuereb, L | 1 |
| Chae, YS; Jeong, JH; Jung, JH; Lee, DH; Lee, IH; Lee, J; Lee, SJ; Park, HY | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Batra, A; Gupta, VG; Naik, RD | 1 |
| Cristofanilli, M; Huang, X; Turner, NC | 1 |
| McCaw, ZR; Vassy, JL; Wei, LJ | 1 |
| André, F; Arnedos, M; Bayar, MA; Colleoni, M; Cristofanilli, M; DeMichele, A; Giorgetti, C; Harbeck, N; Huang Bartlett, C; Liu, Y; Loi, S; Loibl, S; Michiels, S; Turner, NC; Zhang, Z; Zhu, Z | 1 |
| Chen, L; He, S; Hu, X; Jeong, LS; Jia, L; Jia, X; Li, C; Li, L; Liu, G; Liu, X; Lu, Y; Ni, S; Shao, ZM; Sun, H; Yu, J; Yu, K; Zhang, J; Zhang, W; Zhang, Y; Zhao, H; Zhou, L | 1 |
| Cao, E; Ge, R; Gong, C; Guan, X; Hu, X; Li, W; Li, Y; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhang, S; Zhang, Y; Zhao, Y | 1 |
| Abraham, J; Budd, GT; Eziokwu, AS; Jia, X; Kruse, M; Montero, AJ; Moore, HCF; Varella, L | 1 |
| Arteaga, CL; Balko, JM; Bardia, A; Bauer, JA; Behdad, A; Cristofanilli, M; Croessmann, S; Cruz, MR; Dugger, TC; Ericsson, PG; Formisano, L; Guerrero-Zotano, AL; Guo, Y; Hanker, AB; He, W; Jansen, VM; Lanman, RB; Lee, KM; Lu, Y; Mayer, IA; Miller, M; Nagy, RJ; Nixon, MJ; O'Shaughnessy, J; Sanders, ME; Schwarz, LJ; Servetto, A; Shyr, Y; Solovieff, N; Su, F; Sudhan, DR | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Linden, HH; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA | 1 |
| Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y | 1 |
| Cai, Z; Enatsu, S; Ishiguro, H; Omori, Y | 1 |
| Burki, TK | 1 |
| Li, J; Shao, Z; Wang, Z | 1 |
| Chen, C; Korangath, P; Li, S; Merino, VF; Nie, G; Pai, P; Stearns, V; Sukumar, S; Sun, S; Wang, G; Yuan, J | 1 |
| Benelli, M; Bergqvist, M; Biagioni, C; Biganzoli, L; Boccalini, G; Bonechi, M; Chia, S; De Luca, F; Di Leo, A; Galardi, F; Gradishar, WJ; Malorni, L; Mattsson, K; McCartney, A; Migliaccio, I; Pestrin, M; Piccart, M; Romagnoli, D; Schiavon, G | 1 |
| Bradbury, I; Campbell, C; Di Leo, A; Ellis, M; Jiang, Z; Ohno, S; Pritchard, KI; Robertson, JFR | 1 |
| Guan, X; Li, C; Li, L; Liu, B; Ma, F; Qian, H; Xu, B; Yi, Z | 1 |
| André, F; Campone, M; Ciruelos, E; Conte, P; Hirawat, S; Inoue, K; Iwata, H; Juric, D; Kaufman, B; Loibl, S; Longin, AS; Lu, YS; Mayer, IA; Mills, D; Pápai, Z; Rubovszky, G; Rugo, HS; Takahashi, M; Wilke, C; Yamashita, T | 1 |
| Clarke, RB; Dragoni, I; Gee, JM; Howell, SJ; Kedward, T; NicAmhlaoibh, R; Sabin, V; Santiago-Gómez, A; Simões, BM; Sims, AH; Trivier, E | 1 |
| Alba, E; Álvarez, I; Antolín, S; Antón, A; Baena-Cañada, JM; Bermejo, B; Carrasco, E; Chacón, JI; Cirauqui, B; Cruz, J; Del Barco, S; Escudero, MJ; Guerrero-Zotano, A; Martín, M; Martínez-Jáñez, N; Muñoz, M; Ramos, M; Rodríguez-Lescure, Á; Ruiz, V; Ruíz-Borrego, M; Sevillano, E | 1 |
| Demidenko, E; Fields, JL; Hampsch, RA; Hosford, SR; Kettenbach, AN; Miller, TW; Shee, K; Traphagen, NA; Wells, JD | 1 |
| Chen, HW; Cheung-Lau, G; Comin-Anduix, B; Deng, G; Garcia, AJ; Hamilton, N; Jung, ME; Márquez-Garbán, DC; Pietras, RJ; Xing, Y | 1 |
| Barry, WT; Burstein, HJ; Come, SE; DeMichele, A; Guo, H; Huang Bartlett, C; Jeselsohn, R; Koehler, M; Mayer, EL; Miller, K; Mulvey, T; Overmoyer, B; Rugo, HS; Waks, AG; Winer, EP | 1 |
| Markham, A | 1 |
| Aktas, B; Barry, WT; Carey, LA; Carrasco, E; Casas, M; Cirrincione, CT; De la Haba-Rodríguez, J; Dickler, MN; Furlanetto, J; Garcia-Saenz, JA; Guerrero-Zotano, A; Hahn, O; Hudis, C; Hyslop, T; Loibl, S; Martín, M; Martinez-Jañez, N; Mehta, K; Morales, S; Partridge, A; Rodriguez-Martin, C; Winer, E | 1 |
| E Nagai, S; Futsuhara, K; Hata, S; Inoue, K; Kaneko, S; Kimizuka, K; Kurosumi, M; Nakano, S; Saito, T; Sakurai, T; Yamada, H | 1 |
| Yardley, DA | 1 |
| Dustin, D; Fuqua, SAW; Gu, G | 1 |
| Blake, RA; Chalouni, C; Chen, IP; Daemen, A; De Bruyn, T; Friedman, LS; Giltnane, JM; Guan, J; Hafner, M; Hager, JH; Hartman, SJ; Heidersbach, A; Houtman, R; Ingalla, E; Kategaya, L; Kleinheinz, T; Li, J; Martin, SE; Metcalfe, C; Modrusan, Z; Nannini, M; Oeh, J; Sampath, D; Ubhayakar, S; Wang, X; Wertz, IE; Young, A; Yu, M; Zhou, W | 1 |
| He, M; Hu, XC; Ji, L; Jiang, YZ; Li, JJ; Shao, ZM; Wang, ZH; Zuo, WJ | 1 |
| Chia, SK; Wilson, S | 1 |
| Bourgeois, H; de Boer, RH; Ferrero, JM; Gansert, JL; Jacot, W; Kaufman, PA; Kennecke, H; Loh, E; McCaffery, I; McGreivy, J; Robertson, JF; Suzuki, S; Zhu, M | 1 |
| Cope, S; Das, R; Howlett, M; Ouwens, M; Turner, P | 1 |
| Channon, E; Dixon, JM; Ellis, IO; Gee, JM; Hyman-Taylor, P; Jahan, A; Nicholson, RI; Robertson, JF; Sibbering, DM | 1 |
| Haaland, B; Lopes, G; Montero, AJ; Tan, PS | 1 |
| Coser, KR; McSweeney, KR; Rivizzigno, D; Shioda, K; Shioda, T; Yeh, WL | 1 |
| Campbell, DC; Johnston, R; McDade, SS; Nugent, S; Panov, KI; Ray, S; Waugh, D | 1 |
| Balatti, V; Byrd, JC; Cascione, L; Consiglio, J; Coppola, V; Croce, CM; De Luca, L; Freitas, MA; Gasparini, P; Guan, J; Hofmeister, CC; Lagana, A; Marcucci, G; Nuovo, G; Palmieri, D; Pichiorri, F; Piovan, C; Rocci, A; Shapiro, CL; Talabere, T; Volinia, S; You, J | 1 |
| Dowsett, M; Gao, Q; Isacke, CM; Mackay, A; Martin, LA; Morandi, A; Pancholi, S; Plaza-Menacho, I; Robertson, D; Zvelebil, M | 1 |
| Diaz, MR; Yee, D; Zhang, X | 1 |
| Buck, MB; Fritz, P; Joffroy, C; Knabbe, C; Popp, SL; Stope, MB | 1 |
| Al-Mubarak, M; Amir, E; Ocana, A; Sacher, AG; Seruga, B; Vera-Badillo, F | 1 |
| Anderson, D; Dueck, AC; Flynn, P; Northfelt, D; Perez, EA; Rowland, K; Steen, P; Tan, WW | 1 |
| Alencar, VM; Audeh, MW; Brown, K; Chan, A; de Oliveira, C; Hyams, DM; Klein, P; Lombard, J; Mookerjee, B; Snyder, R; Vinholes, J; Xu, J | 1 |
| Insawang, T; Pelden, S; Thuwajit, C; Thuwajit, P | 1 |
| Cheng, SC; Hsia, SM; Wang, KL; Wang, PS; Wang, SW; Yeh, JY | 1 |
| Belling, KC; Bjerre, C; Brünner, N; Ditzel, HJ; Do, KN; Gupta, R; Lademann, U; Lykkesfeldt, AE; Nielsen, HB; Rigina, O; Schrohl, AS; Stenvang, J; Vinther, L; Wang, J; Würtz, SØ; Yadav, R | 1 |
| Buzdar, AU | 3 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Cui, J; Leonard, M; Li, Y; Nephew, K; Zhang, L; Zhang, X | 1 |
| Giannopoulou, E; Kalofonos, HP; Koutras, AK; Lymperatou, D | 1 |
| Antoon, JW; Beckman, BS; Burow, ME; Collins-Burow, B; David, O; Elliott, S; Lai, R; Martin, EC; Nam, SY; Nephew, KP; Nitzchke, AM; Rhodes, LV; Salvo, VA; Shan, B; Tang, Y; Wang, G; Xiong, W | 1 |
| Arteaga, CL; Balko, JM; Cook, RS; Earp, HS; Hicks, DJ; Hutchinson, K; Kuba, MG; Massarweh, S; Morrison, MM; Perou, CM; Prat, A; Sánchez, V; Stanford, JC; Williams, AJ; Williams, MM; Young, C | 1 |
| Cheng, JC; Huang, HF; Leung, PC; Zhang, Y | 1 |
| Bilban, M; Giessrigl, B; Gollinger, M; Jäger, W; Jeitler, M; Kalipciyan, M; Krieger, S; Krupitza, G; Mader, RM; Schmidt, WM | 1 |
| Mehta, A; Tripathy, D | 1 |
| Agboke, FA; Creswell, K; Fan, P; Jordan, VC; McDaniel, RE; Sweeney, EE; Zou, X | 1 |
| Blakely, LJ; Houts, AC; Schwartzberg, LS; Somer, BG; Stepanski, EJ; Walker, MS; Wang, G; Wheeler, BM | 1 |
| Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J | 1 |
| Bondarenko, IN; Di Leo, A; Garnett, S; Jerusalem, G; Khasanov, R; Lichinitser, MR; Malorni, L; Martin, M; Pedrini, JL; Pendergrass, K; Petruzelka, L; Rukazenkov, Y; Smirnova, I; Torres, R; Verhoeven, D | 1 |
| Black, EP; Elledge, R; Kadamyan-Melkumian, V; Massarweh, S; Romond, E; Shelton, B; Stevens, M; Van Meter, E | 1 |
| Fujita, T; Gondo, N; Hattori, M; Horio, A; Ichikawa, M; Idota, A; Iwata, H; Kondo, N; Sawaki, M; Ushio, A | 1 |
| Harris, LN; Williams, N | 1 |
| Bulun, SE; Buranapramest, M; Coon, JS; Dubash, AD; Green, KJ; Huang, CC; Moy, I; Parker, JB; Todorović, V; Zhao, H | 1 |
| Chen, H; Chen, Y; He, Y; Li, Z; Pan, J; Shang, D; Wan, L; Wang, H; Wang, X; Zhu, Z | 1 |
| Barrow, D; Dutkowski, CM; Gee, JM; Guichard, SM; Hutcheson, IR; Jordan, NJ; Mottram, HJ; Nicholson, RI | 1 |
| Fan, W; Han, N; Huang, Y; Jiang, D; Wang, S; Xu, L; Xu, M; Zhou, L | 1 |
| Anderson, E; Hansen, A; Jensen, T; Knudsen, S; Kuter, I; Laing, N; Lindemann, J; Mazin, W | 1 |
| Hansen, SK; Kirkegaard, T; Larsen, SL; Lykkesfeldt, AE; Reiter, BE; Sørensen, BS | 1 |
| Chesney, J; Clem, AL; Clem, BF; Imbert-Fernandez, Y; Kerr, DA; Lanceta, L; O'Neal, J; Spaulding, R; Telang, S | 1 |
| Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T | 1 |
| Arroyo Vozmediano, ML; Blanco, M; Calderón, MJ; Ciruelos, E; Cortes-Funes, H; Manso, L; Muñoz, C; Parrilla, L; Pascual, T; Sancho, B; Vega, E | 1 |
| Avila, E; Barrera, D; Camacho, J; Díaz, L; Esparza-López, J; García-Becerra, R; García-Quiroz, J; Halhali, A; Ibarra-Sánchez, MJ; Larrea, F; Medina-Franco, H; Ordaz-Rosado, D; Santos-Martínez, N | 1 |
| Fan, Y; Gong, DD; Man, CF; Xu, J | 1 |
| Dolfi, SC; Haffty, BG; Hirshfield, KM; Jäger, AV; Medina, DJ; Yang, JM | 1 |
| Kirkegaard, T; Kveiborg, M; Lykkesfeldt, AE; Yde, CW | 1 |
| Abu-Asab, M; Baumann, WT; Clarke, PA; Clarke, R; Cook, KL; Hu, R; Parmar, J; Schwartz-Roberts, JL; Wärri, A | 1 |
| Bradner, J; Coarfa, C; Creighton, CJ; Feng, Q; Fu, X; He, B; Hilsenbeck, SG; Lanz, R; Mitsiades, CS; Mitsiades, N; Nardone, A; O'Malley, BW; Osborne, CK; Schiff, R; Shea, MJ; Song, Y; Wang, L; Zhang, Z | 1 |
| Elguero, S; Liu, JH; Patel, B | 1 |
| A'hern, R; Anderson, E; Anderson, H; Dowsett, M; Dunbier, AK; Gao, Q; Ghazoui, Z; Kuter, I; Lindemann, J; Mackay, A; Martin, LA; Patani, N; Ribas, R; Walker, J; Wellings, R | 1 |
| Califaretti, N; Chia, SK; Clemons, MJ; Cochrane, B; Dent, RA; Levine, MN; Parpia, S; Pond, GR; Pritchard, KI; Rayson, D; Robidoux, A; Song, X; Warr, D | 1 |
| Clarke, PA; Clarke, R; Cook, KL; Cruz, MI; Soto-Pantoja, DR; Wärri, A; Zwart, A | 1 |
| Arteaga, CL; Chen, H; Gagea, M; González-Angulo, AM; Liu, S; Liu, W; Lu, Y; Meng, X; Meric-Bernstam, F; Miller, T; Mills, GB; Murph, M; Zhang, F | 1 |
| Filardo, EJ; Huang, A; Magruder, HT; Quinn, JA; Reichner, J; Schwartzbauer, JE | 1 |
| Deng, H; Liu, LJ; Wang, ML; Wang, ZY; Yin, L; Zhang, XT | 1 |
| Andò, S; Barone, I; Brown, PH; Fuqua, SA; Iacopetta, D; O'Malley, BW; Rechoum, Y; Rovito, D; Weigel, NL | 1 |
| Al-Qaisi, A; Awasthi, M; Chen, A; Chen, L; Kadamyan-Melkumyan, V; Massarweh, S; Romond, E | 1 |
| Anur, P; Biswal, NC; Contreras, A; Creighton, CJ; Davies, BR; Fu, X; Giuliano, M; Gray, JW; Guichard, SM; Gutierrez, C; Heiser, LM; Herrera, S; Hilsenbeck, SG; Joshi, A; Karlin, KL; Klinowska, T; Kumar, V; Lee, AV; Mills, GB; Morrison, G; Nanda, S; Nardone, A; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Smith, PD; Spellman, P; Wang, T; Westbrook, TF | 1 |
| Auclair, C; Bièche, I; Karam, M; Legay, C; Ricort, JM; Vacher, S | 1 |
| Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ | 1 |
| Barry, WT; Blackwell, KL; Burstein, HJ; Chew, HK; Cirrincione, CT; Hudis, CA; Lake, DE; Ma, C; Tolaney, SM; Winer, EP | 1 |
| Bak, M; Duun-Henriksen, AK; Kirkegaard, T; Lykkesfeldt, AE; Lænkholm, AV; Pedersen, AM; Rasmussen, BB; Thomsen, MB; Thrane, S; Yde, CW | 1 |
| Brown, M; de Vries, EF; de Vries, EG; Glaudemans, AW; Hospers, GA; Kema, IP; Schröder, CP; van Faassen, M; van Kruchten, M; van Lanschot, MC | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Anderson, E; Garnett, S; Gee, JM; Kuter, I; Lindemann, J; Nicholson, RI; Robertson, JF | 1 |
| Abramson, V; Allen, EV; Arteaga, CL; Bafna, S; Balko, JM; Bhola, NE; Dugger, TC; Estrada, MV; Giltnane, JM; Jansen, VM; Mayer, I; Meszoely, I; Sanders, M; Ye, F | 1 |
| Agarwal, VR; Barth, RJ; Bean, JR; Chen, VS; Dillon, LM; Hosford, SR; Marotti, JD; Miller, TW; Muller, KE; Owens, P; Rosenkranz, KM; Schwartz, GN; Shee, K; Symonds, LK; Yang, W | 1 |
| Kanomata, N; Kurebayashi, J; Moriya, T; Shimo, T; Yamashita, T | 1 |
| Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P | 1 |
| Deng, F; Esfahani, SA; Heidari, P; Leece, AK; Mahmood, U; Shoup, TM; Vasdev, N | 1 |
| Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW | 1 |
| Anzeneder, T; Benes, V; Burwinkel, B; Büttner, R; Deuschle, U; Heck, S; Lichter, P; Nicholson, RI; Sauter, G; Schlotter, M; Schneeweiss, A; Schroeter, P; Simon, R; Sinn, HP; Thewes, V; Zapatka, M | 1 |
| Anderson, L; Chen, D; Conklin, D; Dering, J; Desai, AJ; Finn, RS; Hurvitz, SA; Kalous, O; Kolarova, T; Linnartz, R; O'Brien, NA; Slamon, DJ | 1 |
| Iwase, H; Yamamoto, Y | 1 |
| Chen, S; Chen, Z; Wang, Y; Warden, C | 1 |
| Aktas, B; Anton, A; Carrasco, E; De la Haba-Rodriguez, JR; Garcia-Saenz, JÁ; Gil, M; Guerrero, A; Liedtke, C; Loibl, S; Margeli, M; Martín, M; Martinez, N; Mehta, K; Morales, S; Muñoz, M; Ramos, M; Schoenegg, W; von Minckwitz, G; Wachsmann, G | 1 |
| Munster, PN; Park, J; Raha, P; Thomas, S; Thurn, KT | 1 |
| Choi, KC; Go, RE; Hwang, KA; In, SJ; Kim, SH | 1 |
| Di Leo, A; Guarducci, C; Hart, CD; Malorni, L; Migliaccio, I | 1 |
| Qi, X; Ren, K; Song, J; Wang, J | 1 |
| Bak, M; Duun-Henriksen, AK; Kirkegaard, T; Laenkholm, AV; Larsen, SL; Lykkesfeldt, AE; Rasmussen, BB; Yde, CW | 1 |
| Berset, C; Hasler-Strub, U; Hawle, H; Mamot, C; Mueller, A; Neven, P; Perey, L; Rochlitz, C; Rondeau, S; Rudolf, CB; Wiliders, H; Winterhalder, R; Zaman, K | 1 |
| Araki, K; Fukada, I; Hosoda, M; Ichinokawa, K; Ishida, N; Ito, Y; Iwase, T; Kobayashi, K; Kobayashi, T; Sakai, T; Takahashi, S; Yamamoto, M; Yamashita, H | 1 |
| Cheng, J; Hong, Q; Jia, X; Lei, L; Li, D; Li, J; Liu, G; Mo, M; Shao, Z; Shen, Z; Wang, Y | 1 |
| Benes, P; Brezovsky, J; Daniel, L; Nehybova, T; Smarda, J | 1 |
| Alley, HM; Arndt, KT; Crowder, R; Dann, SG; Eisele, K; Ellis, MJ; Griffin, E; Lai, JP; Li, S; McDonnell, DP; Norris, JD; Primeau, T; Shao, J; VanArsdale, T; Wardell, SE | 1 |
| André, F; Cristofanilli, M; Giorgetti, C; Harbeck, N; Huang Bartlett, C; Iwata, H; Koehler, M; Loi, S; Loibl, S; Randolph, S; Ro, J; Turner, NC; Verma, S; Zhang, K | 1 |
| Harding, E | 1 |
| Campbell, H; Davies, BR; Dowsett, M; Gao, Q; Guest, SK; Johnston, S; Liccardi, G; Marangoni, E; Martin, LA; Pancholi, S; Polanska, UM; Rani, A; Ribas, R; Simigdala, N; Thuleau, A | 1 |
| Bachelot, T; Bally, O; Heudel, P; Kassem, L; Tredan, O; Vanacker, H | 1 |
| Aurisicchio, L; Ciliberto, G; Cook, RS; Hicks, D; Lim, J; McKernan, C; Morrison, MM; Simion, C; Sweeney, C; Vaught, DB; Williams, MM | 1 |
| Chan, HJ; Chen, S; Li, H; Liu, Z; Mortimer, J; Yuan, YC | 1 |
| Bachelot, T; Bonnefoi, H; Breton-Callu, C; Dalenc, F; Daly, C; de Lara, CT; Debled, M; Fournier, M; Gros, A; Iggo, R; Lortal, B; MacGrogan, G; Madranges, N; Mauriac, L; Nikolski, M; Pulido, M; Quenel-Tueux, N; Rabbitts, P; Rudewicz, J; Soueidan, H; Wood, H | 1 |
| Agrawal, A; Cheung, KL; Ellis, IO; Gee, JM; Gutteridge, E; Nicholson, RI; Robertson, JF | 1 |
| Alnæs, GI; Bhanot, G; Bjørklund, SS; Børresen-Dale, AL; Ganesan, S; Kerrigan, J; Kristensen, VN; Kumar, S; Ming, Y; Naume, B; Sachidanandam, R; Seiler, M | 1 |
| Egawa, C; Okishiro, M; Takatsuka, Y | 1 |
| Hao, Y; Koo, V; Li, N; Lin, PL; Ohashi, E; Rogerio, J; Wu, EQ; Xie, J | 1 |
| Cygankiewicz, AI; Jacenik, D; Krajewska, WM | 1 |
| Komm, BS; Pickar, JH | 1 |
| Caprioglio, D; Fletcher, SP | 1 |
| Berger, D; Fattout, Y; Kazlauskaite, R; Usha, L; Waheed, S | 1 |
| Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R | 1 |
| Laczó, I; Landherr, L; Nagykálnai, T; Pikó, B | 1 |
| Bigley, G; Bihani, T; Chresta, CM; Cosulich, SC; Curwen, J; D'Cruz, CM; Davies, BR; Delpuech, O; Green, S; Grondine, M; Guichard, SM; Howard, Z; Klinowska, T; McEwen, R; Pass, M; Pike, KG; Polanska, UM; Yates, JW | 1 |
| Ali, S; Balasubramanian, S; Chenna, A; Chumsri, S; DeFazio-Eli, L; DeRidder, A; Goicocheal, L; Huang, W; Perez, EA; Wallweber, G; Weidler, J | 1 |
| Dewar, JA; Ellis, MJ; Feltl, D; Hewson, N; Jasiówka, M; Llombart-Cussac, A; Robertson, JF; Rukazenkov, Y | 1 |
| Acar, A; Alférez, DG; Andó, S; Brennan, K; Catalano, S; Chemi, F; Clarke, RB; Eyre, R; Farnie, G; Gandhi, A; Gee, J; Howell, A; Howell, SJ; Landberg, G; Marangoni, E; O'Brien, CS; Rydén, L; Santiago-Gómez, A; Sarmiento-Castro, A; Silva, A; Simões, BM; Sims, AH; Spence, K; Ucar, A; Yu, L | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Adachi, K; Amano, S; Enomoto, K; Fujisaki, S; Gonda, K; Masuo, Y; Matsuo, S; Nagashima, S; Sakurai, K; Suzuki, S; Tomita, R; Umeda, N | 1 |
| Dittmer, A; Dittmer, J; Lange, T; Leyh, B; Martens, JW | 1 |
| Kimura-Tsuchiya, R; Saji, S; Sasaki, E | 1 |
| Akiyama, F; Araki, K; Horii, R; Ishida, N; Ito, Y; Ohno, S; Takahashi, S | 1 |
| Ademuyiwa, F; Ellis, MJ; Griffith, M; Griffith, OL; Guo, Z; Han, J; Hoog, J; Lockhart, C; Luo, J; Ma, CX; Mardis, E; Nagaraj, G; Naughton, M; Pluard, T; Ramu, A; Skidmore, ZL; Spies, NC; Suresh, R; Thomas, S; Trani, L | 1 |
| Andrews, P; Carter, B; Gai, L; Kao, KR; Popadiuk, C; Tzenov, YR; Voisey, K; Whelan, K | 1 |
| Li, Y; Liu, Y; Liu, Z; Luo, A; Qu, X; Shi, W; Wang, S; Yu, X | 1 |
| Bates, D; Bean, JR; Demidenko, E; Dillon, LM; Eastman, AR; Hosford, SR; Lewis, LD; Liu, SC; Marotti, JD; Miller, TW; Nannini, MA; Pang, J; Salphati, L; Shee, K; Yang, W; Zhang, X | 1 |
| Creekmore, A; Crowder, R; Doyle, A; Ellis, MJ; Erlichman, C; Gao, F; Guo, Z; Hoog, J; Lockhart, AC; Ma, CX; Naughton, M; Pluard, T; Sanchez, C | 1 |
| Jiang, T; Li, C; Li, R; Qu, X; Shi, W; Wang, Y; Yu, X | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, J; Hayes, DF; Hertz, DL; Hortobagyi, GN; Kidwell, KM; Livingston, RB; Mehta, RS; Rae, JM; Tirumali, NR; Vandenberg, TA | 1 |
| Amir, E; Gordon, V; Graham, J; Grenier, D; Niraula, S; Pitz, M | 1 |
| Adamson, D; Mayne, K | 1 |
| Bartlett, CH; Bondarenko, I; Colleoni, M; Cristofanilli, M; DeMichele, A; Harbeck, N; Im, SA; Iwata, H; Jiang, Y; Koehler, M; Loi, S; Masuda, N; Ro, J; Slamon, D; Theall, KP; Turner, NC; Verma, S; Zhang, K | 1 |
| Batson, S; Jones, N; Livings, C; Telford, C | 1 |
| André, F; Bartlett, CH; Bhattacharyya, H; Cristofanilli, M; Harbeck, N; Iwata, H; Iyer, S; Loi, S; Loibl, S; Puyana Theall, K; Ro, J; Turner, N; Verma, S | 1 |
| Ahmed, Y; Chen, H; Hu, L; Li, D; Li, Z; Negi, H; Wu, Z; Zheng, Y; Zhu, Q | 1 |
| Capper, CP; Johnson, MD; Larios, JM; Rae, JM; Sikora, MJ | 1 |
| de Boer, R; Derynck, M; Dickler, M; Ellis, M; Forero-Torres, A; Ganju, V; Gendreau, S; He, J; Johnston, S; Krop, IE; Lackner, M; Lee, SC; Levy, G; Mayer, IA; Melichar, B; Morales, S; Perez, EA; Petrakova, K; Piccart, M; Qiu, J; Schmid, P; Vallentin, S; Winer, E; Yardley, DA | 1 |
| Aimi, J; Amler, LC; Chan, IT; Chen, M; Derynck, MK; Gendreau, S; Hampton, GM; Johnston, S; Krop, I; Lackner, MR; Qiu, J; Savage, H; Schmid, P; Spoerke, JM; Walter, K; Wilson, TR | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Festinese, F; Galli, G; Ganzinelli, M; Gevorgyan, A; Lo Vullo, S; Mariani, L; Martinetti, A; Sottotetti, E | 1 |
| Nakai, M; Takei, H; Uchida, E; Yamashita, K; Yanagihara, K | 1 |
| Barry, WT; Biagioni, C; Bonechi, M; Brown, M; De Tribolet-Hardy, J; Guarducci, C; Jeselsohn, R; Laing, N; Leo, AD; Malorni, L; Migliaccio, I; Winer, EP; Zhao, J | 1 |
| Beyer, JM; Dittmer, A; Dittmer, J; Hellwig, V; Ignatov, A; Kalinski, T; Kirkegaard, T; Lange, T; Leyh, B; Lykkesfeldt, AE; Nass, N; Weiβenborn, C | 1 |
| Hirakawa, H; Ishida, T; Iwabuchi, E; Miki, Y; Ohuchi, N; Ono, K; Onodera, Y; Sasano, H; Suzuki, T | 1 |
| Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Alran, S; Balleyguier, C; Becette, V; Bourgier, C; Boussion, V; Cherel, P; Kerbrat, P; Lavau-Denes, S; Lemonnier, J; Lerebours, F; Martin, AL; Mathieu, MC; Mouret-Fourme, E; Mouret-Reynier, MA; Nabholz, JM; Rivera, S; Salmon, R; Sigal, B; Thibault, F; Trassard, M; Venat-Bouvet, L | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Currin, ER; Krohn, KA; Kurland, BF; Lee, JH; Linden, HM; Link, JM; Mankoff, DA; Peterson, LM; Schubert, EK | 1 |
| Chen, H; Feng, J; Gu, K; Jiang, Z; Li, L; Rukazenkov, Y; Shao, Z; Shen, K; Sun, G; Tong, Z; Wang, X; Xu, B; Zhang, Q | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, AM; Harbeck, N; Iwata, H; Loi, S; Ro, J; Rugo, HS; Schnell, P; Thiele, A; Turner, NC; Verma, S; Zhang, K | 1 |
| Basile, I; Gallud, A; Garcia, M; Gary-Bobo, M; Maynadier, M | 1 |
| Amiri-Kordestani, L; Bloomquist, E; Chen, W; Fourie Zirkelbach, J; Fu, W; Kim, G; Kluetz, PG; Liu, Q; McKee, AE; Palmby, TR; Pazdur, R; Sridhara, R; Tang, S; Tilley, A; Walker, AJ; Wedam, S | 1 |
| Bonnefoi, H; Grellety, T; Iggo, R; MacGrogan, G; Richard, E; Velasco, V | 1 |
| Bao, H; Barry, E; Bihani, T; Bradford, J; Collins, M; D'Cruz, CM; Fawell, S; Goeppert, AU; Hearne, K; Hollingsworth, R; Hurt, E; Jalla, S; Ladd, B; Lai, Z; Mazzola, AM; Mohseni, M; Reimer, C; Renshaw, JG; Weir, HM; Zinda, M | 1 |
| Abrahamsson, A; Dabrosin, C; Mishra, AK | 1 |
| Blondeaux, E; Del Mastro, L; Lambertini, M; Levaggi, A; Poggio, F; Pronzato, P; Vaglica, M | 1 |
| Katzenellenbogen, BS; Piccart, M; Tryfonidis, K; Zardavas, D | 1 |
| Niraula, S; Ocana, A | 1 |
| Kim, JE; Livezey, M; Mao, C; Shapiro, DJ | 1 |
| Arachchige-Don, AP; Donaldson, MS; Horne, MC; Patriarchi, T; Zimmermann, M | 1 |
| Adachi, K; Enomoto, K; Fujisaki, S; Gonda, K; Hara, Y; Hirano, T; Masuo, Y; Nagashima, S; Sakurai, K; Suzuki, S; Tomita, R | 1 |
| Benos, PV; Goff, JP; Huang, J; Normolle, D; Stehle, CJ; Steinman, RA; Woods, P | 1 |
| Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C | 1 |
| Adhikari, VP; Dai, W; Kong, LQ; Li, X; Luo, QQ; Wu, H; Wu, KN; Wu, YT; Zhao, CX | 1 |
| Fukumitsu, C; Hattori, S; Ito, KI; Izumi, H; Kage, M; Kawahara, A; Kuwano, M; Murakami, Y; Ohdo, S; Ono, M; Shibata, T; Takahashi, R; Tanaka, M; Toh, U; Watari, K | 1 |
| Fujii, R; Gohno, T; Hanamura, T; Hayashi, SI; Kaneko, Y; Nagatomo, T; Niwa, T; Tsuboi, K; Yamaguchi, Y | 1 |
| Bondarenko, IM; Cardona-Huerta, S; Cheung, KL; Dvorkin, M; Ellis, MJ; Fazal, M; Grinsted, LM; Manikhas, A; Noguchi, S; Panasci, L; Philco-Salas, MJ; Robertson, JFR; Rowbottom, J; Ruiz-Borrego, M; Shao, Z; Shparyk, Y; Stuart, M; Trishkina, E | 1 |
| Baselga, J; Carlson, KE; Chandarlapaty, S; De Stanchina, E; Fanning, S; Goeppert, AU; Greene, G; Katzenellenbogen, JA; Lawson, M; Li, Z; Martin, TS; Mazzola, AM; Morrow, C; Razavi, P; Smith, A; Toy, W; Uddin, S; Weir, H; Wilson, J; Wong, WL | 1 |
| Fan, W; Huang, Y; Jiang, D; Sui, M; Wang, X | 1 |
| Berger, K; Gligorov, J; Lewis, J; Maass, N; MacDougall, F; Marchetti, P; Montonen, J | 1 |
| Goodwin, A; Lee, CI; Wilcken, N | 1 |
| Bai, F; Chen, Q; Ding, L; Ge, M; Jia, Y; Lin, Q; Lu, Y; Weng, Z; Wu, K | 1 |
| Bruzzone, A; Copsel, S; Davio, C; Gargiulo, L; Lamb, C; Lanari, C; Lüthy, IA; Lydon, J; May, M; Rivero, EM | 1 |
| Endo, T; Hasegawa, K; Higashi, Y; Kamiya, A; Kaneko, J; Kondo, I; Maejima, S; Takatsuno, Y | 1 |
| Altilia, S; Broude, EV; Chen, M; Chumanevich, AA; Győrffy, B; Kiaris, H; Liang, J; Lim, CU; McDermott, MS; Oliver, D; Rae, JM; Roninson, IB; Shtutman, M | 1 |
| André, F; Barrios, CH; Blackwell, K; Bonnefoi, H; Campone, M; Cortes, J; Denduluri, N; Deudon, S; Kahan, Z; Musolino, A; Neven, P; Shi, MM; Soliman, H; Squires, M; Zhang, Y | 1 |
| Bai, J; Hu, Y; Liu, J; Qiu, Y; Zhang, J; Zhang, S; Zhao, J; Zhou, G | 1 |
| Casa, AJ; Cui, X; Dearth, RK; Lee, AV; Litzenburger, BC | 1 |
| Buijs, C; de Vries, EG; Mourits, MJ; Willemse, PH | 1 |
| Kabil, A; Kortenkamp, A; Silva, E | 1 |
| Ben-Yosef, R; Greenberg, J; Inbar, M; Ron, IG; Safra, T; Sarid, D; Yaal-Hahoshen, N | 1 |
| Bigsby, RM; Fan, M; Long, X; Nephew, KP | 1 |
| Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F | 1 |
| Bartsch, R; Gnant, M; Greil, R; Mlineritsch, B; Niernberger, T; Pluschnig, U; Pober, M; Rudas, M; Sevelda, P; Steger, GG; Thaler, J; Wenzel, C; Zielinski, CC | 1 |
| Flemming, J; Franek, JA; Madarnas, Y | 1 |
| Han, SW; Imai, Y; Miyake, J; Nakamura, C; Nakamura, N | 1 |
| McCormack, P; Sapunar, F | 1 |
| Gust, R; Kleuser, B; Malek, D; Pertz, HH; Potteck, H | 1 |
| Creighton, CJ; Hilsenbeck, SG; Huang, S; Malorni, L; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Tsimelzon, A | 1 |
| Kallen, CB; Wang, C; Yu, J | 1 |
| Bieche, I; Cohen, PA; Dumontet, C; Ghayad, SE; Lidereau, R; Spyratos, F; Treilleux, I; Vendrell, JA | 1 |
| Aktary, Z; Andrews, DW; Hu, X; Lam, L; Pasdar, M | 1 |
| Cameron, DA; Camidge, DR; Hirsch, M; Oyee, J | 1 |
| Bines, J; Mauriac, L; Romieu, G | 1 |
| Cheung, KL; Rampaul, RS; Tang, JY | 1 |
| Christiaens, MR; Konstantinovic, ML; Morales, L; Neven, P; Paridaens, R; Tan, PN; Timmerman, D; Wildiers, H | 1 |
| Harbeck, N; Hartmann, M; Jackisch, C; Lux, MP; Oyee, J; Possinger, K; Raab, G; Schneeweiss, A | 1 |
| Christos, PJ; Hershman, DL; Hoschander, S; Li, T; O'Brien, K; Sparano, JA; Vahdat, LT; Wright, JJ | 1 |
| Davis, FB; Davis, PJ; Lin, C; Lin, HY; London, D; Shih, A; Sun, M; Tang, HY | 1 |
| Darbre, PD; Pugazhendhi, D; Sadler, AJ | 1 |
| Aranda, A; González, JJ; González, L; Lazaro-Trueba, I; Lopéz, E; Martín-Pérez, J; Zambrano, A | 1 |
| Gray, WG; Harris, K; Naragoni, S; Sankella, S | 1 |
| Pan, Z; Tan, H; Zhong, Y | 1 |
| Aiyar, S; Fan, P; Kim, TH; Li, Y; Santen, RJ; Wang, JP; Yue, W | 1 |
| Harichand-Herdt, S; O'Regan, R; Zelnak, A | 1 |
| Kanbe, Y; Kwon, LS; Lee, MH; Lee, YH; Morikawa, K; Taniguchi, K; Tsunenari, T; Yamada-Okabe, H; Yoneya, T | 1 |
| Aleskandarany, M; Ball, G; Douglas Macmillan, R; Ellis, IO; Gee, JM; Green, AR; Habashy, HO; Nicholson, RI; Paish, EC; Powe, DG; Rakha, EA; Staka, CM | 1 |
| Dougherty, SM; Klinge, CM; Li, Y; Manavalan, TT; Riggs, KA; Wickramasinghe, NS | 1 |
| Ben-Jonathan, N; Fox, SR; Lapensee, EW; Tuttle, TR | 1 |
| Büssemaker, E; Hagedorn, C; Hausberg, M; Hillebrand, U; Kliche, K; Lang, D; Oberleithner, H; Pavenstädt, H; Reuter, S; Stock, CM; Telgmann, RG | 1 |
| Alonso Muñoz, A; García Alfonso, P; Martínez Marín, V; Muñoz Martín, AJ; Pérez Manga, G; Viñuela Benéitez, MC | 1 |
| Casazza, G; Georgoulias, V; Mauri, D; Mavroudis, D; Polyzos, NP; Valachis, A | 1 |
| Hyder, SM; Liang, Y; Wu, J | 1 |
| Keely, NO; Meegan, MJ | 1 |
| Cho, Y; Clarke, R; Crawford, A; Liu, MC; Nehra, R; Riggins, RB; Shajahan, AN; Wang, Y; Xuan, J; Zwart, A | 1 |
| Flinois, A; Piedbois, P; Thomas-Delecourt, F | 1 |
| Agrawal, A; Cheung, KL; Eastell, R; Hannon, RA; Robertson, JF | 1 |
| Dumontet, C; Ferlini, C; Matera, EL; Saussede-Aim, J | 1 |
| Lianidou, E; Moutsatsou, P; Papoutsi, Z; Strati, A | 1 |
| Cheng, P; Hershberger, PA; Kanterewicz, B; Liu, Y; McCarty, KS; Nichols, M | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Ahmad, I; Amir, E; Chia, S; Clemons, M; Dent, S; Dranitsaris, G; Fralick, M; Freedman, O; Kumar, R; Napolskikh, J; Petrella, T; Rayson, D; Tonkin, K | 1 |
| Amoroso, D; Camerini, A; Donati, S; Garrone, O; Mattiot, VP; Porta, RP; Puccetti, C; Puccinelli, P; Rondini, M; Sgambato, A; Siclari, O; Tartarelli, G; Valsuani, C; Vincenti, M | 1 |
| Conte, P; Frassoldati, A; Guarneri, V | 1 |
| Benn, GK; Bennett, JA; Englert, NA; Goodenough, AK; Lostritto, N; Pentecost, BT; Spink, BC; Spink, DC; Turesky, RJ | 1 |
| Fan, W; Hinsch, C; Jiang, D; Sui, M | 1 |
| Benjaminsen, RV; Christiansen, IJ; Emdal, KB; Frogne, T; Kirkegaard, T; Lykkesfeldt, AE; Norrie, IC; Sonne-Hansen, K | 1 |
| Dewar, J; Ellis, MJ; Feltl, D; Lindemann, J; Llombart-Cussac, A; Macpherson, E; Robertson, JF; Rolski, J | 1 |
| Collins, SC; Coser, KR; Isselbacher, KJ; Mahoney, CJ; Melas, A; Ramaswamy, S; Rosenthal, NF; Shioda, K; Shioda, T; Smith, SL; Wittner, BS | 1 |
| Miles, DW | 1 |
| Bao, Y; Chen, Y; Fan, P; Santen, RJ; Song, RX; Wang, JP; Yue, W; Zhang, Z | 1 |
| Kang, L; Wang, ZY | 1 |
| Barni, S; Gieseking, F; Kaufman, B; Neven, P; Nolè, F; O'Malley, FP; Petruzelka, L; Pritchard, KI; Robertson, JFR; Simon, SD; Steger, GG | 1 |
| Alvarez, L; Bergoc, R; Cocca, C; de Pisarev, DK; García, MA; Peña, D; Pontillo, C; Randi, A | 1 |
| Goerse, R; Haselberger, M; Konwisorz, A; Ortmann, O; Springwald, A; Treeck, O | 1 |
| Baumann, CK; Castiglione-Gertsch, M | 1 |
| Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P | 1 |
| Fan, M; Long, X; Nephew, KP | 1 |
| Badve, S; Bhat-Nakshatri, P; McCune, K; Nakshatri, H; Nephew, KP; Thorat, MA | 1 |
| Byrne, C; Donley, C; Hirst, DG; Jithesh, PV; McCarthy, HO; McKeen, HD; O'Rourke, M; Robson, T; Swanton, C; Valentine, A; Yakkundi, A | 1 |
| Cuesta-Rubio, O; Morello, S; Piccinelli, LA; Pinto, A; Popolo, A; Rastrelli, L; Sorrentino, R | 1 |
| Buck, MB; Joffroy, CM; Knabbe, C; Pfizenmaier, K; Popp, SL; Stope, MB | 1 |
| Borges, VF; Kabos, P | 1 |
| Cheung, KL; Johnston, SJ | 1 |
| Ashworth, A; Geyer, F; Gillett, C; Grigoriadis, A; Iorns, E; Lambros, M; Lopez-Garcia, MA; Mackay, A; Marchio, C; Natrajan, R; Pearson, A; Reis-Filho, JS; Sharpe, R; Turner, N; Tutt, A | 1 |
| Constantinidou, D; Coombes, RC; Hartman, J; Kwok, JM; Lam, EW; Lykkesfeldt, AE; Medema, RH; Millour, J; Myatt, SS; Sivanandan, K; Stavropoulou, AV; Wilson, MS | 1 |
| Birnbaumer, L; Li, Y; Teng, CT | 1 |
| Kawabata, L; Louie, MC; McClellan, A; Siewit, C | 1 |
| Benevides, CF; Chinen, LT; da Silva, SC; do Nascimento Matias, C; Fanelli, MF; Gimenes, DL; Mello, CA | 1 |
| Barnfather, P; Barrett-Lee, P; Bramble, P; Christensen, J; Hayes, E; Hiscox, S; Nicholson, RI | 1 |
| Albergaria, A; Carneiro, V; Machado, JC; Milanezi, F; Oliveira, C; Paredes, J; Pinho, S; Ribeiro, AS; Schmitt, F; Seruca, R; Sousa, B; Sousa, S | 1 |
| Desta, Z; Johnson, MD; Rae, JM; Sikora, MJ | 1 |
| Chung, H; Clarke, R; Mulla, JE; Ning, Y; Riggins, RB; Zwart, A | 1 |
| Brown, JQ; Lem, S; McMahon, CM; Millon, SR; Ostrander, JH; Ramanujam, N; Seewaldt, VL | 1 |
| Iwase, H; Iwata, H; Kamigaki, S; Masuda, N; Nakamura, S; Noguchi, S; Ohno, S; Rai, Y; Taniguchi, H; Yamamoto, N; Yoshida, M | 1 |
| Bald, L; Fayadat-Dilman, L; Grein, J; Hudak, S; Janatpour, MJ; Sathe, M; Vanderlaag, KE | 1 |
| Anaganti, S; Fernandez-Cuesta, L; Hainaut, P; Olivier, M | 1 |
| Doihara, H; Fujita, T; Hara, F; Ikeda, H; Miyoshi, S; Nogami, T; Shien, T; Soh, J; Taira, N; Toyooka, S; Yamamoto, H | 1 |
| Cardoso, F; Chang, J; Fukase, K; Ianuli, C; Kahan, Z; Lindemann, JP; Macpherson, MP; Mauriac, L; Neven, P; Panasci, L; Papai, Z; Pritchard, KI; Rolski, J | 1 |
| Drabsch, Y; Gonda, TJ; Robert, RG | 1 |
| Dye, WW; Elias, A; Finlayson, C; Haughian, JM; Horwitz, KB; Kabos, P; Sartorius, CA; Wang, X | 1 |
| Alvarez, EA; Azzam, D; Chen, Y; Guggisberg, N; Hennessy, BT; Jordà, M; Ju, Z; Slingerland, JM; Wander, SA | 1 |
| Nemacheck, B | 1 |
| Macpherson, L; Matthews, J | 1 |
| Bondarenko, IN; Di Leo, A; Garnett, S; Jerusalem, G; Khasanov, R; Lichinitser, MR; Lindemann, JP; Martin, M; Pedrini, JL; Pendergrass, K; Petruzelka, L; Sapunar, F; Smirnova, I; Torres, R; Verhoeven, D | 1 |
| Bergh, J; Howell, A | 1 |
| Chen, Z; Feng, J; Gu, K; Jiang, Z; Shao, Z; Song, S; Wang, C; Wang, J; Xu, B; Yang, J; Yu, S; Zhang, F; Zhang, Y | 1 |
| Harbeck, N; Kates, R; Overkamp, F; Thomas, A; Warm, M | 1 |
| Burow, ME; Croce, CM; Devlin, C; Di Leva, G; Fang, F; Hartman-Frey, C; Ivan, M; Li, M; Nephew, KP; Rao, X | 1 |
| Blackmore, JK; Foster, EA; Karmakar, S; Smith, CL | 1 |
| Chen, S; Masri, S; Phung, S; Smith, D; Wang, Y; Zhou, D | 1 |
| Beckman, BS; Bratton, MR; Burow, ME; Collins-Burow, BM; Curiel, TJ; Dent, P; Elliott, S; Fonseca, JP; Fuqua, SA; Horton, LW; Hung, MC; Muir, SE; Neel, NF; Nephew, KP; Rhodes, LV; Richmond, A; Salvo, VA; Segar, C; Short, SP; Sobolik-Delmaire, T; Sun, M; Tilghman, SL; Wadsworth, S; Wei, Y; Wood, CE; Worthylake, RA; Yu, D; Zaja-Milatovic, S; Zhu, Y | 1 |
| Grandison, PM; Kang, J; Kannan, N; Kong, X; Liu, DX; Liu, ET; Lobie, PE; Mertani, HC; Miller, LD; Mohankumar, KM; Perry, JK; Tang, J; Zhu, T | 1 |
| Feng, J; He, H; Hu, Q; Huang, J; Wang, X; Yang, F; Zeng, X | 1 |
| Hayes, E; Hiscox, S; Nicholson, RI | 1 |
| Aguirre-Ghiso, J; Bahadur, U; Germain, D; Ishii, Y; Papa, L; Shioda, T; Waxman, S; Yue, Z | 1 |
| Aubé, M; Ayotte, P; Larochelle, C | 1 |
| Croxtall, JD; McKeage, K | 1 |
| Coombes, RC; Januszewski, A; Palmieri, C; Stanway, S | 1 |
| Di Leo, A; Moretti, E; Oakman, C; Santarpia, L | 1 |
| Crowder, RJ; Ellis, MJ; Gao, F; Guintoli, T; Lin, L; Ma, CX; Phommaly, C; Sanchez, CG | 1 |
| Barrow, D; Francies, HE; Gee, JM; Goddard, L; Hutcheson, IR; Knowlden, JM; McClelland, RA; Nicholson, RI | 1 |
| Dowsett, M; Dunbier, A; Ghazoui, Z; Johnston, S; Martin, LA; Pancholi, S; Weigel, MT | 1 |
| Lo, YH; Wang, SC; Yu, L; Zhao, H | 1 |
| Cahill, MA; Fehm, T; Mueck, AO; Neubauer, H; Ruan, X; Seeger, H; Tong, X; Yang, Y | 1 |
| Ao, A; López, JA; Lu, J; Morrison, BJ; Reynolds, BA; Wang, H | 1 |
| Brown, PH; Casa, AJ; Creighton, CJ; Hilsenbeck, SG; Kim, HT; Kuiatse, I; Lazard, Z; Lee, AV; Malik, S; Oesterreich, S; Potter, AS; Tsimelzon, A | 1 |
| de Bont, H; Meerman, J; Moerkens, M; Price, L; Ramaiahgari, S; van de Water, B; Zhang, Y | 1 |
| Arrowsmith, E; Barton, J; Burris, HA; Clark, BL; Hainsworth, JD; Rubin, M; Shipley, D; Yardley, DA | 1 |
| Allen, JD; Alling, N; Haass, NK; Jackson, EA; Martinello-Wilks, R; McGowan, EM; Yagoub, D | 1 |
| Brown, M; Come, SE; Scott, SM | 1 |
| Howell, A; Sapunar, F | 1 |
| Ellis, GK; Gralow, JR; Krohn, KA; Kurland, BF; Lawton, TJ; Linden, HM; Link, JM; Livingston, RB; Mankoff, DA; Peterson, LM; Petra, PH; Schubert, EK; Specht, JM | 1 |
| Stanczyk, FZ | 1 |
| Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H | 1 |
| Knowles, MA; Speirs, V; Tomlinson, DC | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Hirsh, AS; Janarthanan, S; Joung, JK; Lang, M; Lee, J; Maeder, ML; McDermott, U; Ramaswamy, S; Sgroi, DC; Singavarapu, R; Wittner, BS; Yajnik, V | 1 |
| Amano, J; Ito, K; Ito, T; Izumi, H; Kamijo, S; Kohno, K | 1 |
| Arteaga, CL; Balko, JM; Buck, E; Fox, EM; González-Angulo, AM; Kuba, MG; Liu, S; Manning, HC; Miller, TW; Mills, GB; Sánchez, V; Shyr, Y; Smith, RA; Ye, F | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| de Cremoux, P | 1 |
| Flomenberg, N; Goldberg, A; Howell, A; Ko, YH; Lin, Z; Lisanti, MP; Martinez-Outschoorn, UE; Pavlides, S; Pestell, RG; Sotgia, F; Wang, C | 1 |
| Brodie, A; Carboni, JM; Finckenstein, FG; Gottardis, MM; Greer, A; Haluska, P; Harrington, SC; Hou, X; Huang, F; Macedo, LF; Reeves, KA | 1 |
| Januszewski, A; Krell, J; Palmieri, C; Yan, K | 1 |
| Litsas, G | 1 |
| Castanas, E; Kampa, M; Notas, G; Pelekanou, V | 1 |
| Beauchemin, D; Lacombe, C; Van Themsche, C | 1 |
| Oliver, J; Roca, P; Sastre-Serra, J; Valle, A | 1 |
| Schad, A; Schmidt, M; Sleeman, JP; Thaler, S | 1 |
| Ding, L; Kang, L; Wang, ZY; Zhang, X | 1 |
| Anderson, E; Badwe, RA; Bines, J; Emeribe, UA; Finlay, P; Gee, JM; Harbeck, N; Hegg, R; Kuter, I; Lowe, ES; Nicholson, RI; Sapunar, F; Singer, CF | 1 |
| Chen, L; Kamano, S; Sato, T; Yano, S | 1 |
| Edwards, RA; Farrell, NM; Jones, LT; Kraft, JM; Lech, GM; Lee, AR; Newman, MJ; Phantumvanit, V | 1 |
| Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F | 1 |
| Chang, J; Fan, W; Sui, M | 1 |
| Giulianelli, S; Gutkind, JS; Helguero, LA; Lamb, CA; Lanari, C; Martins, R; Molinolo, AA; Soldati, R; Vanzulli, SI; Vaqué, JP; Wargon, V; Zeitlin, E | 1 |
| Andrianaki, M; Azariadis, K; Castanas, E; Kampa, M; Kampouri, E; Lavrentaki, K; Notas, G; Pelekanou, V; Troullinaki, M | 1 |
| Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T | 1 |
| DeMichele, A; Gogineni, K | 1 |
| Layman, R; Li, X; Mrózek, E; Ottman, S; Ramaswamy, B; Schaaf, L; Shapiro, CL | 1 |
| Bago-Horvath, Z; Bartsch, R; Berghoff, A; DeVries, C; Dubsky, P; Fitzal, F; Gnant, M; Mader, RM; Pluschnig, U; Rottenfusser, A; Rudas, M; Steger, GG; Zielinski, CC | 1 |
| Emdal, KB; Guerra, B; Lykkesfeldt, AE; Yde, CW | 1 |
| Di Leo, A; Malorni, L | 1 |
| Guo, J; Jiang, Z; Jin, M; Shen, J; Wang, L; Xie, S | 1 |
| Kazmin, D; McDonnell, DP; Wardell, SE | 1 |
| Chen, S; Reddy, K; Smith, D; Wang, X; Wong, C | 1 |
| Alvarez, I; Estévez, L; Fernández, Y; Lluch, A; Muñoz, M; Seguí, MA; Tusquets, I | 1 |
| Harada, A; Li, C; Oh, Y | 1 |
| Adamoli, L; Aurilio, G; Botteri, E; Colleoni, M; Cullurà, D; Curigliano, G; Esposito, A; Goldhirsch, A; Minchella, I; Munzone, E; Nolè, F; Sciandivasci, A | 1 |
| Aapro, M; Bischoff, J; Brain, E; Cardoso, F; Lück, HJ; Tanner, M; Tjan-Heijnen, VC; Zotano, ÁG | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA | 1 |
| Kawamura, Y; Michihara, S; Moriyama, T; Tanaka, T; Uzawa, Y | 1 |
| Giulianelli, S; Gutkind, JS; Helguero, L; Lamb, C; Lanari, C; Martins, R; Molinolo, AA; Soldati, R; Vanzulli, SI; Vaqué, JP; Wargon, V; Zeitlin, E | 1 |
| Gelber, RD; Goldhirsch, A | 1 |
| Christensen, IJ; Larsen, MS; Lykkesfeldt, AE; Yde, CW | 1 |
| Giese, H; Klitgaard, LG; Kobayashi, H; Purup, S; Sondergaard, TE; Sørensen, JL | 1 |
| Brennan, DJ; Crown, JP; Gallagher, WM; Gremel, G; Higgins, DG; Jirström, K; Madden, SF; Martin, F; McGee, SF; McNally, S; Mulrane, L; O'Connor, DP | 1 |
| Dean, A; Dewar, J; Ellis, MJ; Emerson, L; Feltl, D; Lindemann, JP; Llombart-Cussac, A; Robertson, JF; Rolski, J | 1 |
| Ambrosino, C; Baumann, M; Cirillo, F; De Filippo, MR; Nassa, G; Nyman, TA; Stellato, C; Tarallo, R; Weisz, A | 1 |
| Aranda, E; Cañas, A; De La Haba-Rodríguez, JR; Fuentes, E; Hernández, V; López-Pedrera, C; López-Sánchez, LM; Muñoz-Castañeda, JR; Rodríguez-Ariza, A; Valverde-Estepa, A | 1 |
| Bernhardt, G; Buschauer, A; Keller, M; Lopuch, M; Memminger, M; Pop, N; von Angerer, E | 1 |
| Howell, SJ | 1 |
| Haffty, BG; Li, X; Moran, MS; Wang, J; Yang, Q | 1 |
| Ishitobi, M; Yagi, T; Yoshinami, T | 1 |
| Shiroiwa, T | 1 |
| Bondarenko, IN; Di Leo, A; Garnett, SA; Jerusalem, G; Khasanov, R; Lichinitser, MR; Lindemann, JP; Martin, M; Pedrini, JL; Pendergrass, K; Petruzelka, L; Smirnova, I; Torres, R; Verhoeven, D | 1 |
| Bundred, N; Howell, A | 1 |
| Ali, S; Bates, GJ; Chen, D; Coombes, RC; Egly, JM; Epstein, RJ; Fuller-Pace, FV; Pace, PE; Sarwar, N; Taylor, J; Thirunuvakkarasu, V; Washbrook, E | 1 |
| Conrad, SE; Varma, H | 2 |
| Chan, S | 1 |
| Chan, RY; Chen, WF; Dong, A; Guo, D; Wong, MS | 1 |
| Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A | 1 |
| Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A | 1 |
| Jordan, VC; Lee, ES; Takei, H | 1 |
| Jones, SE | 2 |
| Ali, S; Chan, CM; Dowsett, M; Johnston, SR; Martin, LA | 1 |
| Lauritsen, KJ; List, HJ; Reiter, R; Riegel, AT; Wellstein, A | 1 |
| Bergman, A; Brouwer, A; Giesy, JP; Lemmen, JG; Letcher, RJ; van den Berg, M; van der Burg, B | 1 |
| Chen, H; Hu, G; Wang, X; Xiao, H; Xiao, J; Zhou, J | 1 |
| Vergote, I | 1 |
| Howell, A | 5 |
| Badger, TM; Berhow, MA; Rowlands, JC | 1 |
| Hyder, SM; Stancel, GM | 1 |
| Balkenende, A; Bindels, EM; Lallemand, F; Michalides, R; Verwoerd, D | 1 |
| Bogart, DF; Castañeda, JM; Li, P; Lupu, R; Tsai, MS | 1 |
| Gradishar, WJ; Morrow, M | 1 |
| Carroll, JS; Finney, GL; Hui, R; Lee, CS; Musgrove, EA; Sutherland, RL | 1 |
| Bross, PF; Cohen, MH; Pazdur, R; Williams, GA | 1 |
| Morris, C; Wakeling, A | 1 |
| Czubayko, F; Franke, TF; List, HJ; Martin, MB; Morgan, E; Reiter, R; Stoica, A; Stoica, GE; Wellstein, A | 1 |
| Bigsby, RM; Fan, M; Nephew, KP | 1 |
| Kim, K; Safe, S; Saville, B; Thu, N | 1 |
| Banerjee, S; Banerjee, SK; Saxena, N; Sengupta, K | 1 |
| Hall, JM; Korach, KS | 1 |
| Bianco, NR; Montano, MM; Perry, G; Smith, MA; Templeton, DJ | 1 |
| Briand, P; Jensen, J; Kitlen, JW; Labrie, F; Lykkesfeldt, AE | 1 |
| Chaouat, M; Forgez, P; Gompel, A; Jacob, D; Perrot, JY; Rostène, W; Somaï, S | 1 |
| Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J | 1 |
| Ali, S; Dowsett, M; Farmer, I; Johnston, SR; Marshall, C; Martin, LA | 1 |
| Hoffmann, J; Lichtner, RB; Parczyk, K; Schneider, MR; Sommer, A | 1 |
| Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I | 1 |
| Chen, WF; Huang, MH; Tzang, CH; Wong, MS; Yang, M | 1 |
| Parker, LM; Piccart, M; Pritchard, KI | 1 |
| Gougelet, A; Maillard, S; Marsaud, V; Renoir, JM | 1 |
| Harrison, MP; Holcombe, C; Kohlhardt, SR; Odling-Smee, W; Robertson, JF | 1 |
| Buzdar, A; Come, SE; Ellis, M; Gertler, S; Howell, A; Jones, SE; Kleeberg, UR; Mauriac, L; Morris, C; Osborne, CK; Robertson, JF; Vergote, I; Webster, A | 1 |
| Harrison, MP; Robertson, JF | 1 |
| Carroll, JS; Daly, RJ; Lynch, DK; Musgrove, EA; Renoir, JM; Sarcevic, B; Sutherland, RL; Swarbrick, A | 1 |
| Boester, M; Diedrich, K; Frey, N; Ortmann, O; Porz, S; Treeck, O; Weber, A | 1 |
| Calhoun, KE; Fletcher, WS; Muller, P; Pommier, RF; Toth-Fejel, S | 1 |
| Endemann, G; Faridi, J; Roth, RA; Wang, L | 1 |
| Kano, I; Kano, K; Okubo, T; Suzuki, T; Yokoyama, Y | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jordan, N; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Eckhardt, S | 1 |
| Hortobagyi, GN | 1 |
| Baird, A; Bross, PF; Chen, G; Jee, JM; Lostritto, RT; Morse, DE; Pazdur, R; Rahman, A; Rosario, LA; Williams, G; Williams, GM; Yang, P | 1 |
| Bahr, I; Becker, A; Donner, P; Huber, M; Krätzschmar, JR; Müller, EC; Pohlenz, HD; Schneider, MR; Sommer, A | 1 |
| Stockler, MR; Wilcken, NR | 1 |
| Albanese, C; Cai, D; Chernoff, J; Felekkis, KN; Iyer, A; Lerner, A; Luo, Z; Near, RI; Pestell, RG | 1 |
| Chen, B; Gajdos, C; Jordan, VC; Liu, H; Osipo, C | 1 |
| Hung, H | 1 |
| Edwards, EA; Fulthorpe, R; Liss, SN; Wang, DY | 1 |
| Bowen, D; Davis, JH; DeSoto, JA; Fryar, EB; Hawkins, M; Southerland, WM | 1 |
| Kurebayashi, J; Okubo, S; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Brockdorff, BL; Heiberg, I; Lykkesfeldt, AE | 1 |
| Alarid, ET; Fowler, AM; Lee, AV; Preisler-Mashek, MT; Solodin, N; Zhang, P | 1 |
| Kurebayashi, J; Okubo, S; Sonoo, H; Yamamoto, Y | 1 |
| Howell, A; Mauriac, L; Osborne, CK | 1 |
| Chen, JQ; Cooke, C; Delannoy, M; Yager, JD | 1 |
| Fernández-Salguero, PM; Lorenzo-Benayas, MJ; Pozo-Guisado, E | 1 |
| Danes, JM; Frasor, J; Katzenellenbogen, BS; Komm, B; Lyttle, CR; Stossi, F | 1 |
| Curran, MP; McKeage, K; Plosker, GL | 1 |
| Horwitz, KB; Hyder, SM; Richer, J; Wu, J | 1 |
| Colomer, R; Lupu, R; Menendez, JA | 1 |
| Christensen, GL; Christensen, IJ; Fog, CK; Jepsen, JS; Lykkesfeldt, AE | 1 |
| Hyder, SM; Liang, Y; Uray, IP | 1 |
| Buck, MB; Knabbe, C; Pfizenmaier, K | 1 |
| Barrón-González, A; Castro Romero, I | 1 |
| Koeberle, D; Perey, L; Thuerlimann, B | 1 |
| Birnbaum, D; Cohen, PA; Danis, E; Duchesne, MJ; Magnino, F; Nguyen, C; Pinloche, S; Pons, M; Theillet, C; Vendrell, JA | 1 |
| Balaguer, P; Bonnet, S; Cavaillès, V; Duong, V; Escande, A; Margueron, R; Vignon, F | 1 |
| Nicholson, RI; Osborne, CK; Wakeling, A | 1 |
| Harrison, M; Robertson, JF | 1 |
| Robertson, JF; Vergote, I | 1 |
| Johnston, S | 1 |
| Abram, P; Bajetta, E; Dimery, I; Elledge, R; Howell, A; Lichinitser, MR; Morris, C; Osborne, CK; Robertson, JF; Watanabe, T; Webster, A | 1 |
| Akli, S; Chang, S; Keyomarsi, K; Multani, AS; Pathak, S; Tucker, SL; Wingate, HF; Zhang, N; Zheng, PJ | 1 |
| Bobseine, K; Gray, LE; Wilson, VS | 1 |
| Gärtner, F; Guo, S; Russo, J; Schmitt, FC; Soares, R | 1 |
| Clarke, DA; Come, SE; Erikstein, B; Gertler, S; Harrison, MP; Osborne, KC; Parker, LM; Pippen, J; Robertson, JF | 1 |
| Chang, T; Hayes, EC; Mitra, SW; Peekhaus, NT; Rohrer, SP; Schaeffer, JM; Wilkinson, HA | 1 |
| Bouker, KB; Cao, D; Clarke, R; Fernandez, DR; O'Brien, KA; Riggins, RB; Skaar, TC | 1 |
| Balkenende, A; Floore, A; Griekspoor, A; Jalink, K; Janssen, L; Michalides, R; Neefjes, J; van't Veer, L; Velds, A; Verwoerd, D | 1 |
| Christensen, GL; Freddie, CT; Lykkesfeldt, AE | 1 |
| Cunningham, A; Kern, FG; Manuvakhova, M; Qu, Z; Rentz, SS; Samuel, S; Sun, Y; Thottassery, JV; Upshaw, R; Westbrook, L | 1 |
| Laing, E; Sunder, A; Temple, JL; Wray, S | 1 |
| Gradishar, WJ | 2 |
| Mariani, SM | 1 |
| Body, JJ; Dumon, JC; Fox, J; Journé, F; Kheddoumi, N; Laïos, I; Leclercq, G | 1 |
| Barrett, JT; Delk, JN; Gaddy, VT; Kallab, AM; Porter, AG; Schoenlein, PV | 1 |
| Tobias, JS | 1 |
| Daly, RJ; Kairouz, R; Lyons, RJ; Musgrove, EA; Parmar, J; Swarbrick, A | 1 |
| Hardin, C; Jackson, T; Lefleur, B; Pommier, R; Toth-Fejel, S | 1 |
| Garofalo, C; Sisci, D; Surmacz, E | 1 |
| Body, JJ; Chaboteaux, C; Dumon, JC; Journe, F; Laurent, G; Leclercq, G | 1 |
| de Jong, PC; Dingemans, M; Heneweer, M; Muusse, M; Sanderson, JT; van den Berg, M | 1 |
| Kozubík, A; Machala, M; Plísková, M; Vojtesek, B; Vondrácek, J | 1 |
| Bracke, M; Derycke, L; Mareel, M; Milanezi, F; Paredes, J; Schmitt, F; Stove, C; Stove, V; Van Marck, V | 1 |
| Alao, JP; Ali, S; Coombes, RC; Halim, F; Hart, SM; Lam, EW; Madureira, PA; Sunters, A; Varshochi, R; Vigushin, DM | 1 |
| Franco, S; Frankel, C; Perez, A; Tan-Chiu, E; Vogel, CL | 1 |
| Possinger, K | 1 |
| Balabhadrapathruni, S; Gallo, MA; Santhakumaran, LM; Shirahata, A; Thomas, T; Thomas, TJ | 1 |
| Lynn, J | 1 |
| Owers, R | 1 |
| Harwood, KV | 1 |
| Clarke, R; Nehra, R; Riggins, RB; Zwart, A | 1 |
| Dockery, P; Doolan, CM; Walsh, DE | 1 |
| Castro, AF; Felekkis, KN; Lerner, A; Narsimhan, RP; Near, R; Quilliam, LA; Zheng, Y | 1 |
| Loi, SM; Piccart-Gebhart, MJ | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Bott, RC; Perry, GA; Smith, MF; Welshons, WV | 1 |
| Jakesz, R | 1 |
| Funata, N; Hayashi, S; Hirose, M; Horiguchi, S; Itoh, A; Kawakami, M; Saji, S; Schreiber, SL; Toi, M; Yoshida, M; Yoshida, N | 1 |
| Bundred, N | 1 |
| Carpenter, AE; Frasor, J; Frolova, A; Katzenellenbogen, BS; Rai, D | 1 |
| Borges, VF; Come, SE | 1 |
| Gradishar, WJ; Sahmoud, T | 1 |
| Carlson, RW | 1 |
| Jones, SE; Pippen, J | 1 |
| Dodwell, D; Vergote, I | 1 |
| Come, SE; Elledge, RM; Howell, A; Jones, SE; Mauriac, L; Osborne, CK; Pippen, J; Robertson, JF; Vergote, I | 1 |
| Ponzone, R; Sismondi, P | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Macedo, L | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Long, B; Macedo, L; Sabnis, G | 1 |
| Gorbunova, VA; Howell, A; Lichinitser, MR; Pienkowski, T; Robertson, JF; Watanabe, T | 1 |
| Dowsett, M; Head, J; Johnston, SR; Martin, LA; Smith, I | 1 |
| Gradishar, W | 1 |
| Bratthall, G; Idvall, I; Johnsson, I; Jönsson, D; Nilsson, BO; Wahlin, A | 1 |
| Ali, S; Dowsett, M; Farmer, I; Johnston, SR; Martin, LA | 1 |
| Izewska, P; Jankevics, H; Leufgen, K; Pick, H; Prummer, M; Vogel, H | 1 |
| Castiglione-Gertsch, M; Dellapasqua, S | 1 |
| Abram, P; Howell, A | 1 |
| Gips, M; Kaufman, B; Lluch, A; Mauriac, L; Simon, SD; Steger, GG; Vinholes, J; Wardley, A | 1 |
| Abram, P; Maass, N; Rea, D; Simon, SD; Steger, GG | 1 |
| Dahllund, J; Härkönen, P; Heiskanen, KM; Kallio, A; Zheng, A | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Johnston, SR | 2 |
| Johnston, SR; Nicholson, RI | 1 |
| Dowsett, M; Nicholson, RI; Pietras, RJ | 1 |
| Dowsett, M; Johnston, SR; Martin, LA | 1 |
| Abram, P; Vergote, I | 1 |
| Raina, V | 1 |
| Hyder, SM; Liang, Y; Nawaz, Z; Wu, J | 1 |
| Ariazi, EA; Glidewell-Kenney, C; Ishikawa, T; Jameson, JL; Lee, EJ; Pillai, S; Weiss, J | 1 |
| Jazieh, AR; Nahleh, ZA | 1 |
| Gartenhaus, RB; Jarrett, J; Jordan, VC; Levenson, AS; Osipo, C; Satcher, RL; Simons, LA; Thurn, KE; Veliceasa, D; Volpert, OV | 1 |
| Chan, CM; Dowsett, M; Farmer, I; Johnston, SR; Kimberley, C; Martin, LA; Pancholi, S | 1 |
| Burghardt, R; Li, X; Safe, SH; Smith, R; Zhang, S | 1 |
| Haldar, C; Ortmann, O; Treeck, O | 1 |
| Bell, E; Chandel, NS; Jordan, VC; Kidawi, N; Lewis, JS; Li, T; Meeke, K; Osipo, C; Ross, EA | 1 |
| Body, JJ; Chaboteaux, C; Duvillier, H; Journe, F; Laurent, G; Magne, N | 1 |
| Bradley, LM; Cole, RW; Gierthy, JF; Katz, BH; Spink, BC; Spink, DC | 1 |
| Long, X; Nephew, KP | 1 |
| Kilker, RL; Planas-Silva, MD; Waltz, PK | 1 |
| Etique, N; Flament, S; Grillier-Vuissoz, I | 1 |
| Dodwell, D; Johnston, S; Wardley, A | 1 |
| Bernath, AM; Camoriano, JK; Fishkin, PA; Ingle, JN; Mirchandani, D; Nikcevich, DA; Perez, EA; Rowland, KM; Suman, VJ | 1 |
| Darbre, PD; Pugazhendhi, D; Sadler, AJ; Shaw, LE | 1 |
| Anderson, E; Armer, T; Baildam, AD; Bramley, M; Clarke, RB; Evans, DG; Howell, A | 1 |
| Bennett, LM; Cutter, B; Klotz, DM; Kulp, KS; Latham, ER; Montgomery, JL; Nelson, DO; Shattuck, DL | 1 |
| Altorjai, G; Bartsch, R; Hussian, D; Locker, GJ; Mader, R; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Cheung, KL; Owers, R; Robertson, JF | 1 |
| Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA | 1 |
| Clarke, R; Dai, P; Lou, MA; Lu, JF; Nazarov, V; Wong, LJ | 1 |
| Harrington, WR; Katzenellenbogen, BS; Sengupta, S | 1 |
| Li, J; Liu, J; Sidell, N | 1 |
| Perez, EA; Roy, V | 1 |
| Espelund, U; Jepsen, JS; Juncker-Jensen, A; Lykkesfeldt, AE; Ralfkiaer, U; Worm, J | 1 |
| Buzdar, AU; Robertson, JF | 1 |
| Dodwell, D; Pippen, J | 1 |
| Fernando, R; Foster, JS; Henley, D; Isbill, M; Wimalasena, J | 1 |
| Amant, F; Berteloot, P; Leunen, K; Neven, P; Van Gorp, T; Vergote, I | 1 |
| Chen, B; Cheng, D; Jordan, VC; Liu, H; Louis, TE; Osipo, C; Weichel, AK; Wing, LK | 1 |
| Clément, P; Dietrich, D; Fiche, M; Goldhirsch, A; Hawle, H; Köberle, D; Nolé, F; Paridaens, R; Perey, L; Thürlimann, B; Wildiers, H; Zaman, K | 1 |
| Bell, DW; Coser, KR; Dean, KL; Hilario, PC; Hur, J; Isselbacher, KJ; Okimoto, RA; Shioda, T; Smith, SL; Tobey, EM | 1 |
| Cochrum, RK; Klinge, CM; Riggs, KA; Watts, MB; Wickramasinghe, NS | 1 |
| Zhang, XG; Zhao, QW | 1 |
| Lou, YJ; Zhao, QW | 1 |
| Armstrong, J; Dzagnidze, G; Gee, JM; Janjalia, M; Nemsadze, G; Nicholson, RI; Robertson, JF; Semiglazov, V | 1 |
| Ariazi, EA; Ariazi, JL; Cordera, F; Gill, SD; Jordan, VC; Kim, HR; Lewis-Wambi, JS; Li, T; Pyle, JR; Sharma, CG; Shupp, HA | 1 |
| Halabalaki, M; Kassi, E; Mitakou, S; Moutsatsou, P; Papoutsi, Z | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Brodie, A; Jelovac, D; Sabnis, G | 1 |
| Hardel, V; Jaehde, U; Roth, S; Schaad, S | 1 |
| Benayahu, D; Shur, I; Socher, R; Zemer-Tov, E | 1 |
| Harper, M; Hiscox, S; Jiang, W; Jordan, NJ; McClelland, R; Nicholson, RI; Smith, C | 1 |
| Cameron, DA; Clarke, R; Kuske, B; Langdon, SP; Macleod, KG; Miller, WR; Moore, K; Naughton, C | 1 |
| Borowiec, AS; Coiret, G; Mariot, P; Matifat, F; Ouadid-Ahidouch, H | 1 |
| Bahr, SJ; Pento, JT; Rajah, TT; Tong, GM; Zang, XP | 1 |
| Fritah, A; Redeuilh, G; Sabbah, M | 1 |
| Abbosh, PH; Chen, L; Cheng, AS; Fan, M; Hartman-Frey, C; Huang, TH; Li, L; Nephew, KP; Oyer, SL; Paik, H; Salisbury, JD; Yan, PS | 1 |
| Bertucci, A; Cheng, D; Jordan, VC; Liu, H; Meeke, K; Osipo, C; Weichel, A | 1 |
| Adamoli, L; Ascione, G; Catania, C; De Pas, T; Franceschelli, L; Goldhirsch, A; Magni, E; Medici, M; Nolè, F; Sanna, G; Torrisi, R; Verri, E | 1 |
| Auricchio, F; Bottero, D; Castoria, G; Ciociola, A; De Falco, A; De Stasio, R; Di Domenico, M; Lombardi, M; Migliaccio, A; Nanayakkara, M; Varricchio, L | 1 |
| Lykkesfeldt, AE; Peters, RH; Rasmussen, LM; Stenvang, J; Zaveri, NT | 1 |
| Lareef, MH; Mello, ML; Russo, IH; Russo, J; Vidal, BC | 1 |
| Greil, R; Hauser-Kronberger, C; Mayer, P; Mlineritsch, B; Moik, M; Namberger, K; Psenak, O | 1 |
| Altobelli, G; Biglia, N; Cicatiello, L; Cimino, D; De Bortoli, M; Friard, O; Fuso, L; Ponzone, R; Ravo, M; Scafoglio, C; Sismondi, P; Weisz, A | 1 |
| Esparaz, BT; Garnett, SA; Lower, EE; Wade, JL | 1 |
| Davidson, NE; Fan, W; Huang, Y; Park, BH; Sui, M | 1 |
| Filatova, IS; Planas-Silva, MD | 1 |
| Awada, A; Azerad, MA; Becquart, D; Bols, A; Borms, M; Christiaens, MR; Cocquyt, V; De Greve, J; Demol, J; Dirix, L; Fontaine, C; Goeminne, JC; Martens, M; Neven, P; Paridaens, R; Pelgrims, G; Selleslags, J; Stragier, B; Van Dam, P; Van Den Broecke, R; Van Den Weyngaert, D; Vandenhoven, G; Vergote, I; Vindevoghel, A | 1 |
| Behrens, D; Fichtner, I; Gill, JH | 1 |
| Chen, WF; Gao, QG; Wong, MS | 1 |
| Fichtner, I; Frogne, T; Issinger, OG; Lykkesfeldt, AE; Stenvang, J; Yde, CW | 1 |
| Bianco, S; Chalbos, D; Kersual, N; Lanvin, O; Vanacker, JM | 1 |
| De Stefano, I; Fabrizi, M; Ferlini, C; Gallo, D; Mantuano, E; Mozzetti, S; Scambia, G | 1 |
| Altorjai, G; Bartsch, R; Gnant, M; Jakesz, R; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Robertson, JF | 3 |
| Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR | 1 |
| Boonyaratanakornkit, V; Edwards, DP; Lehrbach, GM; McGowan, EM; Musgrove, EA; Russell, AJ; Saunders, DN; Sergio, CM; Sutherland, RL | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| McDonnell, DP; Sherk, A; Wittmann, BM | 1 |
| Gooderham, NJ; Lauber, SN | 1 |
| Chan, RY; Guo, DA; Lau, WS; Wong, MS | 1 |
| Etique, N; Flament, S; Grillier-Vuissoz, I; Lecomte, J | 1 |
| Carcel-Trullols, J; Evans, TT; Higuchi, M; Mizumachi, T; Naito, A; Xie, CH | 1 |
| Jordan, VC | 2 |
| Chung, WY; Couch, FJ; Daly, PA; Dervan, PA; Farragher, SM; Gorski, JJ; Harkin, DP; Hosey, AM; James, CR; Johnston, PG; Kay, E; McCann, A; Mullan, PB; Mulligan, JM; Murray, MM; Quinn, JE; Scott, AN; Stewart, GE | 1 |
| Aranda, A; De los Santos, M; Martínez-Iglesias, O | 1 |
| Bayliss, J; Diehl, K; El-Ashry, D; Hilger, A; Vishnu, P | 1 |
| Estes, NR; Kern, FG; Manuvakhova, M; Ramanathan, HN; Thottassery, JV; Westbrook, L | 1 |
| Dixon, JM; Faratian, D; Macaskill, EJ; Renshaw, L; Thomas, JS; White, S; Young, OE | 1 |
| Archer, TK; Hu, P; Kinyamu, HK; Martin, J; Teng, C; Wang, L | 1 |
| Jiang, L; Lehmann, L; Wagner, J | 1 |
| Kaufmann, M | 1 |
| Amant, F; Bines, J; Brufsky, A; Buzdar, A; Chia, S; Federico, M; Fein, L; Gradishar, W; Lowe, E; Mauriac, L; Piccart, M; Possinger, K; Rennie, P; Robertson, JF; Romieu, G; Sapunar, F | 1 |
| Hall, LC; Kane, SR; Liu, N; Salazar, EP | 1 |
| Bradley, LM; Gierthy, JF; Pentecost, BT | 1 |
| Chia, S; Gradishar, W | 1 |
| Bliss, JM; Coombes, G; Dodwell, D; Johnston, S; Kilburn, LS | 1 |
| Benjaminsen, RV; de Cremoux, P; Frogne, T; Laenkholm, AV; Lykkesfeldt, AE; Nexo, E; Rasmussen, LM; Riese, DJ; Sonne-Hansen, K; Sorensen, BS; Stenvang, J | 1 |
| Brodie, A; Goloubeva, OG; Macedo, LF; Sabnis, GJ | 1 |
| Body, JJ; Journé, F; Laurent, G; Leclercq, G | 1 |
| Brentani, MM; Nagai, MA | 1 |
| Castillo, LF; Chiesa, IJ; Lüthy, IA | 1 |
| Cathiard, AM; Chambon, M; Garcia, M; Maynadier, M; Nirdé, P; Platet, N; Ramirez, JM | 1 |
| Catherino, WH; Jordan, VC | 1 |
| Coronado-Heinsohn, EB; Hilsenbeck, SG; Manning, DL; McClelland, RA; McCue, BL; Nicholson, RI; Osborne, CK; Wakeling, AE | 1 |
| Gee, JM; Katzenellenbogen, BS; Manning, DL; Montano, MM; Nicholson, RI; Wakeling, AE | 1 |
| DeLuise, M; Hu, XF; Parisot, JP; Sutherland, RL; Wakeling, A; Zalcberg, JR | 1 |
| Pollak, MN; Pratt, SE | 1 |
| Dive, C; Hickman, JA; Morris, ID; Wakeling, AE; Wilson, JW | 1 |
| Briand, P; Larsen, SS; Lykkesfeldt, AE | 1 |
| Howell, A; Robertson, J | 1 |
| Blamey, R; DeFriend, D; Howell, A; Robertson, J; Walton, P | 1 |
| Dowsett, M; Iveson, TJ; Johnston, SR; Smith, IE | 1 |
| Anderson, E; Bell, J; DeFriend, DJ; Howell, A; Mansel, RE; West, CM; Wilks, DP | 1 |
| Binderup, L; Colston, KW; James, SY; Mackay, AG | 1 |
| Briand, P; Lykkesfeldt, AE; Madsen, MW | 1 |
| De Luise, M; Hu, XF; Sutherland, R; Veroni, M; Wakeling, A; Watts, CK; Zalcberg, JR | 1 |
| Anderson, E; Blamey, RW; Bundred, NJ; DeFriend, DJ; Dowsett, M; Howell, A; Mansel, RE; Nicholson, RI; Robertson, JF; Saunders, C | 1 |
| Brünner, N; Clarke, R; Coopman, P; Derocq, D; Garcia, M; Rochefort, H | 1 |
| Bei, M; Brünner, N; Clarke, R; Frandsen, TL; Holst-Hansen, C; Lippman, ME; Thompson, EW; Wakeling, AE | 1 |
| Manning, DL; Nicholson, RI | 1 |
| Huynh, H; Pollak, M; Yang, X | 1 |
| Clerico, L; de Cupis, A; Favoni, RE; Ferrera, A; Noonan, D; Pirani, P | 1 |
| Addeo, R; Altucci, L; Battista, T; Bonapace, IM; Bresciani, F; Cancemi, M; Cicatiello, L; Germano, D; Pacilio, C; Salzano, S; Weisz, A | 1 |
| Brady, A; deFazio, A; Musgrove, EA; Sarcevic, B; Sutherland, RL; Watts, CK | 1 |
| Jordan, VC; Pink, JJ | 1 |
| Benedetti Panici, P; Bonanno, G; de Vincenzo, R; Ercoli, A; Fattorossi, A; Isola, G; Mancuso, S; Pernisco, S; Scambia, G | 1 |
| Anderson, E; Anderson, L; Blamey, RW; DeFriend, DJ; Howell, A; Robertson, JF; Sutcliffe, FA; Walton, P | 1 |
| Foster, JS; Wimalasena, J | 1 |
| Biberger, C; von Angerer, E | 1 |
| Blamey, RW; Francis, AB; Gee, JM; McClelland, RA; Nicholson, RI; Robertson, JF; Wakeling, AE | 1 |
| Baumann, RJ; Bitonti, AJ; Cashman, EA; Cross-Doersen, DE; Dumont, JA; Wallace, CD | 1 |
| Bliss, RD; Browell, DA; Kirby, JA; Lennard, TW | 1 |
| Hafner, F; Holler, E; von Angerer, E | 1 |
| Benedetti Panici, P; Bonanno, G; De Vincenzo, R; Fattorossi, A; Ferlini, C; Isola, G; Mancuso, S; Pernisco, S; Scambia, G | 1 |
| Huynh, H; Pollak, M; Yang, XF | 1 |
| Anderson, E; Blamey, RW; Clarke, R; Dowsett, M; Gee, JM; Howell, A; Manning, DL; McClelland, RA; Nicholson, RI; Robertson, JF; Wakeling, AE | 1 |
| Berelowitz, M; Bruno, JF; Song, J; Xu, Y | 1 |
| Michaelson, CL; Sonnenschein, C; Soto, AM | 1 |
| Brémaud, J; Hameau, MC; Magnien, V; Nique, F; Philibert, D; Planchon, P; Prévost, G; Teutsch, G; Van de Velde, P | 1 |
| Briand, P; Larsen, SS; Lykkesfeldt, AE; Madsen, MW; Reiter, BE | 1 |
| Musgrove, EA; Prall, OW; Sarcevic, B; Sutherland, RL; Watts, CK | 1 |
| Katzenellenbogen, BS; Montano, MM | 1 |
| Couissi, D; Dubois, V; Remacle, C; Schonne, E; Trouet, A | 1 |
| Abbas Abidi, SM; Dmytryk, JJ; Hurt, GM; Mathew, AC; Pento, JT; Rajah, TT | 1 |
| Abbas Abidi, SM; Dmytryk, JJ; Howard, EW; Pento, JT | 1 |
| Catherino, WH; Jordan, VC; Levenson, AS | 1 |
| A'Hern, R; Anderson, E; Clarke, R; Detre, S; Dowsett, M; Ellis, PA; Howell, A; Johnston, SR; Nicholson, R; Robertson, J; Saccani-Jotti, G; Salter, J; Smith, IE | 1 |
| Boysen, B; Brünner, N; Clarke, R; Frandsen, T; Fuqua, SA; Holst-Hansen, C; Jirus, S; Lippman, J; Skaar, TC; Spang-Thomsen, M | 1 |
| Autrup, H; Bonefeld Jørgensen, EC; Hansen, JC | 1 |
| Huynh, H; Nickerson, T; Pollak, M | 1 |
| Jensen, BL; Larsen, SS; Lykkesfeldt, AE; Madsen, MW | 1 |
| Jensen, EV; Knabbe, C; Müller, V | 1 |
| Dickson, RB; El-Ashry, D; Hannum, RS; Kern, FG; Kharbanda, S; Lopez, CA; Lorant, LA; McLeskey, SW; Tobias, CA; Trock, BJ; Zhang, L | 1 |
| Assikis, VJ; Bilimoria, MM; Chen, Z; England, GM; Jordan, VC; Muenzner, HD | 1 |
| Abidi, SM; Dmytryk, JJ; Howard, EW; Pento, JT | 1 |
| Afshari, CA; Annab, LA; Barrett, JC; Risinger, JI; Romagnolo, D; Terry, LA; Thompson, TE | 1 |
| Jordan, VC; Levenson, AS; Tonetti, DA | 1 |
| Averboukh, L; Biswas, DK; Ewaniuk, DS; Jawde, TF; Martin, K; Pardee, AB; Sheng, S; Wang, F | 1 |
| Anderson, KC; Chauhan, D; Ogata, A; Teoh, G; Treon, SP; Urashima, M; Webb, IJ | 1 |
| Assikis, VJ; Bilimoria, MM; Chatterton, R; Cisneros, A; Dragan, YP; England, GM; Jordan, VC; MacGregor, JI; Muenzner, HD; O'Regan, RM; Piette, M; Pitot, HC | 1 |
| Huynh, H; Pollak, M | 1 |
| Musgrove, EA; Prall, OW; Sutherland, RL; Wilcken, NR | 1 |
| Huynh, H; Nickerson, T; Pollak, M; Yang, X | 1 |
| Donepudi, M; Flanagan, L; Nolan, E; VanWeelden, K; Welsh, J | 1 |
| Akinaga, S; Kurebayashi, J; Kurosumi, M; Nakata, T; Otsuki, T; Sonoo, H; Yamamoto, S | 1 |
| Brodie, AM; Grigoryev, DN; Long, BJ; Thiantanawat, A; Tilghman, SL; Yue, W | 1 |
| Hyder, SM; Nawaz, Z; Stancel, GM | 1 |
| Dinda, S; Hurd, C; Khattree, N; Moudgil, VK | 1 |
| Jensen, BL; Lundholt, BK; Lykkesfeldt, AE; Skouv, J | 1 |
| Doihara, H; Kanaya, Y; Ogasawara, Y; Shimizu, N; Shiroma, K | 1 |
| DeGeorge, GL; Gadd, SL; Harnagea-Theophilus, E; Knight-Trent, AH; Miller, MR | 1 |
| Ando, S; Guvakova, MA; Mauro, L; Salerno, M; Sisci, D; Surmacz, E | 1 |
| Codazzi, F; Improta-Brears, T; McDonnell, DP; Meyer, T; Whorton, AR; York, JD | 1 |
| Coronado-Heinsohn, E; Gooch, JL; Hilsenbeck, SG; Jackson, JG; Lee, AV; Osborne, CK; Yee, D | 1 |
| Angus, WG; Jefcoate, CR; Larsen, MC | 1 |
| Ellmén, J; Kaukonen, M; Mäenpää, J; Pasanen, T | 1 |
| Ehlers, EM; Schubert, C | 1 |
| Bach, LA; DeLuise, M; Hu, XF; Leeding, KS; Parisot, JP; Zalcberg, JR | 1 |
| Evans, A; Healy, D; Vollenhoven, B | 1 |
| Atkin, SL; Desai, SB; Green, AR; Kerin, MJ; Newton, CJ; Speirs, V; Walton, DS | 1 |
| Christensen, DJ; Fowlkes, DM; McDonnell, DP; Nagel, SC; Norris, JD; Paige, LA; Wijayaratne, AL | 1 |
| DePasquale, JA | 1 |
| Egeblad, M; Jäättelä, M; Larsen, SS; Lykkesfeldt, AE | 1 |
| Doihara, H; Kunisue, H; Kurebayashi, J; Kurosumi, M; Otsuki, T; Shimizu, N; Sonoo, H; Tanaka, K; Tang, CK; Yamamoto, S | 1 |
| Diel, P; Michna, H; Smolnikar, K | 1 |
| Gehm, BD; Jameson, JL; Jordan, VC; McAndrews, JM | 1 |
| Birchmeier, W; Lichtner, RB; Parczyk, K; Schneider, MR | 1 |
| Huper, G; Iglehart, JD; Lobenhofer, EK; Marks, JR | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q | 1 |
| Archer, C; Assersohn, L; Boeddinghaus, I; Chang, J; Dowsett, M; Ellis, PA; Gregory, RK; Johnston, SR; Mainwaring, P; Powles, TJ; Salter, J; Smith, IE | 1 |
| Atkin, SL; Eycott, K; Green, V; Newton, CJ | 1 |
| Abbondanza, C; Armetta, I; Bontempo, P; Medici, N; Molinari, AM; Moncharmont, B; Napolitano, M; Nigro, V; Nola, E; Puca, GA; Schiavone, EM; Tortora, V; Verdicchio, MA | 1 |
| Bartels, MJ; Carney, EW; Charles, GD; Freshour, NL; Gollapudi, BB; Zacharewski, TR | 1 |
| Diamandis, EP; Grass, L; Jenkins, DJ; Magklara, A; Rosenberg Zand, RS | 1 |
| Addeo, R; Altucci, L; Belsito Petrizzi, V; Boccia, V; Bresciani, F; Cancemi, M; Cicatiello, L; Germano, D; Pacilio, C; Salzano, S; Weisz, A | 1 |
| Dong, HY; Hashimoto, S; Inadera, H; Matsushima, K; Nagai, S; Suzuki, T; Toyoda, N; Yamashita, T | 1 |
| Bundred, NJ; Gandhi, A; Holland, PA; Knox, WF; Potten, CS | 1 |
| Howell, A; Morris, C; Osborne, CK; Wakeling, AE | 1 |
| Chen, X; Danes, C; Herliczek, TW; Keyomarsi, K; Lowe, M | 1 |
| Carroll, JS; Musgrove, EA; Prall, OW; Sutherland, RL | 1 |
| Pento, JT; Rajah, TT | 1 |
| Nomura, Y | 1 |
| Boettger-Tong, H; Chiappetta, C; Huang, JC; Hyder, SM; Mäkelä, S; Nawaz, Z; Stancel, GM | 1 |
| Dowsett, M; Ormerod, MG; Zabaglo, L | 1 |
| Bland, KI; Filardo, EJ; Frackelton, AR; Quinn, JA | 2 |
| Eischeid, A; Jeng, MH; Santen, RJ; Wang, JP; Yue, W | 1 |
| Brockdorff, BL; Lykkesfeldt, AE; Reiter, BE; Skouv, J | 1 |
| Terakawa, N | 1 |
| Fujita, T; Kaiho, S; Kuwabara, K; Ogata, E; Oizumi, I; Okazaki, T; Tanaka, Y | 1 |
| Diel, P; Löffek, S; Michna, H; Schulz, T; Smolnikar, K | 1 |
| De Los Reyes, A; England, G; Jordan, VC; Lee, ES; O'Regan, RM; Schafer, JM; Yao, K | 1 |
| Angus, WG; Campaigne Larsen, M; Jefcoate, CR | 1 |
| Kim, J; Nardulli, AM; Petz, LN; Potthoff, SJ; Wood, JR; Ziegler, YS | 1 |
| Klinga, K; Mayer, D; Morfin, R; Schmitt, M; Schnarr, B | 1 |
| Mokbel, K | 1 |
| Gornbein, J; Koeffler, HP; Miller, CW; Nakachi, K; O'Kelly, J; Said, JW; Sakashita, A; Xie, D | 1 |
| Bernardini, R; Bianchi, A; Cantarella, G; Chiarenza, A; Lazarovici, P; Lempereur, L | 1 |
| Bagchi, IC; Bagchi, MK; Chen, D; Kumar, S; Li, Q; Zhang, M; Zhu, LJ | 1 |
| Sampath, D; Winneker, RC; Zhang, Z | 1 |
| Burow, ME; Green, AE; Henson, MC; McLachlan, JA; O'Neil, JS | 1 |
| Kumar, P; Mark, PJ; Minchin, RF; Ratajczak, T; Ward, BK | 1 |
| Alban, P; Dinda, S; Hurd, C; Khattree, N; Moudgil, VK | 1 |
| Barrett, JC; Kanai, H; Metzler, M; Tsutsui, T | 1 |
| Emery, JG; Fisher, PW; Gowen, M; Kingsbury, WD; Nadeau, DP; Nicholson, TA; Nuttall, ME; Pendrak, I; Suva, LJ; Zhu, Y | 1 |
| Barrow, D; Dutkowski, CM; Gee, JM; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Pamment, J | 1 |
| De Arment, R; Demers, L; Fischer, S; Franks, M; Griffith, J; Leiby, B; Manni, A; Mauger, D; Verderame, M; Washington, S | 1 |
| El-Ashry, D; Holloway, JN; Kern, FG; Lorant, LA; Miller, DL; Oh, AS | 1 |
| Tominaga, T | 1 |
| Anderson, E; Bundred, NJ; Dixon, M; Dowsett, M; Fox, JN; Gee, JM; Morris, C; Nicholson, RI; Rayter, Z; Robertson, JF; Wakeling, AE; Webster, A | 1 |
| Davidson, NE; Ferguson, AT; Herman, JG; Nelson, WG; Phillips, DL; Yang, X | 1 |
| Ahmed, Y; Bentrem, DJ; Chisamore, MJ; Jordan, VC; Tonetti, DA | 1 |
| Kurebayashi, J; Moriya, T; Otsuki, T; Sonoo, H | 1 |
| Janne, OA; Palvimo, JJ; Poukka, H; Safe, S; Samudio, I; Saville, B; Stoner, M; Wormke, M | 1 |
| Parker, MG; Soulez, M | 1 |
| Beckman, BS; Burow, ME; McLachlan, JA; Tang, Y; Weldon, CB | 1 |
| Conrad, SE; Mukherjee, S; Skildum, AJ | 1 |
| Cheung, KL; Robertson, JF | 1 |
| Bogart, DF; Li, P; Lupu, R; Mehmi, I; Tsai, MS | 1 |
| Jeng, MH; Masamura, S; McPherson, R; Santen, R; Santner, S; Shim, WS; Song, R; Wang, JP; Yue, W | 1 |
| Byford, JR; Darbre, PD; Drew, MG; Pope, GS; Sauer, MJ; Shaw, LE | 1 |
| Diel, P; Michna, H; Olff, S; Schmidt, S | 1 |
| Armes, JE; Bouras, T; Chang, AC; Glynne, R; Henderson, MA; Reddel, RR; Southey, MC; Venter, DJ; Willhite, D | 1 |
| Baum, M | 1 |
| O'Shaughnessy, J; Parker, LM; Torosian, M; Vogel, C | 1 |
| Gee, JM; Nicholson, RI; Wakeling, AE | 1 |
| Badia, E; Duchesne, MJ; Freiss, G; Pons, M; Rabenoelina, F; Semlali, A | 1 |
| Elkak, AE; Mokbel, K | 1 |
| Iwasiow, B; Orr, FW; Shiu, RP; Venditti, M | 1 |
| Chrysogelos, SA; Wilson, MA | 1 |
| Carroll, JS; Musgrove, EA; Sutherland, RL; Swarbrick, A | 1 |
| Bouker, KB; Brünner, N; Clarke, R; Davis, N; Gu, Z; Lee, RY; Leonessa, F; Liu, A; Lu, J; Skaar, TC; Wang, Y; Welch, JN; Zhu, Y | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Green, SJ; Herbstritt, CJ; Kough, EC; LaVallee, TM; Pribluda, VS; Zhan, XH | 1 |
| Bowler, J; Wakeling, AE | 2 |
| Bowler, J; Dukes, M; Wakeling, AE | 1 |
179 review(s) available for fulvestrant and Breast Neoplasms
| Article | Year |
|---|---|
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Male; Receptors, Estrogen | 2022 |
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Fulvestrant; Humans; Quality of Life; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2022 |
"The emerging role of capivasertib in breast cancer".
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2022 |
Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen; Tetrahydronaphthalenes | 2022 |
SERDs: a case study in targeted protein degradation.
Topics: Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Proteolysis; Receptors, Estrogen | 2022 |
Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclins; Female; Fulvestrant; Humans | 2022 |
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
Topics: Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2022 |
[Therapeutic strategies for the treatment of endocrine resistant hormone receptor positive advanced breast cancer].
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; Phosphatidylinositol 3-Kinases; Receptors, Estrogen | 2023 |
New treatment options for hormone receptor positive breast cancer in 2023.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2023 |
Pharmacokinetics and Pharmacodynamic of Alpelisib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Thiazoles | 2023 |
Novel Estrogen Receptor-Targeted Agents for Breast Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Fulvestrant; Humans; Receptors, Estrogen | 2023 |
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen | 2023 |
The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2023 |
Addition of
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; MTOR Inhibitors; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2 | 2023 |
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.
Topics: Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Histone Deacetylase Inhibitors; Humans; MTOR Inhibitors; Network Meta-Analysis; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases | 2023 |
Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Network Meta-Analysis | 2023 |
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Neutropenia; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2023 |
An evaluation of fulvestrant for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Metastasis | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2 | 2019 |
An evidence-based review of the outcome of fulvestrant plus a targeted agent versus fulvestrant alone in treating hormone receptor-positive endocrine therapy-resistant metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2019 |
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mutation; Non-Randomized Controlled Trials as Topic; Randomized Controlled Trials as Topic; Tamoxifen | 2019 |
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Japan; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2019 |
Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen | 2020 |
Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Fulvestrant; Humans; Neoplasm Grading; Network Meta-Analysis; Piperazines; Postmenopause; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2020 |
Estrogen receptor-positive (ER
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Fulvestrant; Gene Expression; Humans; Molecular Targeted Therapy; Tamoxifen | 2020 |
Alpelisib to treat breast cancer.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Fulvestrant; Humans; Mutation; Receptor, ErbB-2; Thiazoles | 2020 |
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Quality of Life | 2020 |
Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.
Topics: Bayes Theorem; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Network Meta-Analysis; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
[Hot flushes and breast cancer with positive hormone receptors: Mechanisms and management].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Contraindications, Drug; Estrogen Replacement Therapy; Female; Fulvestrant; Hot Flashes; Humans; Kisspeptins; Ovary; Receptors, Neurokinin-3; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Ribociclib plus fulvestrant in the treatment of breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Progression-Free Survival; Purines; Randomized Controlled Trials as Topic; Survival Rate | 2021 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
[Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?]
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Male; Middle Aged; Multivariate Analysis; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies; Thrombocytopenia | 2021 |
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Randomized Controlled Trials as Topic; Receptors, Estrogen; Treatment Outcome | 2017 |
CDK4/6 inhibitors in HER2-positive breast cancer.
Topics: Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Fulvestrant; Humans; Letrozole; Molecular Targeted Therapy; Nitriles; Protein Kinase Inhibitors; Receptor, ErbB-2; Triazoles | 2017 |
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mutation; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Tamoxifen | 2017 |
Emerging therapies for breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Breast Neoplasms; Clinical Trials as Topic; Drug Carriers; Estradiol; Female; Fulvestrant; Humans; Immunoconjugates; Immunotherapy; Immunotherapy, Adoptive; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyridines; Therapies, Investigational; Tubulin Modulators | 2017 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Triazoles | 2017 |
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Morpholines; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles | 2017 |
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2018 |
Abemaciclib: First Global Approval.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinases; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; United States; United States Food and Drug Administration | 2017 |
Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Receptors, Cell Surface; Receptors, Estrogen; Treatment Outcome | 2018 |
An update on first line therapies for metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Immunotherapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Steroid | 2018 |
Abemaciclib for the treatment of breast cancer.
Topics: Aminopyridines; Benzimidazoles; Biomarkers; Brain Neoplasms; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Humans; Neoplasm Staging; Prognosis | 2018 |
Fulvestrant for the treatment of advanced breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Postmenopause | 2018 |
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome; Triazoles | 2018 |
Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Staging; Piperazines; Purines; Pyridines; Receptor, ErbB-2 | 2019 |
High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Tomography, X-Ray Computed | 2018 |
Breast cancer metastasis to the bladder: a literature review.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cancer Survivors; Carcinoma, Ductal, Breast; Cystoscopy; Estradiol; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Urinary Bladder Neoplasms; Urinary Bladder, Overactive | 2018 |
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen | 2018 |
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fulvestrant; Humans; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Postmenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Survival Analysis; Treatment Outcome | 2018 |
Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Estrogen | 2019 |
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases | 2019 |
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Fulvestrant; Humans; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Complementary Therapies; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Remission Induction; Treatment Outcome | 2019 |
Alpelisib: First Global Approval.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Drug Approval; Female; Fulvestrant; Humans; Male; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Thiazoles; United States; United States Food and Drug Administration | 2019 |
ESR1 mutations in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Humans; Liquid Biopsy; Mutation; Protein Kinase Inhibitors | 2019 |
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome; Triazoles | 2013 |
Fulvestrant for advanced breast cancer: a meta-analysis.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Staging; Treatment Outcome | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2014 |
The renaissance of endocrine therapy in breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Ovariectomy; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome | 2014 |
The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Outcome Assessment, Health Care; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2014 |
Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles; Women | 2014 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2014 |
A good drug made better: the fulvestrant dose-response story.
Topics: Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans | 2014 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles | 2015 |
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Neoplasm Metastasis; Ovariectomy; Postmenopause; Premenopause; Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Fulvestrant; Humans; Postmenopause; Receptor, ErbB-2; Tamoxifen | 2015 |
[Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Everolimus; Female; Fulvestrant; Histone Demethylases; Humans; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
[GPER receptor - the new player in estrogen signaling].
Topics: Animals; Autocrine Communication; Breast Neoplasms; Connective Tissue Growth Factor; Dual Specificity Phosphatase 1; Estradiol; Female; Fulvestrant; Gene Expression Regulation; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-fos; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Tamoxifen; Transcriptional Activation | 2015 |
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Topics: Animals; Breast; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Conjugated (USP); Female; Fulvestrant; Humans; Indoles; Osteoporosis; Postmenopause; Protective Factors; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2015 |
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles; United States | 2015 |
[Fulvestrant (Faslodex®) for hormone sensitive breast cancer. A review].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Postmenopause; Survival Analysis | 2015 |
Development of cell-cycle checkpoint therapy for solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Aurora Kinase A; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Proliferation; Clinical Trials as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Letrozole; Molecular Targeted Therapy; Neoplasm Staging; Nitriles; Nuclear Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2015 |
Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Comparative Effectiveness Research; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic | 2016 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Postmenopause; Treatment Outcome | 2016 |
Endocrine treatment in breast cancer: Cure, resistance and beyond.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Pyridines; Receptors, Estrogen; Tamoxifen | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Fulvestrant for hormone-sensitive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2017 |
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Male; Neoplasms; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Signal Transduction; Treatment Outcome | 2008 |
The influence of endocrine treatments for breast cancer on health-related quality of life.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Mastectomy; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome | 2008 |
Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Postmenopause | 2009 |
Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans | 2008 |
Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause; Receptors, Estrogen | 2009 |
Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Tamoxifen | 2010 |
Targeting tumors using estrogen receptor ligand conjugates.
Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Drug Design; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Ligands; Neoplasm Staging; Neoplasms; Receptors, Estrogen | 2009 |
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genotype; Humans; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2009 |
Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Delivery Systems; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2010 |
Fulvestrant - a novel endocrine therapy for breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Routes; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen | 2010 |
Acquired endocrine resistance in breast cancer: implications for tumour metastasis.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Hyaluronan Receptors; Neoplasm Metastasis; Proto-Oncogene Proteins c-met; src-Family Kinases | 2011 |
Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen | 2011 |
Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Dehydroepiandrosterone Sulfate; Estradiol; Estrone; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Steryl-Sulfatase; Sulfonic Acids; Tamoxifen | 2011 |
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2011 |
Fulvestrant revisited: efficacy and safety of the 500-mg dose.
Topics: Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Maximum Tolerated Dose | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
[Hormone therapy and breast cancer].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Role of fulvestrant in the management of postmenopausal breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Postmenopause; Receptors, Estrogen | 2011 |
[Pharmacological and clinical profiles of Fulvestrant (Faslodex(®)) in the treatment of advanced or recurrenced breast cancer].
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Mice; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Rats; Receptors, Estrogen | 2012 |
Current approaches to the management of Her2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Deoxycytidine; Doxorubicin; Estradiol; Female; Fulvestrant; Gemcitabine; Humans; Megestrol; Ovary; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Letrozole; Nitriles; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Transcriptional Activation; Triazoles | 2012 |
Finding the right dose of fulvestrant in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans | 2013 |
A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Tamoxifen | 2013 |
Advances in the treatment of luminal breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen | 2013 |
Fulvestrant (Faslodex): current status in the therapy of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans | 2002 |
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2002 |
A new estrogen receptor antagonist--an overview of available data.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause | 2002 |
Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans | 2002 |
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Prognosis; Quality of Life; Receptors, Estrogen; Tamoxifen | 2003 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles | 2003 |
Fulvestrant in postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Nitriles; Postmenopause; Survival Rate; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2003 |
Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen | 2003 |
Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Gene Expression Regulation; Genes, erbB-1; Humans; Quinazolines; Signal Transduction | 2004 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans | 2004 |
Fulvestrant: pharmacokinetics and pharmacology.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans | 2004 |
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause | 2004 |
Fulvestrant and the sequential endocrine cascade for advanced breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans | 2004 |
Tamoxifen--what next?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Fulvestrant; Humans; Tamoxifen | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Fulvestrant; Hormone Antagonists; Humans; Receptors, Estrogen | 2004 |
Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Staging; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; United Kingdom | 2004 |
Clinical experience with fulvestrant ('Faslodex'): a nurse's perspective.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome; United Kingdom | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Immunohistochemistry; Injections, Intramuscular; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2005 |
Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Treatment Outcome | 2005 |
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance; Drug Therapy, Combination; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Receptors, Estrogen; Signal Transduction | 2005 |
Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Signal Transduction | 2005 |
Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Postmenopause; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Clinical development of fulvestrant ("Faslodex").
Topics: Aged; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone | 2005 |
The future of fulvestrant ("Faslodex").
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Endocrine therapy--current benefits and limitations.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans | 2005 |
Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans | 2005 |
Life following aromatase inhibitors--where now for endocrine sequencing?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2005 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Fulvestrant ('Faslodex'): current and future role in breast cancer management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Postmenopause; Receptors, Estrogen; Receptors, Somatotropin; Signal Transduction | 2006 |
Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause; Raloxifene Hydrochloride; Tamoxifen | 2006 |
New therapies in the treatment of breast cancer.
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Fulvestrant; Humans; MAP Kinase Signaling System; Paclitaxel; Sirolimus; Vinblastine | 2006 |
Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans | 2006 |
Time to response: comparison of fulvestrant and oral endocrine agents.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?
Topics: Animals; Breast Neoplasms; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2006 |
Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent | 2006 |
Fulvestrant (Faslodex) -- how to make a good drug better.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Receptors, Estrogen | 2008 |
Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen | 2008 |
Gene expression profiles in breast cancer to identify estrogen receptor target genes.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2008 |
Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer.
Topics: Breast Neoplasms; Drug Resistance; Estradiol; Estradiol Congeners; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Polyunsaturated Alkamides; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1995 |
Modern antioestrogens and the coming revolution in women's health care.
Topics: Bone and Bones; Breast Neoplasms; Clomiphene; Estradiol; Estrogen Receptor Modulators; Estrogens, Non-Steroidal; Female; Fulvestrant; Genital Diseases, Female; Humans; Isoflavones; Osteoporosis; Phytoestrogens; Plant Preparations; Plants; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health | 1999 |
Clinical studies of apoptosis and proliferation in breast cancer.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Biomarkers; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Pregnancy; Tamoxifen; Tumor Cells, Cultured | 1999 |
[Pure antiestrogen for treatment of advanced breast cancers].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Tamoxifen; Treatment Outcome | 2000 |
Regulation of vascular endothelial growth factor expression by estrogens and progestins.
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Hormone Antagonists; Humans; Leiomyoma; Lymphokines; Mifepristone; Progestins; Receptors, Estrogen; RNA, Messenger; Signal Transduction; Transcription, Genetic; Uterine Neoplasms; Uterus; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2001 |
Fulvestrant.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Contraindications; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Tamoxifen | 2002 |
Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients.
Topics: Adaptation, Physiological; Animals; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Biological; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Proteins; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transplantation, Heterologous; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2001 |
Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Down-Regulation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen | 2001 |
ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen | 2001 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitriles; Tamoxifen; Triazoles | 2001 |
Prospects for combining hormonal and nonhormonal growth factor inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Quinazolines; Tamoxifen | 2001 |
Pure antiestrogens and breast cancer.
Topics: Antineoplastic Agents, Hormonal; Benzopyrans; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Piperidines; Polyunsaturated Alkamides; Propionates | 2001 |
Fulvestrant (AstraZeneca).
Topics: Animals; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drugs, Investigational; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Receptors, Estrogen; Structure-Activity Relationship; Treatment Outcome | 2002 |
ICI 182,780, a new antioestrogen with clinical potential.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Receptors, Estrogen | 1992 |
Development of novel oestrogen-receptor antagonists.
Topics: Animals; Breast Neoplasms; Drug Design; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Receptors, Estrogen; Tamoxifen | 1991 |
179 trial(s) available for fulvestrant and Breast Neoplasms
| Article | Year |
|---|---|
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Piperazines; Pyridines; Receptor, ErbB-2 | 2021 |
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Progression; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Piperidines; Placebos; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Pyridines | 2022 |
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Postmenopause; Pyrazoles; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Postmenopause; Purines | 2022 |
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Quinolines; Receptor, ErbB-2 | 2022 |
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Male; Mutation; Receptor, ErbB-2 | 2022 |
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Male; Piperazines; Prospective Studies; Pyridines; Thymidine Kinase | 2022 |
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patien
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Circulating Tumor DNA; Female; Fulvestrant; Humans; Mutation; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Ki-67 Antigen; Mechanistic Target of Rapamycin Complex 1; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Female; Fulvestrant; Humans; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials, Phase III as Topic; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles; Trastuzumab | 2022 |
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Piperazines; Pyridines; Receptor, ErbB-2 | 2022 |
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Sulfonamides | 2022 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomar
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Fulvestrant; Humans; Mutation; Postmenopause; Receptor, ErbB-2 | 2022 |
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; East Asian People; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2023 |
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Fulvestrant; Humans; Lymphopenia; Mutation; Neutropenia; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Pulmonary Embolism; Receptor, ErbB-2; Receptors, Estrogen; Venous Thromboembolism | 2023 |
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2022 |
Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2 | 2023 |
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen | 2023 |
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; East Asian People; Estrogens; Female; Fulvestrant; Humans; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen | 2023 |
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breas
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Patient Reported Outcome Measures; Protein Kinase Inhibitors; Quality of Life; Receptor, ErbB-2 | 2023 |
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Fulvestrant; Humans; Mutation; Paclitaxel | 2023 |
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Male; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2 | 2023 |
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2; Trastuzumab | 2023 |
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Topics: Breast Neoplasms; Female; Fulvestrant; Humans; Postmenopause; Proportional Hazards Models | 2023 |
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; North America; Piperazines; Pyridines; Receptor, ErbB-2; United States | 2020 |
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2020 |
A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Receptor, ErbB-2; Receptors, Cell Surface; Retrospective Studies | 2019 |
Efficacy and Determinants of Response to HER Kinase Inhibition in
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Treatment Outcome | 2020 |
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.
Topics: Adult; Aged; Alpha Particles; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy; Denosumab; Female; Fulvestrant; Humans; Injections, Intravenous; Middle Aged; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radioisotopes; Radium; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2020 |
Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Fulvestrant; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prognosis | 2020 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2020 |
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Cinnamates; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Middle Aged; Receptor, ErbB-2; Receptors, Progesterone | 2020 |
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Topics: Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Benzimidazoles; Brazil; Breast Neoplasms; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Humans; Middle Aged; North America; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Signal Transduction; Time Factors; Trastuzumab | 2020 |
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Male; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2020 |
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Body Mass Index; Breast Neoplasms; Confidence Intervals; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Obesity; Odds Ratio; Overweight; Placebos; Progression-Free Survival; Thinness; Weight Loss | 2021 |
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Lapatinib; Middle Aged; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2021 |
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Estrogen Receptor alpha; Female; Fulvestrant; Genotype; Humans; Middle Aged; Molecular Targeted Therapy; Mutation; Prospective Studies; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2020 |
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Health Status; Humans; Kaplan-Meier Estimate; Middle Aged; Patient Reported Outcome Measures; Progression-Free Survival; Proportional Hazards Models; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Japan; Letrozole; Middle Aged; Piperazines; Postmenopause; Premenopause; Progression-Free Survival; Pyridines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Drug Approval; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Patient Reported Outcome Measures; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2021 |
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Imidazoles; Neoplasm Recurrence, Local; Oxazepines; Phosphatidylinositol 3-Kinases; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Male; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2021 |
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Topics: Age Factors; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Topics: Adolescent; Adult; Aged; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2021 |
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2021 |
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Prognosis; Receptor, ErbB-2 | 2021 |
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Topics: Adolescent; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Pyridines; Receptor, ErbB-2 | 2021 |
Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA-Mutated Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Receptor, ErbB-2; Thiazoles | 2021 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Premenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2021 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate | 2017 |
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2017 |
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Interactions; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Goserelin; Humans; Middle Aged; Piperazines; Premenopause; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2017 |
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cytochrome P-450 CYP2D6; Disease-Free Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Tamoxifen | 2017 |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2018 |
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Azepines; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Pyrimidines | 2018 |
First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Survival Rate; Time Factors; Treatment Outcome | 2018 |
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Fulvestrant; Humans; Infusions, Intravenous; Injections, Intramuscular; Italy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Piperazines; Prognosis; Proportional Hazards Models; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Survival Analysis; Trastuzumab; Treatment Outcome | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Pyridines; Quality of Life; Viscera | 2018 |
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; China; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Japan; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Taiwan; Triazoles | 2018 |
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 6; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Piperazines; Pyridines; Receptors, Estrogen | 2018 |
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Quality of Life; Surveys and Questionnaires | 2018 |
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Drug Synergism; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment Outcome | 2018 |
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Progression-Free Survival; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2019 |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Goserelin; Humans; Neoplasm Metastasis; Premenopause; Tamoxifen | 2018 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Postmenopause; Survival Analysis | 2018 |
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.
Topics: Adult; Aged; Breast Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Survival Rate | 2018 |
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; DNA, Neoplasm; Female; Fulvestrant; Gene Expression Profiling; Humans; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Postmenopause; Prognosis; RNA, Neoplasm; Th1 Cells | 2018 |
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Estrogens; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Piperazines; Progesterone; Progression-Free Survival; Proportional Hazards Models; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Steroid; Survival Analysis | 2018 |
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Piperazines; Placebos; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2019 |
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Outcome Assessment, Health Care; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Research Design | 2018 |
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Maximum Tolerated Dose; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Receptors, Estrogen; Thiazoles; Time Factors | 2019 |
A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Fulvestrant; Humans; Maximum Tolerated Dose; Middle Aged; Naphthalenes; Neoplasm Metastasis; Postmenopause; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Estrogen | 2019 |
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin E; Female; Fulvestrant; Gene Expression Profiling; Humans; Neoplasm Metastasis; Oncogene Proteins; Piperazines; Progression-Free Survival; Proportional Hazards Models; Pyridines; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger | 2019 |
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Estrogen Receptor Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Postmenopause; Progression-Free Survival | 2019 |
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Metastasis; Prognosis; Thymidine Kinase | 2019 |
Alpelisib for
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Diarrhea; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2019 |
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2019 |
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estradiol; Feasibility Studies; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Evaluation Studies as Topic; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Tamoxifen | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult | 2019 |
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Topics: Aged; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Postmenopause; Receptor, ErbB-2 | 2013 |
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Grading; Nitriles; Postmenopause; Preoperative Care; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2013 |
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Receptors, Estrogen; Vascular Endothelial Growth Factor A | 2013 |
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factor 2; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Estradiol; Female; Fluorouracil; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Middle Aged; Odds Ratio; Receptors, Estrogen | 2014 |
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure | 2014 |
Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests | 2014 |
Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Postmenopause; Real-Time Polymerase Chain Reaction; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2014 |
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Peptides; Piperidines; Postmenopause; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2014 |
Everolimus-induced hematologic changes in patients with metastatic breast cancer.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Erythrocyte Count; Erythrocyte Indices; Estradiol; Everolimus; Female; Fulvestrant; Hematologic Diseases; Humans; Leukocyte Count; Leukopenia; Neoplasm Metastasis; Sirolimus; Thrombocytopenia | 2015 |
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Hormones; Humans; Lapatinib; Middle Aged; Postmenopause; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2014 |
Pictilisib stalls advanced ER+/PR+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Estradiol; Female; Fulvestrant; Humans; Indazoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides | 2015 |
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Germany; Hormones; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Spain; Treatment Outcome; Triazoles; Vascular Endothelial Growth Factor A | 2015 |
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Disease Progression; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Placebos; Postmenopause; Protein Kinase Inhibitors | 2015 |
Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Retrospective Studies; Treatment Outcome | 2016 |
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2015 |
Palbociclib for hormone receptor-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Piperazines; Postmenopause; Premenopause; Proportional Hazards Models; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Survival Rate; Treatment Outcome | 2015 |
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Treatment Outcome; Triazoles | 2015 |
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Estradiol; Female; Fulvestrant; Heterocyclic Compounds, 3-Ring; Humans; Hyperglycemia; Hypoglycemic Agents; Maximum Tolerated Dose; Middle Aged; Nitriles; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.
Topics: Anastrozole; Breast Neoplasms; Drug Interactions; Estradiol; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2016 |
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas
Topics: Adult; Aged; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Piperazines; Pyridines; Receptor, ErbB-2; Treatment Outcome | 2016 |
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Patient Reported Outcome Measures; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2016 |
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2016 |
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Estrogens; Female; Fulvestrant; Humans; Indazoles; Middle Aged; Mutation; Protein Kinase Inhibitors; Sulfonamides | 2016 |
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Epidermal Growth Factor; Estradiol; Female; Fulvestrant; Gene Expression Profiling; Hepatocyte Nuclear Factor 3-alpha; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Signal Transduction; Transcription Factor AP-2; Transcriptome | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Piperazines; Prospective Studies; Pyridines; Retrospective Studies; Triazoles | 2016 |
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Female; Follow-Up Studies; France; Fulvestrant; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Survival Rate; Triazoles | 2016 |
Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; China; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Patient Safety; Postmenopause; Proportional Hazards Models | 2016 |
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2016 |
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Survival Analysis; Treatment Outcome | 2017 |
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Austria; Breast Neoplasms; Estradiol; Female; Fulvestrant; Genes, erbB-2; Humans; Kaplan-Meier Estimate; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Registries | 2009 |
Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptors, Estrogen | 2008 |
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Viscera | 2009 |
Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrium; Endosonography; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause | 2009 |
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Farnesyltranstransferase; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2009 |
Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot study.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Peptides; Pilot Projects; Postmenopause; Treatment Outcome | 2009 |
Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol; Cholesterol, LDL; Endometrium; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Lipid Metabolism; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Postmenopause; Progesterone; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Triglycerides | 2009 |
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 2009 |
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Treatment Outcome | 2010 |
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Canada; Disease Progression; Double-Blind Method; Estradiol; Estrogen Antagonists; Europe; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Receptors, Estrogen; Time Factors; Treatment Outcome | 2010 |
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Topics: Antineoplastic Agents, Hormonal; Brazil; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Europe; Female; Fulvestrant; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Odds Ratio; Postmenopause; Proportional Hazards Models; Quality of Life; Receptors, Estrogen; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Disease Progression; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Time Factors; Treatment Outcome; Triazoles | 2011 |
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2011 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2012 |
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Recurrence; Triazoles | 2012 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone | 2012 |
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Goserelin; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Premenopause | 2012 |
Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Methotrexate; Middle Aged; Postmenopause; Receptors, Estrogen; Retrospective Studies | 2012 |
Combination anastrozole and fulvestrant in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2012 |
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Neoplasm Staging; Nitriles; Treatment Outcome; Triazoles | 2012 |
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Time Factors; Treatment Outcome | 2013 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; North America; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Logistic Models; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2002 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2003 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles | 2003 |
Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Area Under Curve; Breast Neoplasms; Chemistry, Pharmaceutical; Delayed-Action Preparations; Estradiol; Female; Fulvestrant; Half-Life; Humans; Injections, Intramuscular; Postmenopause; Tamoxifen | 2003 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Treatment Outcome; Triazoles | 2003 |
Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer.
Topics: Aged; Aged, 80 and over; Area Under Curve; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Selective Estrogen Receptor Modulators | 2003 |
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2004 |
Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Area Under Curve; Breast Neoplasms; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Half-Life; Humans; Metabolic Clearance Rate; Middle Aged; Postmenopause | 2004 |
Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Metastasis; Postmenopause; Treatment Outcome | 2004 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Nitriles; Postmenopause; Survival Analysis; Survival Rate; Triazoles | 2005 |
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Genes, erbB-2; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Treatment Outcome | 2005 |
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Treatment Outcome | 2006 |
Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoembryonic Antigen; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Mucin-1; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Treatment Outcome | 2006 |
Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Postmenopause; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Tamoxifen; Treatment Outcome | 2006 |
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Salvage Therapy; Treatment Outcome | 2007 |
Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Follicular Phase; Fulvestrant; Humans; Ki-67 Antigen; Luteal Phase; Middle Aged; Receptors, Estrogen; Receptors, Progesterone | 2007 |
Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Empathy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Palliative Care; Program Evaluation; Prospective Studies; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome | 2007 |
Evaluation of fulvestrant in clinical practice: use of an electronic data registry.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Postmenopause; Treatment Outcome | 2007 |
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Belgium; Breast Neoplasms; Endocrine System; Estradiol; Estrogens; Female; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2008 |
Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Ki-67 Antigen; Middle Aged; Neoplasms, Hormone-Dependent; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2008 |
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Placebos; Postmenopause; Quality of Life; Receptors, Estrogen | 2008 |
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Tolerance; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Tamoxifen | 1995 |
Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Tamoxifen | 1995 |
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Ki-67 Antigen; Menopause; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Receptors, Estrogen; Receptors, Progesterone | 1994 |
Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Follicle Stimulating Hormone; Fulvestrant; Humans; Luteinizing Hormone; Middle Aged; Sex Hormone-Binding Globulin | 1996 |
Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Biopsy; Breast Neoplasms; Combined Modality Therapy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Longitudinal Studies; Middle Aged; Paraffin Embedding; Placebos; Receptors, Estrogen; Tamoxifen | 1997 |
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Ki-67 Antigen; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2001 |
838 other study(ies) available for fulvestrant and Breast Neoplasms
| Article | Year |
|---|---|
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Topics: Animals; Breast Neoplasms; Cell Division; Estrogen Antagonists; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tumor Cells, Cultured | 1997 |
(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
Topics: Administration, Oral; Animals; Benzopyrans; Binding, Competitive; Breast Neoplasms; Cytosol; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Female; Humans; Mice; Molecular Structure; Ovariectomy; Piperidines; Propionates; Raloxifene Hydrochloride; Receptors, Estrogen; Stereoisomerism; Structure-Activity Relationship; Uterus | 1997 |
Synthesis and biological evaluation of stilbene-based pure estrogen antagonists.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mice; Organ Size; Stilbenes; Structure-Activity Relationship; Uterus | 2004 |
Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells.
Topics: Adenylyl Cyclases; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Estrogens; GTP-Binding Protein alpha Subunits, Gs; Humans; Kidney; Membrane Proteins; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Sulfur Radioisotopes; Transfection | 2005 |
Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Humans; Oxathiins; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Uterus | 2005 |
Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Coumarins; Estrogens; Humans; Ligands; Luciferases; Models, Molecular; Molecular Structure; Promoter Regions, Genetic; Receptors, Estrogen; Thymidine Kinase; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured | 2007 |
Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Genes, Reporter; Humans; Inhibitory Concentration 50; Molecular Conformation; Protein Binding; Receptors, Estrogen; Receptors, Progesterone; Tetrahydroisoquinolines | 2007 |
Effect of fluorination on the pharmacological profile of 11beta isomers of fulvestrant in breast carcinoma cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Humans | 2009 |
9,11-Secosterols with antiproliferative activity from the gorgonian Eunicella cavolini.
Topics: Adenocarcinoma; Animals; Anthozoa; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Estrogens; Female; Humans; Male; Molecular Structure; Prostatic Neoplasms; Sterols | 2009 |
Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).
Topics: Acrylates; Adaptor Proteins, Signal Transducing; Binding, Competitive; Breast Neoplasms; Bridged Bicyclo Compounds; Carbonic Anhydrases; Cell Line, Tumor; Cyclofenil; Down-Regulation; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Ligands; Microfilament Proteins; Neuropeptides; Nuclear Proteins; Radioligand Assay; Receptors, Progesterone; RNA, Messenger; Structure-Activity Relationship; Transcription, Genetic; Trefoil Factor-1; Tumor Suppressor Proteins | 2010 |
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Humans; Hydrophobic and Hydrophilic Interactions; Isoflavones; Mice; Mice, Nude; Models, Molecular; Receptors, Progesterone; Response Elements; Structure-Activity Relationship; Transcription, Genetic; Xenograft Model Antitumor Assays | 2010 |
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
Topics: Antineoplastic Agents; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Female; Humans; Magnetic Resonance Spectroscopy; Male; Models, Chemical; Ovarian Neoplasms; Prostatic Neoplasms; Pterocarpans; Receptors, Estrogen; Stereoisomerism | 2011 |
Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.
Topics: Breast Neoplasms; Catalysis; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular; Transcription, Genetic | 2013 |
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Dogs; Drug Discovery; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Heterografts; Humans; Mice; Proteolysis; Rats; Selective Estrogen Receptor Modulators; Small Molecule Libraries; Tamoxifen | 2015 |
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cinnamates; Clinical Trials, Phase I as Topic; Down-Regulation; Drug Design; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Indoles; Injections, Intramuscular; X-Ray Diffraction | 2015 |
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cinnamates; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Indazoles; Rats; Structure-Activity Relationship; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
Topics: Administration, Oral; Animals; Biological Availability; Boronic Acids; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Mice, Inbred C57BL; Selective Estrogen Receptor Modulators; Signal Transduction; Stereoisomerism; Sterols; Tamoxifen | 2016 |
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice, Nude; Models, Molecular; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Thiophenes | 2017 |
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
Topics: Acrylates; Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Dogs; Drug Discovery; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice, Inbred C57BL; Molecular Docking Simulation; Proteolysis; Tetrahydroisoquinolines | 2017 |
Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.
Topics: Acrylamides; Adamantane; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Esters; Estrogen Antagonists; Estrogen Receptor alpha; Female; Humans; Ketones; Radioligand Assay; Stereoisomerism; Structure-Activity Relationship | 2017 |
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Drug Design; Drug Discovery; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice; Mice, Nude; Rats; Rats, Sprague-Dawley; Rats, Wistar; Selective Estrogen Receptor Modulators; Thiophenes; Xenograft Model Antitumor Assays | 2018 |
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzopyrans; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Mice; Rats; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dogs; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Heterocyclic Compounds, 3-Ring; Humans; Indazoles; Male; MCF-7 Cells; Mice, SCID; Microsomes, Liver; Molecular Structure; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2019 |
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Topics: Animals; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation; Proteolysis; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Thiophenes; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclization; Drug Discovery; Female; Humans; Lipids; Molecular Structure; Selective Estrogen Receptor Modulators; Structure-Activity Relationship | 2020 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Click Chemistry; DNA; Estrogen Antagonists; Estrogen Receptor alpha; Female; Half-Life; Humans; Indoles; Kinetics; Mice; Small Molecule Libraries; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2021 |
Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Estrogen Receptor Antagonists; Female; Humans; MCF-7 Cells; Molecular Structure; Receptors, Estrogen; Structure-Activity Relationship; Thiophenes; Tumor Cells, Cultured | 2021 |
Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Development; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Tetrahydroisoquinolines; Tumor Cells, Cultured | 2021 |
Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Female; Humans; Receptors, Estrogen; Unfolded Protein Response | 2022 |
Discovery of Thieno[2,3-
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor alpha; Female; Humans; Indazoles; MCF-7 Cells; Mice; Receptors, Estrogen; Thiophenes | 2022 |
Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD).
Topics: Administration, Oral; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor alpha; Female; Humans; Indoles; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2022 |
MLL3 is a de novo cause of endocrine therapy resistance.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Breast Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mutation; Tamoxifen | 2021 |
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Progesterone; Survival Rate; United States; United States Food and Drug Administration | 2021 |
[Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Peritoneal Neoplasms | 2021 |
Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report.
Topics: Acidosis, Lactic; Aminopyridines; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Metformin; Middle Aged; Purines; Renal Insufficiency | 2022 |
Observational real world data with palbociclib associated to hormone therapy for advanced breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2021 |
Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer.
Topics: Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cinnamates; Collagen; Drug Combinations; Enhancer of Zeste Homolog 2 Protein; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Indazoles; Laminin; Mammary Glands, Human; Mechanotransduction, Cellular; p38 Mitogen-Activated Protein Kinases; Phenotype; Proteoglycans; Tamoxifen; Tissue Culture Techniques; Transcriptome | 2021 |
The role of estrogen receptor signaling in suppressing the immune response to cancer.
Topics: Animals; Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Immunity; Mice; Receptors, Estrogen; Tumor Microenvironment | 2021 |
Regulation of TET2 gene expression and 5mC oxidation in breast cancer cells by estrogen signaling.
Topics: 5-Methylcytosine; Breast Neoplasms; Cell Line, Tumor; Dioxygenases; DNA-Binding Proteins; Down-Regulation; Enhancer Elements, Genetic; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Oxidation-Reduction; Protein Binding; Signal Transduction; Transcription, Genetic | 2022 |
The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer.
Topics: Breast Neoplasms; Estrogens; Female; Fulvestrant; HLA Antigens; HLA-A Antigens; Humans; Interferons; Ki-67 Antigen; Receptors, Estrogen; RNA, Small Interfering | 2022 |
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Trastuzumab; Treatment Outcome | 2022 |
A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2022 |
[Two Cases of Carcinoma en Cuirasse, as Cutaneous Metastasis of Breast Cancer].
Topics: Aged; Breast; Breast Neoplasms; Carcinoma; Female; Fulvestrant; Humans; Skin Neoplasms | 2022 |
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endocrine Gland Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasm Recurrence, Local; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Receptors, Neuropeptide Y; Tamoxifen | 2022 |
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2022 |
Targeting Metabolic Adaptations in the Breast Cancer-Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy.
Topics: Animals; Breast Neoplasms; Diet; Female; Fulvestrant; Glucose; Humans; Hydrogels; Liver Neoplasms; Mice; Receptors, Estrogen; Tumor Microenvironment | 2022 |
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2022 |
Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Japan; Piperazines; Pyridines; Receptor, ErbB-2 | 2022 |
The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies | 2022 |
Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Pyridines; Receptors, Estrogen | 2022 |
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Letrozole; Thiazoles | 2022 |
The efficacy and safety of alpelisib in breast cancer: A real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Retrospective Studies | 2022 |
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Letrozole; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2022 |
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Paclitaxel; Piperazines; Postmenopause; Purines; Pyridines | 2022 |
Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Japan; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Retrospective Studies | 2022 |
[A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy].
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lung Neoplasms; Mastectomy; Neoplasm Recurrence, Local | 2022 |
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
Topics: Androgen Receptor Antagonists; Androgens; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Naphthalenes; Piperidines; Pyrrolidines; Radiation Tolerance; Receptors, Androgen; Receptors, Estrogen; Tamoxifen; Thiazoles; Triazoles | 2022 |
Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Letrozole; Patient-Centered Care; Pharmacies; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indazoles; Neoplasm Recurrence, Local; Pyridines | 2022 |
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Letrozole; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2022 |
Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diterpenes; Estrogen Receptor alpha; Female; Fulvestrant; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger; TOR Serine-Threonine Kinases | 2022 |
[Long-Term Survival of a Patient with Triple-Negative Breast Cancer with Hormone Receptor Status Conversion between Primary and Metastatic Tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fulvestrant; Humans; Mastectomy; Middle Aged; Triple Negative Breast Neoplasms | 2022 |
Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Ligands; Proteolysis; Ubiquitin-Protein Ligases | 2022 |
Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
Topics: Breast Neoplasms; Cell Proliferation; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mutation; Protein Domains; Transcription, Genetic | 2022 |
Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Fulvestrant; Humans; MicroRNAs; Middle Aged; Retrospective Studies | 2022 |
A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Tapering; Duration of Therapy; Female; Fulvestrant; Humans; Retrospective Studies | 2023 |
Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dendrimers; Female; Fulvestrant; Humans; Lapatinib | 2022 |
Identification of estrogen receptor down-regulators for endocrine resistant breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Receptors, Estrogen | 2022 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene | 2022 |
Generation of 3D Spheroids Using a Thiol-Acrylate Hydrogel Scaffold to Study Endocrine Response in ER
Topics: Acrylates; Breast Neoplasms; Estrogens; Female; Fulvestrant; Humans; Hydrogels; Spheroids, Cellular; Sulfhydryl Compounds | 2022 |
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; TOR Serine-Threonine Kinases | 2022 |
Abemaciclib and Fulvestrant for Bilateral Choroidal Metastasis From Breast Carcinoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans | 2022 |
Clinical Translation: Targeting the Estrogen Receptor.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Receptors, Estrogen; Tamoxifen | 2022 |
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
Topics: Animals; Aromatase Inhibitors; Breast Neoplasms; Carbolines; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Mice; Mutation; Progesterone; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2022 |
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Topics: Aminopyridines; Benzimidazoles; Biomarkers; Breast Neoplasms; C-Reactive Protein; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Lymphocyte Count; Lymphocytes; Prognosis; Protein Kinase Inhibitors; Receptors, Estrogen; Retrospective Studies | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.
Topics: Biology; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Receptor, ErbB-2 | 2023 |
Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; EGF Family of Proteins; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Risk Factors | 2023 |
The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged | 2022 |
Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Retrospective Studies | 2022 |
The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Furylfuramide; Humans; Ligands; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Sumoylation; Tamoxifen | 2023 |
Capivasertib Doubles PFS in Some Breast Cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2023 |
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Middle Aged; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2 | 2023 |
Second Oral SERD Shines in ER+ Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen | 2023 |
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; Genomics; Humans; Letrozole; Receptor, ErbB-2 | 2023 |
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2023 |
ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Protein Isoforms; Tamoxifen; Tretinoin | 2023 |
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Genomics; Humans; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Receptors, Estrogen; Tumor Suppressor Protein p53 | 2023 |
Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Prediabetic State; Receptor, ErbB-2; Retrospective Studies | 2023 |
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Male; Receptor, ErbB-2; Retrospective Studies | 2023 |
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Japan; Receptor, ErbB-2; Receptors, Estrogen; Triple Negative Breast Neoplasms | 2023 |
A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Denmark; Female; Fulvestrant; Humans; Receptor, ErbB-2; Retrospective Studies | 2023 |
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2 | 2023 |
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Topics: Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Phosphatidylinositol 3-Kinases; Signal Transduction | 2023 |
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Quality of Life; Receptor, ErbB-2 | 2023 |
Combined chemo-endocrine therapy as a potential new option for HR+/HER2- advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine.
Topics: Breast Neoplasms; Female; Fulvestrant; Humans; Prospective Studies; Receptor, ErbB-2; Vinorelbine | 2023 |
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Japan; Middle Aged; Receptor, ErbB-2 | 2023 |
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplastic Cells, Circulating; Receptors, Estrogen | 2023 |
Small change - big consequence: The impact of C15-C16 double bond in a D‑ring of estrone on estrogen receptor activity.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrone; Female; Fulvestrant; Humans; Molecular Docking Simulation; Receptors, Estrogen; Tamoxifen | 2023 |
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.
Topics: Breast Neoplasms; Female; Fulvestrant; Humans; Mitogen-Activated Protein Kinase Kinases; Neurofibromin 1; NFI Transcription Factors; Protein Kinase Inhibitors; Proteogenomics; Receptors, Estrogen; RNA, Messenger | 2023 |
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Postmenopause; Receptor, ErbB-2; Retrospective Studies | 2023 |
Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fulvestrant; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Signal Transduction; Tamoxifen | 2023 |
Cost-Effectiveness Analysis of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib for Inoperable or Recurrent Breast Cancer.
Topics: Breast Neoplasms; Cost-Effectiveness Analysis; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans | 2023 |
Effects of
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Estradiol; Female; Fulvestrant; Genotype; Humans; Nitriles; Triazoles | 2023 |
Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2023 |
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor-positive Breast Cancer.
Topics: Bayes Theorem; Breast Neoplasms; Female; Fulvestrant; Humans; Receptors, Estrogen | 2023 |
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Mutation; Receptor, ErbB-2 | 2023 |
Precision medicine: PI3K targeting in advanced breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Mutation; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; PTEN Phosphohydrolase; Thiazoles | 2019 |
Breast reconstruction in the patient with stable, metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Life Expectancy; Mammaplasty; Mastectomy; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Quality of Life | 2020 |
Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Databases, Factual; Disease-Free Survival; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Receptor, ErbB-2; Retrospective Studies | 2020 |
A role for fulvestrant monotherapy in the first-line treatment of ER+ metastatic breast cancer?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Fulvestrant; Humans; Receptors, Estrogen | 2020 |
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Mice; Xenograft Model Antitumor Assays | 2020 |
Abemaciclib plus fulvestrant for breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2019 |
DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer.
Topics: Benzhydryl Compounds; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; CpG Islands; DNA Methylation; Epigenesis, Genetic; Female; Focal Adhesions; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Long Interspersed Nucleotide Elements; MCF-7 Cells; Phenols; Receptors, Estrogen | 2019 |
CDK4/6 inhibitors prolong OS.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Fulvestrant; Humans; Receptor, ErbB-2 | 2019 |
Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Middle Aged; Pharmacogenomic Testing; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2020 |
Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin.
Topics: Adipocytes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Communication; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Leptin; MCF-7 Cells; Neoplastic Stem Cells; Signal Transduction; STAT3 Transcription Factor; Tamoxifen; Tumor Microenvironment | 2019 |
Protein‑ and growth‑modulatory effects of carcinoma‑associated fibroblasts on breast cancer cells: Role of interleukin‑6.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Proliferation; Culture Media, Conditioned; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; Interleukin-6; Tumor Cells, Cultured | 2020 |
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2020 |
First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Follow-Up Studies; Fulvestrant; Humans; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, Liquid; Estradiol; Female; Fulvestrant; Humans; Immunoassay; Middle Aged; Postmenopause; Reproducibility of Results; Tandem Mass Spectrometry | 2020 |
mSWI/SNF Component ARID1A Mediates Breast Cancer Treatment Response.
Topics: Breast Neoplasms; Cell Cycle Proteins; DNA-Binding Proteins; Fulvestrant; Histone Deacetylase 1; Humans; Nuclear Proteins; Tamoxifen; Transcription Factors | 2020 |
Capivasertib inhibits a key pathway in metastatic breast cancer.
Topics: Aromatase; Breast Neoplasms; Estrogens; Fulvestrant; Humans; Neoplasm Recurrence, Local | 2020 |
A single droplet digital PCR for ESR1 activating mutations detection in plasma.
Topics: Breast Neoplasms; Circulating Tumor DNA; Estrogen Receptor alpha; Exons; Female; Fulvestrant; Gene Frequency; Humans; Mutation; Piperazines; Plasma; Polymerase Chain Reaction; Prospective Studies; Pyridines | 2020 |
UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.
Topics: Animals; Breast Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, Nude; Tamoxifen; Ubiquitin Thiolesterase; Up-Regulation | 2020 |
Novel breast cancer treatment leads to hyperglycaemia.
Topics: Aged; Antineoplastic Agents, Hormonal; Blood Glucose; Blood Glucose Self-Monitoring; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Hyperglycemia; Monitoring, Ambulatory; Phosphoinositide-3 Kinase Inhibitors; Prediabetic State; Thiazoles | 2020 |
[Challenges and countermeasures in the treatment of luminal breast cancer].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Fulvestrant; Humans; Neoplasm Recurrence, Local; Receptors, Estrogen; Vascular Endothelial Growth Factor A | 2020 |
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
The Predictive Value of Early Changes in
Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Fulvestrant; Humans; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Receptors, Estrogen | 2020 |
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Retinoblastoma Protein; RNA Interference; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Effects of ICI 182,780, an ERα and ERβ antagonist, and G-1, a GPER agonist, on autophagy in breast cancer cells.
Topics: Analysis of Variance; Autophagy; Blotting, Western; Breast Neoplasms; Cell Proliferation; Cell Survival; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Flow Cytometry; Fulvestrant; Humans; MCF-7 Cells; Receptors, G-Protein-Coupled; Reproducibility of Results; Sirolimus; Time Factors; Transfection | 2020 |
Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; China; Circulating Tumor DNA; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Progression-Free Survival; Retrospective Studies; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Toremifene | 2020 |
CDK4/6 inhibition in HER2-positive breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Trastuzumab | 2020 |
Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chymases; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; HSC70 Heat-Shock Proteins; Humans; Immunohistochemistry; Lysosomal-Associated Membrane Protein 2; Lysosomes; Phosphorylation; Protein Stability; Receptors, Estrogen; Receptors, G-Protein-Coupled; RNA, Small Interfering; Signal Transduction; Tamoxifen; Transcription Factors | 2020 |
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cinnamates; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Indoles; Mammary Neoplasms, Experimental; Mice, Nude; Postmenopause; Selective Estrogen Receptor Modulators | 2020 |
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2 | 2020 |
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2 | 2020 |
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2 | 2020 |
Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Topics: Aminopyridines; Breast Neoplasms; Fulvestrant; Humans; Purines | 2020 |
Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply.
Topics: Aminopyridines; Breast Neoplasms; Fulvestrant; Humans; Purines | 2020 |
Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment.
Topics: Antineoplastic Agents, Hormonal; Berberine Alkaloids; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dopamine Antagonists; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Models, Molecular; Protein Conformation; Tamoxifen | 2020 |
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Drug Administration Schedule; Estrogens; Fatigue; Febrile Neutropenia; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Mucositis; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Thrombocytopenia | 2020 |
Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antrodia; Bone Neoplasms; Breast Neoplasms; Female; Fulvestrant; Humans; Magnetic Resonance Imaging; Middle Aged; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Immunoassay; Postmenopause | 2020 |
Fasting-mimicking diet and hormone therapy induce breast cancer regression.
Topics: Animals; Biological Factors; Breast Neoplasms; Diet Therapy; Diet, Healthy; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Fasting; Female; Fulvestrant; Humans; Insulin; Insulin-Like Growth Factor I; Leptin; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Piperazines; PTEN Phosphohydrolase; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Immunoassay; Postmenopause | 2020 |
Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series.
Topics: Adult; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Progression-Free Survival; Retrospective Studies; Safety; Time-to-Treatment; Treatment Outcome | 2020 |
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Lapatinib; Mice; Mice, Nude; Oncogene Proteins, Fusion; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; Isoquinolines; Mice; Mice, Inbred NOD; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyridines; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2020 |
Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Narrative Medicine; Neoplasm Recurrence, Local; Re-Irradiation; Receptors, Estrogen | 2020 |
Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition.
Topics: Breast Neoplasms; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; MCF-7 Cells; Models, Theoretical; Receptors, Estrogen | 2020 |
Fulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Immunity, Innate; MCF-7 Cells; Mice, Nude; Microdialysis; Neovascularization, Pathologic; Receptors, Estrogen; Tamoxifen; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zebrafish | 2020 |
Identification of Antiestrogen-Bound Estrogen Receptor α Interactomes in Hormone-Responsive Human Breast Cancer Cell Nuclei.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Tamoxifen | 2020 |
Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Fulvestrant; Health Care Costs; Humans; Markov Chains; Quality-Adjusted Life Years | 2020 |
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Purines; Receptors, Estrogen; Thiazoles | 2021 |
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Prospective Studies; Pyridines; Receptor, ErbB-2; Survival Rate; Tamoxifen; Thymidine Kinase | 2020 |
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Clinical Trials, Phase III as Topic; Female; Fulvestrant; Gene Dosage; Humans; Multicenter Studies as Topic; Mutation; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Estrogen | 2021 |
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2021 |
Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Fulvestrant; Humans; Imidazoles; Magnetic Resonance Imaging; MCF-7 Cells; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Oxazepines; Protein Kinase Inhibitors; Receptors, Estrogen; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Estrogens; Female; Fulvestrant; Humans; Male; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2020 |
Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; China; Disease Progression; Duration of Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Liver Neoplasms; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Time Factors | 2020 |
Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Fatty Acid Synthase, Type I; Female; Fulvestrant; Humans; MAP Kinase Signaling System; MCF-7 Cells; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Proteins; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Tamoxifen | 2020 |
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Selective Estrogen Receptor Modulators; Signal Transduction; Steroids; Structure-Activity Relationship | 2020 |
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of
Topics: Breast Neoplasms; Estrogen Receptor alpha; Fulvestrant; Gene Expression; Humans; Mutation | 2021 |
Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Progression-Free Survival; Proportional Hazards Models; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Young Adult | 2020 |
The complex balance of PI3K inhibition.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Fulvestrant; Humans; Imidazoles; Oxazepines; Phosphatidylinositol 3-Kinases; Receptors, Estrogen | 2021 |
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Furans; Gene Expression Regulation, Neoplastic; Humans; Ketones; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2020 |
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Fulvestrant; Gene Expression; Humans; Lapatinib; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; RNA-Binding Proteins; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
SOLAR1s: alpelisib returns to earth?
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Fulvestrant; Humans; Thiazoles | 2021 |
Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction | 2021 |
Icb-1 expression inhibits growth and fulvestrant response of breast cancer cells and affects survival of breast cancer patients.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Reverse Transcriptase Polymerase Chain Reaction | 2021 |
Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Estrogen Receptor alpha; Fulvestrant; Humans; Inhibitory Concentration 50; Ki-67 Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Tamoxifen | 2021 |
[Locally Advanced Breast Cancer Successfully Treated with Abemaciclib and Fulvestrant-A Case Report].
Topics: Aged; Aminopyridines; Axilla; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Neoplasm Recurrence, Local | 2020 |
Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cohort Studies; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; United States | 2021 |
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Receptors, Estrogen; Signal Transduction | 2021 |
Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Staging; Postmenopause; Prognosis; Receptors, Estrogen; Retrospective Studies; Treatment Outcome | 2021 |
TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions.
Topics: 5-Methylcytosine; Animals; Breast Neoplasms; Chromatin Assembly and Disassembly; Databases, Genetic; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Enhancer Elements, Genetic; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; GATA3 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Xenograft Model Antitumor Assays | 2021 |
Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Models, Biological; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2021 |
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyridines; Survival Analysis; Treatment Outcome | 2021 |
Collagen I Fibrous Substrates Modulate the Proliferation and Secretome of Estrogen Receptor-Positive Breast Tumor Cells in a Hormone-Restricted Microenvironment.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Collagen Type I; Female; Fulvestrant; Humans; Receptors, Estrogen; Tumor Microenvironment | 2021 |
Detection of Estrogen Receptor Alpha and Assessment of Fulvestrant Activity in MCF-7 Tumor Spheroids Using Microfluidics and SERS.
Topics: Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Female; Fulvestrant; Gold; Humans; MCF-7 Cells; Metal Nanoparticles; Microfluidics | 2021 |
Neratinib: an option for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Disease Management; Female; Fulvestrant; Humans; Neoplasm Metastasis; Oxazoles; Pyridines; Quality of Life; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Embolia Cutis Medicamentosa (Nicolau Syndrome) Secondary to Intramuscular Fulvestrant Injection: A Case Report.
Topics: Aged, 80 and over; Breast Neoplasms; Buttocks; Female; Fulvestrant; Humans; Injections, Intramuscular; Nicolau Syndrome | 2022 |
Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Staging; Sequence Analysis, RNA | 2021 |
[A Case of Palbociclib plus Fulvestrant‒Resistant Metastatic Breast Cancer That Responded to Abemaciclib plus Fulvestrant].
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Pyridines | 2021 |
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Estrogen Receptor alpha; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mutation; Neoplasm Metastasis; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome | 2021 |
Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Liver Failure, Acute; Receptor, ErbB-2 | 2021 |
[A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyridines | 2021 |
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Fulvestrant; Genomics; Humans; Mice; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Proto-Oncogene Proteins pp60(c-src); Receptors, Estrogen; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2021 |
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Delivery of Health Care; Female; Fulvestrant; Humans; Postmenopause; Purines; Receptor, ErbB-2 | 2021 |
Patient-derived scaffolds as a drug-testing platform for endocrine therapies in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Endocrine Cells; Female; Fulvestrant; Gene Expression; Humans; Male; MCF-7 Cells; Middle Aged; Piperazines; Pluripotent Stem Cells; Pyridines; Up-Regulation | 2021 |
ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Zinc Finger E-box Binding Homeobox 2 | 2021 |
The evolving use of SERDs in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Indoles; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2021 |
Cell Line-Specific Network Models of ER
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Computer Simulation; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; HEK293 Cells; Humans; MCF-7 Cells; Models, Theoretical; Myeloid Cell Leukemia Sequence 1 Protein; Receptors, Estrogen; Retinoblastoma Binding Proteins; Signal Transduction; Thiazoles; Ubiquitin-Protein Ligases | 2021 |
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Protein Isoforms; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Thiophenes | 2021 |
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; Drug Combinations; Female; Fulvestrant; Humans; Neoplasm Staging; Progression-Free Survival; Receptor, ErbB-2; Treatment Outcome | 2021 |
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2021 |
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Italy; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2021 |
A New Spin on Antibody-Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Estradiol; Fulvestrant; Humans; Nanoparticles; Receptor, ErbB-2; Trastuzumab | 2017 |
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Treatment Failure; Treatment Outcome | 2017 |
FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gene Amplification; Goserelin; Humans; Piperazines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2017 |
Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Embarrassment; Female; Fulvestrant; Humans | 2017 |
Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; E2F1 Transcription Factor; Estradiol; Estrogens; Female; Fulvestrant; Gene Knockdown Techniques; Humans; Mitosis; Phosphorylation; Proto-Oncogene Proteins c-mdm2; Retinoblastoma Protein; Signal Transduction; Tumor Suppressor Protein p53 | 2017 |
Effect of dioxin and 17β-estradiol on the expression of cytochrome P450 1A1 gene via an estrogen receptor dependent pathway in cellular and xenografted models.
Topics: Animals; Breast Neoplasms; Cytochrome P-450 CYP1A1; Estradiol; Estrogens; Female; Fulvestrant; Heterografts; Humans; MCF-7 Cells; Mice, SCID; Polychlorinated Dibenzodioxins; Receptors, Aryl Hydrocarbon; Receptors, Estrogen; RNA, Messenger; Signal Transduction; Xenobiotics | 2017 |
Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Cost-Benefit Analysis; Drug Costs; Estradiol; Female; Fulvestrant; Humans; Markov Chains; Nitriles; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2017 |
Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer.
Topics: Adipose Tissue; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cells, Cultured; Chemotherapy, Adjuvant; Disease Models, Animal; Drug Delivery Systems; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mammaplasty; Mice; Mice, Nude; Transplantation, Autologous | 2017 |
Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Medical Oncology; Nitriles; Piperazines; Pyridines; Triazoles | 2017 |
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor Resistant Metastatic Breast Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Middle Aged | 2017 |
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Retrospective Studies; Time-to-Treatment; Treatment Failure | 2018 |
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Germany; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen | 2018 |
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Drug Resistance, Neoplasm; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Lymphatic Metastasis; Middle Aged; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2018 |
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Mutation; Selective Estrogen Receptor Modulators; Tamoxifen | 2017 |
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Piperazines; Progression-Free Survival; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Thrombocytopenia | 2018 |
Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemoprevention; Chromatography, Liquid; Disease Models, Animal; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Germ-Line Mutation; Humans; Tandem Mass Spectrometry; Tissue Distribution; Xenograft Model Antitumor Assays | 2018 |
A new era for treatment development in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Fulvestrant; Humans; Neoadjuvant Therapy; Piperazines; Pyridines; Trastuzumab | 2018 |
Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Iodine Radioisotopes; Mice; Mice, Inbred BALB C; Mice, Nude; Receptors, Estrogen; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Topics: Aniline Compounds; Animals; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Estrogen Antagonists; Female; Fulvestrant; Gene Targeting; Humans; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Receptors, Estrogen; Signal Transduction; Sulfonamides; Up-Regulation | 2018 |
[Long-Term Effect of Fulvestrant for Locally Advanced Breast Cancer in an Elderly Patient - A Case Report].
Topics: Aged; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Estradiol; Female; Fulvestrant; Humans; Time Factors | 2018 |
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Drug Synergism; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Mice; Models, Biological; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid | 2018 |
Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptors, Steroid; Treatment Outcome; Viscera | 2018 |
Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MCF-7 Cells; MicroRNAs; Proto-Oncogene Proteins c-abl | 2018 |
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Electronic Health Records; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salvage Therapy; Time Factors | 2019 |
Breast cancer: Changes in clonal dynamics predict response to palbociclib.
Topics: Breast Neoplasms; Circulating Tumor DNA; Fulvestrant; Humans; Piperazines; Pyridines | 2018 |
Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; MicroRNAs; Tamoxifen | 2018 |
RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., et al.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Estradiol; Fulvestrant; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2018 |
Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Everolimus; Female; Fulvestrant; Health Care Costs; Humans; Japan; Markov Chains; Middle Aged; Models, Economic; Postmenopause; Quality-Adjusted Life Years; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Toremifene | 2018 |
[CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases | 2018 |
Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Obesity; Overweight; Postmenopause; Retrospective Studies; Sweden; Treatment Outcome | 2018 |
In Vitro Estrogenic and Breast Cancer Inhibitory Activities of Chemical Constituents Isolated from Rheum undulatum L.
Topics: Anthraquinones; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Emodin; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Glucosides; Humans; Molecular Structure; Plant Extracts; Plant Roots; Rheum; Stilbenes; Structure-Activity Relationship | 2018 |
Fulvestrant in management of hormone receptor-positive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Practice Guidelines as Topic; Treatment Outcome | 2018 |
Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor.
Topics: Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Databases, Pharmaceutical; Drug Evaluation, Preclinical; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression; Humans; Insulin Receptor Substrate Proteins; Ligands; MCF-7 Cells; Membrane Proteins; Models, Chemical; Models, Molecular; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; User-Computer Interface | 2018 |
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Estrogens; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Neoplasms, Hormone-Dependent; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen | 2018 |
SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Middle Aged; Neoplasm Metastasis; Snail Family Transcription Factors | 2018 |
High collagen density augments mTOR-dependent cancer stem cells in ERα+ mammary carcinomas, and increases mTOR-independent lung metastases.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Collagen; Collagen Type I; Collagen Type I, alpha 1 Chain; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Microenvironment | 2018 |
[Experience of Fulvestrant for Hormone Receptor-Positive HER2-Negative Advanced and Metastatic Breast Cancer].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2018 |
A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Knockdown Techniques; Genome, Human; GTP-Binding Protein beta Subunits; Humans; MCF-7 Cells; Tamoxifen | 2018 |
Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report.
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fulvestrant; Gastroenteritis; Humans; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2018 |
In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Computer Simulation; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mitoxantrone; Neoplasm Metastasis; Reproducibility of Results; Tamoxifen; Thioridazine | 2018 |
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Middle Aged; Mutation; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles | 2018 |
Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.
Topics: Breast Neoplasms; Chromatin Assembly and Disassembly; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Proteins; Sumoylation; Tamoxifen; Transcription, Genetic | 2019 |
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Patient Satisfaction; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Surveys and Questionnaires; Treatment Outcome | 2019 |
[A Case of Bone Marrow Carcinomatosis of Occult Breast Cancer Treated Effectively with Fulvestrant].
Topics: Antineoplastic Agents, Hormonal; Bone Marrow Neoplasms; Breast Neoplasms; Diagnosis, Differential; Female; Fulvestrant; Humans; Middle Aged; Treatment Outcome | 2018 |
Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.
Topics: Breast Neoplasms; Circulating Tumor DNA; Clonal Evolution; Drug Resistance; Fulvestrant; Humans; Mutation; Piperazines; Precision Medicine; Pyridines | 2018 |
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Piperazines; Practice Patterns, Physicians'; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2019 |
Survival data from PALOMA-3 reported.
Topics: Breast Neoplasms; Fulvestrant; Humans; Piperazines; Pyridines | 2018 |
Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Lung Neoplasms; MCF-7 Cells; Mutation; Neoplasm Invasiveness; Proto-Oncogene Proteins c-myc; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Exome Sequencing; Female; Fulvestrant; Genetic Heterogeneity; Humans; Jumonji Domain-Containing Histone Demethylases; MCF-7 Cells; Nuclear Proteins; Repressor Proteins; Retinoblastoma-Binding Protein 2; Transcriptome | 2018 |
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Ligands; MCF-7 Cells; Mutant Proteins; Mutation; Piperazines; Protein Binding; Protein Domains; Protein Structure, Secondary; Pyridines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2018 |
Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; RNA, Long Noncoding; Tamoxifen | 2018 |
Acquired HER2 mutations in ER
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; HEK293 Cells; Humans; MCF-7 Cells; Mutation; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen | 2019 |
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Heterografts; Humans; Indoles; MCF-7 Cells; Mice; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen | 2019 |
The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Estrogen Receptor alpha; Female; Fulvestrant; Genetic Variation; Germ-Line Mutation; Humans; Incidence; MCF-7 Cells; Middle Aged; Phosphorylation; Survival Analysis; Tamoxifen; Treatment Outcome | 2019 |
Gastric Metastasis Mimicking Linitis Plastica 20 Years after Primary Breast Cancer. A Case Report.
Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Carcinoma, Lobular; Diagnosis, Differential; Female; Fulvestrant; Gastroscopy; GATA3 Transcription Factor; Humans; Immunohistochemistry; Linitis Plastica; Predictive Value of Tests; Stomach Neoplasms; Time Factors; Treatment Outcome | 2018 |
Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; MCF-7 Cells; Neoplastic Stem Cells; Receptors, Estrogen | 2019 |
Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
Topics: Adult; Breast Neoplasms; Circulating Tumor DNA; Disease Progression; Drug Resistance, Neoplasm; Female; Fulvestrant; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Staging; Postmenopause; Probability; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Risk Factors; Treatment Outcome | 2019 |
Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
Topics: Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Datasets as Topic; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Neoplasm Proteins; Protein-Tyrosine Kinases; Signal Transduction; Tamoxifen | 2019 |
Oestradiol measurement during fulvestrant treatment for breast cancer.
Topics: Adolescent; Adult; Breast Neoplasms; Chromatography, Liquid; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Tandem Mass Spectrometry; Young Adult | 2019 |
Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fulvestrant; Furans; Humans; Ketones; MCF-7 Cells; Tamoxifen; Trastuzumab | 2019 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
Palbociclib and Fulvestrant in Breast Cancer.
Topics: Breast Neoplasms; Fulvestrant; Humans; Piperazines; Pyridines | 2019 |
Palbociclib and Fulvestrant in Breast Cancer. Reply.
Topics: Breast Neoplasms; Fulvestrant; Humans; Piperazines; Pyridines | 2019 |
Palbociclib and Fulvestrant in Breast Cancer.
Topics: Breast Neoplasms; Fulvestrant; Humans; Piperazines; Pyridines | 2019 |
Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Forkhead Box Protein O3; Fulvestrant; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NEDD8 Protein; Pyrimidines; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays | 2019 |
Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2019 |
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Pyridines; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; MCF-7 Cells; Mice; Mutation; Naphthalenes; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Quinolines; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Fulvestrant; Humans; Japan; Middle Aged; Patient Preference; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Socioeconomic Factors; Surveys and Questionnaires | 2019 |
Fulvestrant plus anastrozole for metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Fulvestrant enables better outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fulvestrant; Humans | 2019 |
Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Injections, Intralesional; Mammary Glands, Animal; MCF-7 Cells; Mice; Rats; Xenograft Model Antitumor Assays | 2019 |
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Everolimus; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Patient Selection; Precision Medicine; Receptors, Steroid; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2019 |
PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression; Humans; MCF-7 Cells; Meta-Analysis as Topic; Neoplasm Metastasis; Neoplastic Stem Cells; p21-Activated Kinases; Prognosis; Receptors, Estrogen; Small Molecule Libraries; Tamoxifen | 2019 |
Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Drug Combinations; Fulvestrant; Humans; Mutation; Thiazoles | 2019 |
Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
Topics: Animals; Breast Neoplasms; Cell Death; Cell Nucleus; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; JNK Mitogen-Activated Protein Kinases; MCF-7 Cells; Mice; Receptors, Estrogen; Signal Transduction; Time Factors; Transcriptional Activation; Transcriptome; Tumor Suppressor Protein p53; Unfolded Protein Response | 2019 |
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytokines; Estrogen Antagonists; Female; Fulvestrant; Humans; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Mice, Inbred BALB C; Mice, Nude; Receptors, Estrogen | 2019 |
Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prospective Studies; Receptors, Estrogen; Retrospective Studies; Time Factors; Treatment Outcome | 2019 |
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Fulvestrant; HEK293 Cells; Heterografts; Humans; Indazoles; Ligands; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Polymorphism, Single Nucleotide; Proteolysis; Receptors, Estrogen; Signal Transduction; Transcription, Genetic | 2019 |
Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Decision-Making; Diagnosis, Differential; Disease Management; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Treatment Outcome | 2019 |
IGF-1R inhibition: right direction, wrong pathway?
Topics: Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent | 2013 |
Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Costs; Estradiol; Fulvestrant; Humans; Survival Analysis; United Kingdom | 2013 |
Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
Topics: Apoptosis; Breast Neoplasms; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; RNA Interference; src-Family Kinases; Tamoxifen | 2013 |
Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.
Topics: Androgen Antagonists; Androgens; Anilides; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Male; MCF-7 Cells; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen; Ribosomes; RNA, Neoplasm; RNA, Ribosomal; Signal Transduction; Tosyl Compounds; Transcription, Genetic | 2013 |
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
Topics: Animals; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Genes, Neoplasm; Guanine; HEK293 Cells; Humans; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleolin; Oligodeoxyribonucleotides; Phosphoproteins; RNA-Binding Proteins; Transcription, Genetic; Up-Regulation | 2013 |
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Topics: Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cohort Studies; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glial Cell Line-Derived Neurotrophic Factor; Humans; Kaplan-Meier Estimate; Letrozole; MCF-7 Cells; Middle Aged; Nitriles; Oligonucleotide Array Sequence Analysis; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Triazoles | 2013 |
Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Ligands; MCF-7 Cells; Mitogen-Activated Protein Kinase 3; Phosphorylation; Receptors, Estrogen; RNA Interference; RNA, Messenger; Signal Transduction | 2013 |
Antiestrogens suppress effects of transforming growth factor-β in breast cancer cells via the signaling axis estrogen receptor-α and Y-box Binding Protein-1.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Signal Transduction; Survival Rate; Tamoxifen; Transforming Growth Factor beta; Y-Box-Binding Protein 1 | 2013 |
The trefoil factor 1 (TFF1) protein involved in doxorubicin‑induced apoptosis resistance is upregulated by estrogen in breast cancer cells.
Topics: Antibiotics, Antineoplastic; Antibodies, Neutralizing; Apoptosis; Blotting, Western; Breast Neoplasms; Catalase; Cell Proliferation; Doxorubicin; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; MCF-7 Cells; Protein Array Analysis; Receptors, Estrogen; Trefoil Factor-1; Tumor Suppressor Proteins | 2013 |
Anti-Proliferative Effects of Evodiamine on Human Breast Cancer Cells.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 7; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Quinazolines | 2013 |
TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.
Topics: Blotting, Western; Breast Neoplasms; Cell Proliferation; Clone Cells; Cluster Analysis; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tissue Inhibitor of Metalloproteinase-1; Transcriptome | 2013 |
Combination endocrine treatments unproven in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2013 |
Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Histone Deacetylase 1; Humans; Mediator Complex Subunit 1; Mice; Promoter Regions, Genetic; Receptors, Estrogen; RNA Polymerase II; Trefoil Factor-1; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
The exposure of breast cancer cells to fulvestrant and tamoxifen modulates cell migration differently.
Topics: Animals; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Invasiveness; Receptors, Estrogen; Tamoxifen | 2013 |
MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinogenesis; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Kinase 5; Mice; Mitogen-Activated Protein Kinase 7; Neoplasms, Experimental; RNA, Small Interfering; Signal Transduction | 2013 |
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Dosage; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Survival Analysis; Transcriptome; Xenograft Model Antitumor Assays | 2013 |
Homeobox A7 stimulates breast cancer cell proliferation by up-regulating estrogen receptor-alpha.
Topics: Breast Neoplasms; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Knockdown Techniques; Homeodomain Proteins; Humans; MCF-7 Cells; Receptors, Estrogen; Receptors, Progesterone; Up-Regulation | 2013 |
Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Chromosomal Proteins, Non-Histone; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Methyltransferases; Piperazines; Pyridines; Receptors, Estrogen; Receptors, G-Protein-Coupled; Transcription Factors; Tumor Cells, Cultured | 2013 |
Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Cadherins; Cell Proliferation; Estradiol; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; MCF-7 Cells; Mitogen-Activated Protein Kinases; Nuclear Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Snail Family Transcription Factors; src-Family Kinases; Transcription Factors; Twist-Related Protein 1; Tyrphostins | 2014 |
[Assessment of the clinical efficacy and safety of fulvestrant in heavily pretreated patients with hormone-receptor positive metastatic breast cancer-a single-institution experience].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Recurrence | 2013 |
Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells.
Topics: Actin Cytoskeleton; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Estrogens; Female; Focal Adhesions; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Membrane Proteins; Microscopy, Confocal; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2015 |
Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
Topics: Breast Neoplasms; Calpain; Cell Adhesion; Collagen; Down-Regulation; Drug Combinations; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Silencing; Humans; Laminin; MAP Kinase Signaling System; MCF-7 Cells; Phosphorylation; Proteoglycans; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction | 2014 |
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor Antagonists; Everolimus; Female; Fulvestrant; Humans; Immunosuppressive Agents; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases | 2014 |
Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mice; Mice, Nude; Mitosis; Paclitaxel; Random Allocation; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2014 |
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Immunoprecipitation; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; src-Family Kinases | 2014 |
Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).
Topics: Apoptosis; Biological Transport; Breast Neoplasms; Cell Survival; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Fructosediphosphates; Fulvestrant; Gene Expression Regulation, Neoplastic; Glucose; Glycolysis; Humans; Lymphatic Metastasis; MCF-7 Cells; Phosphofructokinase-2; Response Elements | 2014 |
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach.
Topics: Breast Neoplasms; Calcitriol; Cell Line, Tumor; Cyclin D1; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Receptors, Calcitriol | 2014 |
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Etoposide; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proto-Oncogene Proteins c-mdm2; Receptors, Estrogen; RNA, Messenger; Tumor Suppressor Protein p53 | 2014 |
The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Humans; MCF-7 Cells; Phenylalanine; Phosphorylation; Protease Inhibitors; Receptor, ErbB-3; Thiophenes | 2014 |
Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.
Topics: Animals; Apoptosis; Autophagy; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Flow Cytometry; Fulvestrant; Humans; Mice; Mice, Nude; Microscopy, Confocal; Models, Theoretical; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2014 |
An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
Topics: Animals; Azepines; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenomics; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Histone-Lysine N-Methyltransferase; Humans; Mice; Nuclear Proteins; Repressor Proteins; RNA-Binding Proteins; Signal Transduction; Tamoxifen; Transcription Factors; Triazoles | 2014 |
Misperception of estrogen activity in patients treated with an estrogen receptor antagonist.
Topics: Adult; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Reagent Kits, Diagnostic | 2014 |
Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
Topics: Animals; Apoptosis; Autophagy; Blotting, Western; Breast Neoplasms; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Hydroxychloroquine; Immunoenzyme Techniques; Macrophages; Mice; Mice, Nude; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
Topics: Acinar Cells; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dasatinib; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, IGF Type 1; Receptors, Estrogen; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
The G protein-coupled estrogen receptor-1, GPER-1, promotes fibrillogenesis via a Shc-dependent pathway resulting in anchorage-independent growth.
Topics: Actins; Animals; Benzhydryl Compounds; Breast Neoplasms; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fibronectins; Focal Adhesions; Fulvestrant; Humans; Mice; Mutation; Phenols; Phosphorylation; Receptors, Estrogen; Receptors, G-Protein-Coupled; Shc Signaling Adaptor Proteins; Signal Transduction; Stress Fibers | 2014 |
ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Humans; Neoplastic Stem Cells; Tamoxifen | 2014 |
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Androgen; Tamoxifen; Triazoles | 2014 |
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Doxycycline; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
Topics: Aged; Aged, 80 and over; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Survival Analysis; Tamoxifen; TRPP Cation Channels; Vimentin | 2014 |
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Topics: Apoptosis; Aurora Kinase A; Biomarkers, Tumor; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Cyanoacrylates; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Fulvestrant; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; RNA Interference; Survival Analysis; Tamoxifen; Triazoles | 2015 |
Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Receptors, Estrogen; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Breast Neoplasms; Cell Cycle Proteins; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Random Allocation; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Xenograft Model Antitumor Assays | 2015 |
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Endocrine Gland Neoplasms; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; MCF-7 Cells; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Furans; Humans; Ketones; Neoplastic Stem Cells; Tamoxifen | 2016 |
Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mice, Nude; Positron-Emission Tomography; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2015 |
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Tamoxifen; Triazoles | 2015 |
Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Recurrence, Local; Nuclear Receptor Coactivator 3; Receptors, Estrogen; Tamoxifen | 2015 |
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Targeted Therapy; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Glutamine; Humans; MCF-7 Cells; Molecular Targeted Therapy; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2 | 2015 |
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression; Gene Expression Profiling; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Ligands; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Benzophenone-1 and nonylphenol stimulated MCF-7 breast cancer growth by regulating cell cycle and metastasis-related genes via an estrogen receptor α-dependent pathway.
Topics: Adenocarcinoma; Benzophenones; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Endocrine Disruptors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Proteins; Osmolar Concentration; Phenols; Photosensitizing Agents; RNA, Messenger | 2015 |
[Effects of Ad-p53 plus fulvestrant on induced apoptosis in MCF-7 breast cancer cells].
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; MCF-7 Cells; Tumor Suppressor Protein p53 | 2015 |
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Aurora Kinase B; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mitosis; Neoplasm Recurrence, Local; Organophosphates; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Survival Analysis; Tamoxifen | 2015 |
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Letrozole; MAP Kinase Signaling System; Mice; Mice, Nude; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Nitriles; Postmenopause; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Transcription, Genetic; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Wedelolactone induces growth of breast cancer cells by stimulation of estrogen receptor signalling.
Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coumarins; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; HEK293 Cells; Humans; MCF-7 Cells; Molecular Docking Simulation; Response Elements; Signal Transduction; Transcription Factor AP-1; Transcriptional Activation | 2015 |
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mutation; Piperazines; Pyridines; Selective Estrogen Receptor Modulators; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
Palbociclib Extends Survival in Advanced Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Piperazines; Protein Kinase Inhibitors; Pyridines; Survival Analysis; Treatment Outcome | 2015 |
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fulvestrant; Gene Expression Profiling; Humans; Mice; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrimidines; Pyrroles; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Transcriptional Activation; Xenograft Model Antitumor Assays | 2015 |
Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Membrane Glycoproteins; Mice; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2016 |
SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.
Topics: alpha 1-Antitrypsin; Antineoplastic Agents, Hormonal; Binding Sites; Biomarkers, Tumor; Breast Neoplasms; Chromatin Immunoprecipitation; Computational Biology; Databases, Genetic; Enzyme Induction; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Kaplan-Meier Estimate; MCF-7 Cells; Oligonucleotide Array Sequence Analysis; Prognosis; Promoter Regions, Genetic; Protein Binding; Receptor, ErbB-2; Receptors, Estrogen; RNA Interference; Time Factors; Transfection | 2015 |
Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
Topics: Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Receptors, Progesterone | 2016 |
Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Codon, Initiator; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genetic Variation; HEK293 Cells; HeLa Cells; Hep G2 Cells; Humans; MCF-7 Cells; Oxidoreductases; Phenols; Prognosis; Pyrazoles; Receptors, Estrogen; Sequence Analysis, RNA; Survival Analysis; Tamoxifen | 2015 |
[Efficacy and Safety of the Selective Estrogen Receptor Down-Regulator "Fulvestrant" in Japanese Patients with Advanced, Recurrent, ER-Positive Postmenopausal Breast Cancer].
Topics: Aged; Aged, 80 and over; Asian People; Breast Neoplasms; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Retrospective Studies; Treatment Outcome | 2015 |
Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Treatment Outcome | 2015 |
An alternative synthesis of the breast cancer drug fulvestrant (Faslodex®): catalyst control over C-C bond formation.
Topics: Antineoplastic Agents; Breast Neoplasms; Catalysis; Estradiol; Fulvestrant | 2015 |
False Increase of Estradiol Levels in a 36-Year-Old Postmenopausal Patient With Estrogen Receptor-Positive Breast Cancer Treated With Fulvestrant.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chromatography, Liquid; Estradiol; Estrogens; False Positive Reactions; Female; Fulvestrant; Humans; Immunoassay; Postmenopause; Receptors, Estrogen; Tandem Mass Spectrometry | 2016 |
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Estradiol; Female; Fulvestrant; HEK293 Cells; Humans; Immunoblotting; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Morpholines; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrimidines; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Estradiol; Female; Fulvestrant; Humans; Mastectomy, Segmental; Middle Aged; Protein Kinase Inhibitors; Protein Multimerization; Receptor, ErbB-2; Retreatment; Trastuzumab | 2015 |
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents, Hormonal; Basic Helix-Loop-Helix Transcription Factors; Benzazepines; Breast Neoplasms; Calcium-Binding Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Isoenzymes; Jagged-1 Protein; Membrane Proteins; Mice; Neoplastic Stem Cells; p-Aminoazobenzene; Proto-Oncogene Proteins; Receptor, Notch4; Receptors, Estrogen; Receptors, Notch; Retinal Dehydrogenase; Serrate-Jagged Proteins; Signal Transduction; Survival Analysis; Tamoxifen; Transcription Factor HES-1; Xenograft Model Antitumor Assays | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Middle Aged; Neoplasm Metastasis; Recurrence | 2015 |
Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis.
Topics: B-Cell Lymphoma 3 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Antagonists; Fibroblasts; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 5; MCF-7 Cells; Mesenchymal Stem Cells; Proto-Oncogene Proteins; Signal Transduction; Transcription Factors | 2015 |
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Pathology, Molecular; Piperazines; Precision Medicine; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab | 2016 |
Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Retrospective Studies; Time-to-Treatment | 2015 |
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2016 |
Selective estrogen receptor modulators and betulinic acid act synergistically to target ERα and SP1 transcription factor dependent Pygopus expression in breast cancer.
Topics: Antineoplastic Agents; Betulinic Acid; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hydroxytestosterones; Intracellular Signaling Peptides and Proteins; Microarray Analysis; Pentacyclic Triterpenes; Promoter Regions, Genetic; Selective Estrogen Receptor Modulators; Signal Transduction; Sp1 Transcription Factor; Tamoxifen; Triterpenes | 2016 |
MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Autophagy; Base Sequence; Binding Sites; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression; Humans; Ion Channels; MCF-7 Cells; MicroRNAs; Mitochondrial Proteins; RNA Interference; Tamoxifen; Uncoupling Protein 2 | 2015 |
PI3K Inhibitor Improves PFS in BELLE-2 Trial.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Congresses as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Treatment Outcome | 2016 |
Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Indazoles; MCF-7 Cells; Mice; Mice, Inbred NOD; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Therapeutic Index | 2016 |
Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Breast Neoplasms; Cell Line, Tumor; Estradiol; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Membrane Proteins; MicroRNAs; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; TOR Serine-Threonine Kinases; Transfection | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Acceptance and Adherence of Endocrine Therapy in Women with Metastatic Breast Cancer: Is Parenteral Treatment Effective?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Infusions, Parenteral; Middle Aged; Patient Acceptance of Health Care; Patient Compliance; Treatment Outcome | 2016 |
Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Imidazoles; Insulin-Like Growth Factor I; MCF-7 Cells; Mucoproteins; Oncogene Proteins; Protein Binding; Proteins; Proteolysis; Pyrazines; RNA Interference; Signal Transduction; Time Factors; Transfection | 2016 |
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Proteins; Receptors, Estrogen | 2016 |
Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Obesity; Postmenopause; Receptors, Estrogen; Risk Factors; Treatment Outcome | 2016 |
Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response.
Topics: Biomarkers, Pharmacological; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Integrin beta1; MCF-7 Cells; Membrane Proteins; Neoplasm Recurrence, Local; RNA | 2016 |
In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA).
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; COS Cells; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Immunohistochemistry; MCF-7 Cells; Middle Aged; Protein Multimerization; Tamoxifen | 2017 |
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Breast Neoplasms, Male; Disease-Free Survival; Estradiol; Estrogen Receptor alpha; Female; Fluorodeoxyglucose F18; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2 | 2017 |
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Leupeptins; MCF-7 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 2016 |
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2016 |
The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours.
Topics: Animals; Antineoplastic Agents; Apocrine Glands; Breast Neoplasms; Cellular Microenvironment; Disease Models, Animal; Estradiol; Female; Fulvestrant; Heterografts; Humans; Ki-67 Antigen; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone | 2016 |
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mutation; Piperazines; Pyridines; Receptors, Estrogen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Steroids; Tamoxifen; Triple Negative Breast Neoplasms; Up-Regulation | 2016 |
Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mutation; Progestins; Tamoxifen; Unfolded Protein Response | 2016 |
Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
Topics: Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin G2; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Knockdown Techniques; Humans; Metformin; Mitogen-Activated Protein Kinase Kinases; Neoplasm Recurrence, Local; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-raf; Receptors, Estrogen; Retinoblastoma Protein; RNA Interference; Signal Transduction; Survival Analysis; Up-Regulation | 2016 |
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Multiple Metastatic Breast Cancer Patients].
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplasm Metastasis; Recurrence | 2016 |
Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Estradiol; Estrogen Receptor alpha; Exosomes; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Interleukin-1; MicroRNAs; Paracrine Communication; Receptors, Estrogen; Signal Transduction; Stromal Cells | 2017 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles | 2017 |
Chemosensitization role of fulvestrant in combination with chemotherapy in postmenopausal hormone receptor positive and human epidermal growth factor negative metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Hormones; Humans; Neoplasm Metastasis; Postmenopause; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2016 |
Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.
Topics: Adult; Animals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Phosphorylation; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2017 |
Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epigenesis, Genetic; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; MCF-7 Cells; Promoter Regions, Genetic; Signal Transduction | 2017 |
Activating
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cinnamates; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Indoles; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Domains; Xenograft Model Antitumor Assays | 2017 |
Benefit Mixed with Caution for Buparlisib.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Morpholines; Postmenopause; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2017 |
Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Receptors, Estrogen; Tumor Cells, Cultured | 2017 |
Everolimus Boosts Endocrine Therapy for Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Synergism; Estradiol; Everolimus; Female; Fulvestrant; Humans; Postmenopause; Survival Analysis; Treatment Outcome | 2017 |
Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Databases, Factual; Drug Prescriptions; Estradiol; Female; France; Fulvestrant; Germany; Humans; Italy; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome | 2017 |
An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Flow Cytometry; Fulvestrant; Humans; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2017 |
A Novel Effect of β-Adrenergic Receptor on Mammary Branching Morphogenesis and its Possible Implications in Breast Cancer.
Topics: Animals; Breast Neoplasms; Catecholamines; Cell Adhesion; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Estradiol; Estrogens; Female; Fulvestrant; Humans; Isoproterenol; Mammary Glands, Animal; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Morphogenesis; Receptors, Adrenergic, beta-2; Receptors, Estrogen; Tamoxifen | 2017 |
[Two Cases of Lung Metastasis from Breast Cancer Successfully Treated with Endocrine Therapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Letrozole; Lung Neoplasms; Nitriles; Treatment Outcome; Triazoles | 2016 |
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase 8; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Mice; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Protein Kinase Inhibitors; Transcription, Genetic; Transcriptome; Xenograft Model Antitumor Assays | 2017 |
HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Resorcinols; Signal Transduction | 2017 |
Estrogens and genomic instability in human breast cancer cells--involvement of Src/Raf/Erk signaling in micronucleus formation by estrogenic chemicals.
Topics: Benzhydryl Compounds; Benzo(a)pyrene; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Fulvestrant; Genomic Instability; Humans; Kinetochores; Micronuclei, Chromosome-Defective; Phenols; raf Kinases; Receptors, Estrogen; Signal Transduction; src-Family Kinases; Tamoxifen | 2008 |
Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Topics: Apigenin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fluorescence Recovery After Photobleaching; Fulvestrant; Genes, Reporter; Histone Acetyltransferases; Humans; Hydroxytestosterones; Nuclear Receptor Coactivator 3; Protein Binding; Protein Kinases; Protein Transport; Trans-Activators; Transcription, Genetic | 2008 |
Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dydrogesterone; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Hormone Replacement Therapy; Humans; In Vitro Techniques; Norpregnenes; Progestins; Receptors, Estrogen; RNA, Messenger | 2008 |
Monitoring of hormonal drug effect in a single breast cancer cell using an estrogen responsive GFP reporter vector delivered by a nanoneedle.
Topics: Antineoplastic Agents, Hormonal; Biological Assay; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA; Estradiol; Fulvestrant; Genes, Reporter; Genetic Vectors; Green Fluorescent Proteins; Humans; Microinjections; Needles; Transfection | 2009 |
17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30.
Topics: Breast Neoplasms; Cell Line, Tumor; Enzyme Activation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Silencing; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Transforming Growth Factor beta | 2008 |
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Ovariectomy; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Xenograft Model Antitumor Assays | 2008 |
Two estrogen response element sequences near the PCNA gene are not responsible for its estrogen-enhanced expression in MCF7 cells.
Topics: Base Sequence; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Proliferating Cell Nuclear Antigen; Protein Binding; Protein Biosynthesis; Response Elements; RNA, Messenger; Transfection; Up-Regulation | 2008 |
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fetal Proteins; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Microtubule-Associated Proteins; Middle Aged; Models, Biological; Neoplasm Proteins; Nephroblastoma Overexpressed Protein; Nuclear Proteins; Phenotype; Prognosis; Recurrence; RNA, Messenger; Securin; Tamoxifen | 2009 |
Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
Topics: Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Connexins; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen | 2009 |
Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Estradiol; Fulvestrant; Hormone Replacement Therapy; Humans; Neoplasm Staging; Receptors, Estrogen; Substrate Specificity | 2008 |
The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Estradiol; Female; Fulvestrant; Humans; Intestinal Obstruction; Middle Aged; Neoplasm Metastasis | 2008 |
Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Estradiol; Female; Fulvestrant; Germany; Humans; Markov Chains; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone | 2009 |
Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells.
Topics: Androgen Antagonists; Androgens; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Flutamide; Fulvestrant; Humans; Integrin alphaVbeta3; Oligopeptides; Receptors, Androgen; RNA, Small Interfering | 2009 |
Use of global gene expression patterns in mechanistic studies of oestrogen action in MCF7 human breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis | 2009 |
Activation of the unliganded estrogen receptor by prolactin in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Ligands; Phosphorylation; Prolactin; Response Elements; Trefoil Factor-1; Tumor Suppressor Proteins | 2009 |
Phytoestrogens regulate mRNA and protein levels of guanine nucleotide-binding protein, beta-1 subunit (GNB1) in MCF-7 cells.
Topics: Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; DNA Primers; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genistein; GTP-Binding Protein beta Subunits; Humans; Phytoestrogens; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm | 2009 |
Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines.
Topics: Autocrine Communication; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Ki-67 Antigen; Neoplasm Proteins | 2009 |
Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Receptors, Estrogen; Tamoxifen; Tissue Distribution; Tumor Cells, Cultured | 2009 |
Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Humans; Mice; Mice, Nude; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Xenograft Model Antitumor Assays | 2009 |
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Topics: Adult; Antigens, CD; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Estradiol; Female; Flavonoids; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Mitogen-Activated Protein Kinases; Morpholines; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Receptors, Estrogen; Receptors, Transferrin; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; RNA, Messenger; Tamoxifen; Time Factors; Tissue Array Analysis; Transferrin; Treatment Outcome | 2010 |
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells.
Topics: 3' Untranslated Regions; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cycloheximide; Dactinomycin; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; MicroRNAs; Nucleic Acid Synthesis Inhibitors; Promoter Regions, Genetic; Protein Synthesis Inhibitors; ras GTPase-Activating Proteins; RNA-Binding Proteins; RNA, Antisense; Tamoxifen | 2009 |
Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells.
Topics: Apoptosis; Benzhydryl Compounds; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Resistance; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Phenols; Vinblastine | 2009 |
Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study.
Topics: Adenocarcinoma; Adrenergic beta-Antagonists; Antihypertensive Agents; Arginine; Benzopyrans; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Size; Dose-Response Relationship, Drug; Drug Combinations; Elasticity; Endothelial Cells; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Ethanolamines; Female; Fulvestrant; Genes, Reporter; Humans; Metoprolol; Nanotechnology; Nebivolol; Nitric Oxide; Nitrites; Tamoxifen; Time Factors; Transfection | 2009 |
[Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Estrogen Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Retrospective Studies; Time Factors; Treatment Outcome | 2009 |
Estrogen regulation of thrombospondin-1 in human breast cancer cells.
Topics: Animals; Blotting, Northern; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mammary Glands, Animal; Mice; Promoter Regions, Genetic; Receptors, Estrogen; Thrombospondin 1 | 2009 |
Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Breast Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation; Gene Regulatory Networks; Humans; Interferon Regulatory Factor-1; Membrane Proteins; NF-kappa B; Phenotype; Regulatory Factor X Transcription Factors; Signal Transduction; Transcription Factors; X-Box Binding Protein 1 | 2009 |
[Fulvestrant use in clinical practice in France: a pharmacoepidemiologic study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cancer Care Facilities; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Female; France; Fulvestrant; Humans; Middle Aged | 2009 |
Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.
Topics: Breast Neoplasms; Carcinoma; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Promoter Regions, Genetic; Receptors, Estrogen; RNA, Messenger; Signal Transduction; Tamoxifen; Transcription, Genetic; Transfection; Tubulin | 2009 |
Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells.
Topics: Alternative Splicing; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Ellagic Acid; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Telomerase | 2009 |
Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
Topics: Adenocarcinoma; Amino Acid Motifs; Amino Acid Substitution; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Point Mutation; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factor AP-1; Transfection | 2010 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Area Under Curve; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Models, Statistical; Neoplasm Metastasis; Palliative Care; Risk Assessment; ROC Curve; Treatment Outcome; Young Adult | 2009 |
The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Inflammation; Lipid Metabolism; Liver; Menopause; Neoplasms, Hormone-Dependent; Progesterone; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators | 2009 |
Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells.
Topics: Aryl Hydrocarbon Hydroxylases; Base Sequence; Biotransformation; Breast Neoplasms; Carcinogens; Cell Line, Tumor; Chromatography, Liquid; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; DNA Adducts; DNA Primers; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2009 |
Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Separation; DNA Fragmentation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Flow Cytometry; Fulvestrant; Humans; Prohibitins; Transfection; Vinblastine; Vinorelbine | 2010 |
Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Morpholines; Oncogene Proteins v-erbB; Signal Transduction | 2010 |
Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor.
Topics: Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromosome Mapping; Clone Cells; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Flow Cytometry; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genome-Wide Association Study; Humans; Membrane Proteins; Mitochondrial Proteins; Oligonucleotide Array Sequence Analysis; Tamoxifen | 2009 |
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytotoxins; Drug Carriers; Drug Delivery Systems; Drug Resistance, Neoplasm; Epothilones; Estradiol; Female; Fulvestrant; Humans; Intracellular Signaling Peptides and Proteins; Nanoparticles; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Salvage Therapy; TOR Serine-Threonine Kinases | 2009 |
Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Receptor, IGF Type 1; Signal Transduction | 2010 |
Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Genome, Human; Humans; Isothiocyanates; Leupeptins; Phosphorylation; Signal Transduction | 2010 |
Activity of fulvestrant in HER2-overexpressing advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Models, Biological; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Up-Regulation | 2010 |
Hexachlorobenzene induces cell proliferation and IGF-I signaling pathway in an estrogen receptor alpha-dependent manner in MCF-7 breast cancer cell line.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP1A1; DNA Fragmentation; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation; Hexachlorobenzene; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; Pesticides; Phosphorylation; Receptor, Insulin; Receptors, Aryl Hydrocarbon; RNA, Messenger; Signal Transduction; Tyrosine | 2010 |
Knockdown of ICB-1 gene enhanced estrogen responsiveness of ovarian and breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Ovarian Neoplasms; RNA, Small Interfering; Tamoxifen; Tumor Cells, Cultured | 2010 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Nitriles; Pyrrolidines; Receptor, Endothelin A; Tamoxifen; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Keratins; Oligonucleotides; Proteasome Endopeptidase Complex; Receptors, Estrogen; Tamoxifen | 2010 |
Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Fulvestrant; GATA3 Transcription Factor; Gene Regulatory Networks; Hepatocyte Nuclear Factor 3-alpha; Humans; Insulin; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prognosis; T-Box Domain Proteins; Tamoxifen; Transcription, Genetic | 2010 |
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Immunophilins; Immunoprecipitation; Kaplan-Meier Estimate; Meta-Analysis as Topic; Phosphorylation; Protein Binding; RNA Interference; Serine; Signal Transduction; Tacrolimus Binding Proteins; Tamoxifen; Transfection | 2010 |
Antiproliferative activity of brown Cuban propolis extract on human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Clusia; Cuba; Estradiol; Female; Flow Cytometry; Fulvestrant; Humans; Mitosis; Propolis | 2009 |
Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Forkhead Transcription Factors; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immune Tolerance; Tamoxifen; Transforming Growth Factor beta | 2010 |
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fibroblast Growth Factor 2; Fulvestrant; Gene Amplification; Gene Silencing; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Phosphorylation; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 2010 |
FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Topics: Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mutagenesis, Site-Directed; Promoter Regions, Genetic; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2010 |
Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
Topics: Acetylation; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclopentanes; ERRalpha Estrogen-Related Receptor; Estradiol; Fulvestrant; Gene Expression; Histones; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Transport; Quinolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; RNA Interference; Tamoxifen | 2010 |
Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance.
Topics: Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Estradiol; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, cdc; Humans; Immunoglobulins; Promoter Regions, Genetic; S Phase; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Prolonged time to progression with fulvestrant for metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Estradiol; Female; Fulvestrant; Genes, erbB-2; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies | 2011 |
Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Endocrine System; Enzyme Inhibitors; Estradiol; Focal Adhesion Protein-Tyrosine Kinases; Fulvestrant; Humans; Inhibitory Concentration 50; Phenotype; Quinolones; Sulfones; Tamoxifen | 2011 |
ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPbeta in CDH3 gene activation.
Topics: Antineoplastic Agents; Breast Neoplasms; Cadherins; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Chromatin Assembly and Disassembly; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Promoter Regions, Genetic; Signal Transduction; Transcription Factors; Up-Regulation | 2010 |
Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth.
Topics: Alkynes; Benzoxazines; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Cyclopropanes; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gynecomastia; Humans; In Vitro Techniques; Inhibitory Concentration 50; Male; Reverse Transcriptase Inhibitors | 2010 |
IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Caspases; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-1; Interferon-gamma; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; STAT1 Transcription Factor; Tumor Cells, Cultured | 2010 |
Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status.
Topics: Breast Neoplasms; Cell Line, Tumor; Epithelial Cells; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Flavin-Adenine Dinucleotide; Fulvestrant; Humans; Mammary Glands, Human; Microscopy, Confocal; NAD; Oxidation-Reduction; RNA, Messenger; Tamoxifen | 2010 |
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Cyclin D1; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Flow Cytometry; Fulvestrant; Humans; Immunization; Inhibitor of Apoptosis Proteins; Membrane Potential, Mitochondrial; Microtubule-Associated Proteins; Mucoproteins; Oncogene Proteins; Proteins; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survivin; Tamoxifen | 2010 |
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Flow Cytometry; Fulvestrant; Humans; Immunoenzyme Techniques; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Tumor Suppressor Protein p53 | 2011 |
The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Protein Isoforms; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; tau Proteins; Taxoids | 2010 |
MYB suppresses differentiation and apoptosis of human breast cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Butyrates; Cell Differentiation; Cell Line; Cell Line, Tumor; Drug Synergism; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression; Green Fluorescent Proteins; Humans; Mice; Microscopy, Fluorescence; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myb; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tetradecanoylphorbol Acetate; Vitamin E; Vitamins | 2010 |
Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Keratin-5; Neoadjuvant Therapy; Phenotype; Receptors, Progesterone; Tamoxifen | 2011 |
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; G1 Phase; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Quinazolines; src-Family Kinases; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
A better injection site.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular | 2010 |
Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Aryl Hydrocarbon Receptor Nuclear Translocator; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Kaempferols; Polychlorinated Dibenzodioxins; Receptors, Aryl Hydrocarbon; Resveratrol; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Stilbenes; Teratogens; Transcription, Genetic | 2010 |
Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Multicenter Studies as Topic; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Germany; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Postmenopause; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
Topics: Antineoplastic Agents; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Selective Estrogen Receptor Modulators; Signal Transduction; Transforming Growth Factor beta; Up-Regulation | 2011 |
Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.
Topics: Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Multigene Family; Nuclear Receptor Coactivator 3; Nuclear Receptor Coactivators; Tamoxifen; Transcriptional Activation | 2011 |
SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.
Topics: Apoptosis; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cytoprotection; Enzyme Induction; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Genetic Loci; Humans; Models, Biological; Molecular Sequence Data; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Signal Transduction; Transcription, Genetic; Transcriptional Activation | 2011 |
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Receptors, CXCR4; Receptors, Estrogen | 2011 |
Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Topics: Animals; Antibodies; Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microarray Analysis; Neoplasm Invasiveness; Peptides; Prognosis; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Survival Rate; Tamoxifen; Transplantation, Heterologous; Trefoil Factor-3 | 2010 |
Complete estrogen receptor blocker ICI182,780 promotes the proliferation of vascular smooth muscle cells.
Topics: Animals; Breast Neoplasms; Cell Division; Cell Line; Cyclin D1; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Receptors, Estrogen; S Phase | 2011 |
Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fluorescent Antibody Technique; Fulvestrant; Green Fluorescent Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Receptors, Estrogen; Tamoxifen; Tumor Burden; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2011 |
Differential effects of a complex organochlorine mixture on the proliferation of breast cancer cell lines.
Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dihydrotestosterone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Hydrocarbons, Chlorinated; Neoplasms, Hormone-Dependent; Receptors, Androgen; Regression Analysis | 2011 |
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Staging; Postmenopause; Premenopause; Receptors, Estrogen; Treatment Outcome | 2011 |
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Estradiol; Estrogens; Everolimus; Female; Fulvestrant; Humans; Imidazoles; Morpholines; Mutation; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Intracellular Signaling Peptides and Proteins; Neuregulin-1; Receptor, ErbB-3; Receptor, ErbB-4; Receptors, Estrogen; Signal Transduction | 2011 |
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Models, Biological; Nitriles; Postmenopause; Receptors, Estrogen; Recurrence; Triazoles | 2011 |
Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-oncogene in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Benzamides; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Flow Cytometry; Fulvestrant; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-abl; Pyrimidines; RNA Interference | 2011 |
The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Proliferation; Contraceptive Agents, Female; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Membrane Proteins; Receptors, Progesterone | 2011 |
Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen | 2011 |
Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth.
Topics: Adaptor Proteins, Signal Transducing; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Down-Regulation; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Oligonucleotide Array Sequence Analysis; Prognosis; Pyridones; Receptor, IGF Type 1 | 2012 |
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Humans; Insulin-Like Growth Factor I; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Tamoxifen | 2011 |
Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorimetry; Culture Media, Serum-Free; Deoxyuridine; DNA; Drug Design; Estradiol; Estrogens; Fingolimod Hydrochloride; Fluorescent Dyes; Fulvestrant; Humans; Isopropyl Thiogalactoside; Membrane Potential, Mitochondrial; Mitochondria; Propylene Glycols; Reproducibility of Results; Sphingosine; Tetrazolium Salts; Thiazoles; Tumor Suppressor Protein p14ARF | 2011 |
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2011 |
Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1?
Topics: Breast Neoplasms; Contraceptive Agents, Female; Estradiol; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Membrane Proteins; Receptors, Progesterone | 2011 |
Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fibroblast Growth Factor 1; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phospholipase C gamma; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Estrogen; Signal Transduction; Tamoxifen | 2012 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Induction of stable drug resistance in human breast cancer cells using a combinatorial zinc finger transcription factor library.
Topics: Breast Neoplasms; Cell Line, Tumor; Cluster Analysis; Combinatorial Chemistry Techniques; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Peptide Library; Transcription Factors; Treatment Outcome; Zinc Fingers | 2011 |
Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvant; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Intracellular Signaling Peptides and Proteins; Luciferases, Renilla; Receptor Cross-Talk; Response Elements; Signal Transduction; Tamoxifen; Y-Box-Binding Protein 1 | 2012 |
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein-Tyrosine Kinases; Pyrazines; Random Allocation; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; RNA Interference; Signal Transduction; Tamoxifen; Xenograft Model Antitumor Assays | 2011 |
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fibroblasts; Fulvestrant; Humans; Hypoglycemic Agents; Intracellular Signaling Peptides and Proteins; Ketone Bodies; Lactic Acid; Metformin; Mitochondria; Oxides; Phosphoric Monoester Hydrolases; Poly(ADP-ribose) Polymerase Inhibitors; Tamoxifen; Tumor Microenvironment | 2011 |
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oligonucleotide Array Sequence Analysis; Pyrazoles; Receptor, IGF Type 1; Receptor, Insulin; Tamoxifen; Triazines; Triazoles; Xenograft Model Antitumor Assays | 2011 |
Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Patient Education as Topic; Postmenopause | 2011 |
Interplay of estrogen receptors and GPR30 for the regulation of early membrane initiated transcriptional effects: A pharmacological approach.
Topics: Breast Neoplasms; Cell Line, Tumor; Cluster Analysis; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Protein Isoforms; Receptors, Estrogen; Receptors, G-Protein-Coupled; Serum Albumin, Bovine; Transcriptome | 2012 |
PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogens; Female; Fulvestrant; Humans; PAX2 Transcription Factor; Phenotype; Transfection | 2011 |
Chronic leptin treatment sensitizes MCF-7 breast cancer cells to estrogen.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Humans; Janus Kinase 2; Leptin; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Tamoxifen | 2011 |
RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Cellular Senescence; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Proteolysis; Signal Transduction; Tumor Suppressor Proteins | 2012 |
Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Hydroxytestosterones; Immunoblotting; Immunoprecipitation; Morpholines; Phosphorylation; Signal Transduction | 2012 |
Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.
Topics: Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Markov Chains; Models, Economic; Monte Carlo Method; Postmenopause; Receptors, Estrogen; United States | 2012 |
Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Paclitaxel; Prohibitins; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2012 |
Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
Topics: Animals; Breast Neoplasms; Cell Growth Processes; Cell Nucleus; Cyclin D1; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Humans; Mammary Neoplasms, Experimental; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Receptors, Progesterone | 2012 |
Early membrane initiated transcriptional effects of estrogens in breast cancer cells: First pharmacological evidence for a novel membrane estrogen receptor element (ERx).
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; DNA-Binding Proteins; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Oligonucleotide Array Sequence Analysis; Potassium Channels, Tandem Pore Domain; Proto-Oncogene Proteins c-myc; Receptors, Estrogen; Serum Albumin, Bovine; Signal Transduction; Transcriptome | 2012 |
NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; NF-kappa B; NF-kappa B p50 Subunit; Phosphatidylinositol 3-Kinases; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Transcription Factor RelA; Transcription Factor RelB | 2012 |
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2012 |
The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Prohibitins; Proto-Oncogene Proteins c-bcl-2; Transfection; Up-Regulation | 2012 |
Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Humans; MCF-7 Cells; Protein Conformation; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic | 2012 |
IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Caspase 7; Cell Line, Tumor; DNA, Complementary; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Library; Heat-Shock Proteins; Humans; Insulin-Like Growth Factor Binding Protein 3; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Interaction Mapping; Tamoxifen; Two-Hybrid System Techniques | 2012 |
Puerarin exerted anti-osteoporotic action independent of estrogen receptor-mediated pathway.
Topics: Acid Phosphatase; Amino Acids; Animals; Breast Neoplasms; Cell Proliferation; Diet; Estradiol; Female; Fulvestrant; Humans; Isoflavones; MCF-7 Cells; Mice; Osteocalcin; Osteoporosis; Ovariectomy; Pueraria; Receptors, Estrogen | 2012 |
[The role of estrogen receptor alpha in breast cancer cell proliferation mediated by progestins].
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Cell Proliferation; Chromatin Immunoprecipitation; Cyclin D1; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Genes, myc; Humans; Mammary Neoplasms, Experimental; Medroxyprogesterone Acetate; Murinae; Progestins; Receptors, Progesterone; Transcription, Genetic | 2012 |
Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Nitriles; Prognosis; Triazoles | 2012 |
Carboplatin treatment of antiestrogen-resistant breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; bcl-2-Associated X Protein; bcl-X Protein; Breast Neoplasms; Carboplatin; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression; Humans; MCF-7 Cells; Proto-Oncogene Proteins c-bcl-2; Tamoxifen | 2012 |
Estrogenic effects of fusarielins in human breast cancer cell lines.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epoxy Compounds; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Female; Fulvestrant; Fungal Proteins; Fusarium; Humans; Indicators and Reagents; MCF-7 Cells; Oxazines; Plant Extracts; Receptors, Estrogen; Xanthenes | 2012 |
miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Movement; Cell Survival; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; MCF-7 Cells; MicroRNAs; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Tamoxifen; Tissue Array Analysis; Transcriptome; Treatment Outcome | 2012 |
Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Nucleus; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Ligands; MCF-7 Cells; Multiprotein Complexes; Protein Conformation; Proteomics; Selective Estrogen Receptor Modulators | 2013 |
Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors.
Topics: Antineoplastic Agents, Hormonal; Antirheumatic Agents; Auranofin; Benzothiazoles; Breast Neoplasms; CD24 Antigen; Cell Proliferation; Cell Survival; Cyclin D1; Cysteine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Homeostasis; Humans; Hyaluronan Receptors; MCF-7 Cells; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Messenger; RNA, Small Interfering; S-Nitrosothiols; Spheroids, Cellular; Thioredoxin-Disulfide Reductase; Toluene; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2012 |
The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts.
Topics: Animals; Arginine; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mice; Mice, Nude; Neuropeptide Y; Receptors, Estrogen; Receptors, Neuropeptide Y; Tamoxifen | 2012 |
Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA-Activated Protein Kinase; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Nuclear Proteins; Rad51 Recombinase; Radiation-Sensitizing Agents; Receptors, Estrogen | 2013 |
[Endocrine therapy for advanced breast cancer].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
[Economic evaluation of treatment on breast cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Costs and Cost Analysis; Estradiol; Female; Fulvestrant; Furans; Humans; Ketones; Trastuzumab | 2012 |
Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera.
Topics: Amino Acid Sequence; Animals; Antibodies; Breast Neoplasms; COS Cells; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Humans; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Phosphorylation; Protein Serine-Threonine Kinases; Receptors, Estrogen; Serine; Signal Transduction; Tamoxifen | 2002 |
Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2002 |
New alternative to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2002 |
Fulvestrant (faslodex) for advanced breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Multicenter Studies as Topic; Postmenopause | 2002 |
Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng.
Topics: Breast Neoplasms; Central Nervous System Agents; Drugs, Chinese Herbal; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Ginsenosides; HeLa Cells; Humans; Isoflavones; Luciferases; Panax; Phytoestrogens; Plant Preparations; Radioligand Assay; Receptors, Estrogen; Saponins; Thymidine; Tritium; Tumor Cells, Cultured | 2002 |
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Lymphokines; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Topics: Adaptor Proteins, Signal Transducing; ATPases Associated with Diverse Cellular Activities; Blotting, Northern; Blotting, Western; Breast Neoplasms; Carrier Proteins; Cell Division; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Nuclear Proteins; Nuclear Receptor Co-Repressor 2; Nuclear Receptor Interacting Protein 1; Phosphoproteins; Phosphorylation; Proteasome Endopeptidase Complex; Protozoan Proteins; Receptors, Estrogen; Receptors, Progesterone; Repressor Proteins; RNA, Messenger; Tamoxifen; Transcription Factors; Tumor Cells, Cultured | 2002 |
A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Estradiol; Fulvestrant; Gene Expression Regulation, Neoplastic; Half-Life; Humans; Nuclear Receptor Coactivator 3; RNA, Messenger; Transcription Factors; Transforming Growth Factor beta; Tretinoin; Tumor Cells, Cultured | 2002 |
In vitro antiestrogenic effects of aryl methyl sulfone metabolites of polychlorinated biphenyls and 2,2-bis(4-chlorophenyl)-1,1-dichloroethene on 17beta-estradiol-induced gene expression in several bioassay systems.
Topics: Adenocarcinoma; Animals; Biphenyl Compounds; Breast Neoplasms; Carps; Cell Line; Cell Survival; Cytochrome P-450 CYP1A1; Dichlorodiphenyl Dichloroethylene; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Hepatocytes; Humans; Luciferases; Male; Polychlorinated Biphenyls; Rats; Tamoxifen; Vitellogenins | 2002 |
Estrogenicity of organophosphorus and pyrethroid pesticides.
Topics: Animals; Binding, Competitive; Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogens, Non-Steroidal; Female; Fulvestrant; Humans; Insecticides; Nitriles; Organothiophosphorus Compounds; Proteins; Pyrethrins; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; RNA, Messenger; Trefoil Factor-1; Tritium; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2002 |
Estrogenic and antiproliferative properties of soy sapogenols in human breast cancer cells in vitro.
Topics: Blotting, Northern; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Non-Steroidal; Female; Fulvestrant; Gene Expression; Glycine max; Humans; Isoflavones; Oleanolic Acid; Phytoestrogens; Plant Extracts; Plant Preparations; Receptors, Estrogen; RNA, Messenger; Saponins; Tumor Cells, Cultured | 2002 |
Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780.
Topics: Breast Neoplasms; Endothelial Growth Factors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Receptors, Progesterone; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Cycle Proteins; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; DNA-Binding Proteins; E2F Transcription Factors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; G1 Phase; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proto-Oncogene Proteins; Receptors, Estrogen; Recombinant Fusion Proteins; S Phase; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2002 |
Cyr61 promotes breast tumorigenesis and cancer progression.
Topics: Adenocarcinoma; Breast Neoplasms; Collagen; Cysteine-Rich Protein 61; Disease Progression; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Endothelial Growth Factors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Laminin; Lymphokines; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proteoglycans; Receptors, Estrogen; Recombinant Fusion Proteins; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Advances in endocrine therapy of metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Treatment Outcome | 2002 |
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
Topics: Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Phosphorylation; Protein Serine-Threonine Kinases; Retinoblastoma Protein; S Phase; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
FDA drug approval summaries: fulvestrant.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Postmenopause; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; United States; United States Food and Drug Administration | 2002 |
Estradiol rapidly activates Akt via the ErbB2 signaling pathway.
Topics: Androstadienes; Breast Neoplasms; Chromones; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Genistein; Humans; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Isoforms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Serine; Signal Transduction; Sirolimus; Tumor Cells, Cultured; Tyrphostins; Wortmannin | 2003 |
The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Immunoblotting; Multienzyme Complexes; NEDD8 Protein; Neoplasms, Hormone-Dependent; Proteasome Endopeptidase Complex; Receptors, Estrogen; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Ubiquitin-Activating Enzymes; Ubiquitins | 2003 |
Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
Topics: Base Composition; Base Sequence; Binding Sites; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Fulvestrant; Gene Expression Regulation; Molecular Sequence Data; Point Mutation; Promoter Regions, Genetic; Protein Structure, Tertiary; Receptors, Estrogen; Sp1 Transcription Factor; Tamoxifen; Tumor Cells, Cultured; Zinc Fingers | 2003 |
Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Line, Tumor; Cycloheximide; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Synthesis Inhibitors; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transfection; Vascular Endothelial Growth Factor A | 2003 |
Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.
Topics: Breast Neoplasms; Carcinoma; Cell Division; Chemokine CXCL12; Chemokines, CXC; Cycloheximide; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mitogens; Ovarian Neoplasms; Protein Isoforms; Protein Synthesis Inhibitors; Receptors, CXCR4; Receptors, Estrogen; RNA, Messenger; Tumor Cells, Cultured | 2003 |
Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Breast Neoplasms; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Activation; Epithelial Cells; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Guanine; Humans; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Xeroderma Pigmentosum Group A Protein | 2003 |
Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Topics: Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Division; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Humans; Ligands; Membrane Proteins; Piperidines; Presenilin-2; Protein Binding; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Time Factors; Tumor Cells, Cultured | 2003 |
Antiestrogens are pro-apoptotic in normal human breast epithelial cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Breast; Breast Neoplasms; Caspase 3; Caspases; Cells, Cultured; Enzyme Induction; Epithelial Cells; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, p53; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Stimulation, Chemical; Tamoxifen; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
Topics: Adaptation, Physiological; Breast Neoplasms; Cell Division; Culture Media; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Insulin; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Receptor, ErbB-2; Receptors, Estrogen; Serine; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.
Topics: Binding, Competitive; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Oligonucleotide Array Sequence Analysis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2003 |
Inhibitory actions of genistein in human breast cancer (MCF-7) cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genistein; Humans; Kinetics; Neoplasm Proteins; Protein Synthesis Inhibitors; RNA, Messenger; Tumor Cells, Cultured | 2003 |
Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Ligands; MAP Kinase Kinase Kinases; Multienzyme Complexes; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Tamoxifen; Transcription, Genetic | 2003 |
p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p27; DNA-Binding Proteins; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Growth Substances; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Co-Repressor 2; Receptors, Estrogen; Repressor Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
H-ras dependent estrogenic effects of epidermal growth factor in the estrogen-independent breast cancer cell line MDA-MB-231.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Epidermal Growth Factor; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Response Elements | 2003 |
Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant.
Topics: Breast Neoplasms; Cell Division; Dehydroepiandrosterone Sulfate; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Receptors, Estrogen; Tumor Cells, Cultured | 2003 |
Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo.
Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Genes, Reporter; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oncogene Proteins; Phosphorylation; Plasmids; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Response Elements; RNA, Messenger; Tamoxifen; Time Factors; Transcription, Genetic; Transfection | 2003 |
Estimation of estrogenic and anti-estrogenic activities of some phthalate diesters and monoesters by MCF-7 cell proliferation assay in vitro.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Esters; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogens; Fulvestrant; Growth Inhibitors; Humans; Phthalic Acids | 2003 |
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Combinations; Drug Resistance; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tamoxifen | 2003 |
Future directions in the endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine System; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome; Humans; Oligonucleotide Array Sequence Analysis; Proteome; Proteomics; RNA, Messenger | 2004 |
Fulvestrant: spreading the word, but not too thinly.
Topics: Breast Neoplasms; Clinical Trials as Topic; Duplicate Publications as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Information Dissemination; Publishing; Statistics as Topic; Treatment Outcome | 2003 |
AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Animals; Breast Neoplasms; Carrier Proteins; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cyclin D1; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Guanine Nucleotide Exchange Factors; Humans; Mice; Molecular Sequence Data; Neoplasms, Hormone-Dependent; NIH 3T3 Cells; p21-Activated Kinases; Promoter Regions, Genetic; Protein Biosynthesis; Protein Serine-Threonine Kinases; Proteins; Rabbits; rac1 GTP-Binding Protein; Transfection | 2003 |
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Fas Ligand Protein; Female; Fulvestrant; Humans; In Situ Nick-End Labeling; Membrane Glycoproteins; Mice; Mice, Nude; Polymerase Chain Reaction; Receptor, ErbB-2; Tamoxifen; Transforming Growth Factor alpha; Transplantation, Heterologous | 2003 |
Inhibition of estrogen receptor alpha expression and function in MCF-7 cells by kaempferol.
Topics: Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Immunohistochemistry; Insulin Receptor Substrate Proteins; Kaempferols; Phosphoproteins; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Transfection | 2004 |
Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1.
Topics: Breast Neoplasms; Cycloheximide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Galactosyltransferases; Gene Expression Regulation; Humans; Insulin-Like Growth Factor Binding Protein 4; Neoplasm Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Pesticides; Phytoestrogens; Protein Synthesis Inhibitors; Puromycin; Receptors, Estrogen; Regulatory Factor X Transcription Factors; Tamoxifen; Transcription Factors; Tumor Cells, Cultured; X-Box Binding Protein 1 | 2004 |
The interaction of the steroidal antagonist faslodex and methotrexate.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Division; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Methotrexate; Tumor Cells, Cultured | 2003 |
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptors, Estrogen; Signal Transduction; Tumor Cells, Cultured | 2004 |
Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
Topics: Blotting, Western; Breast Neoplasms; Cell Fusion; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Flow Cytometry; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 2; Microscopy, Phase-Contrast; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2003 |
Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen.
Topics: Breast Neoplasms; Cell Division; Cell Line; Cell Line, Tumor; Cell Nucleus; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Promoter Regions, Genetic; Protein Structure, Tertiary; Receptors, Estrogen; Serine; Tetracyclines; Transcriptional Activation | 2004 |
Spreading the word, but not too thinly.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Editorial Policies; Estradiol; Female; Fulvestrant; Humans; Nitriles; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Retrospective Studies; Treatment Outcome; Triazoles | 2004 |
Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells.
Topics: Antibody Specificity; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; DNA, Mitochondrial; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression; Humans; Immunohistochemistry; Microscopy, Confocal; Microscopy, Immunoelectron; Mitochondria; Protein Sorting Signals; Receptors, Estrogen; Subcellular Fractions; Transcription, Genetic | 2004 |
Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation.
Topics: Antioxidants; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Glycogen Synthase Kinase 3; Humans; Phosphatidylinositol 3-Kinases; Phosphorylation; Polymerase Chain Reaction; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Resveratrol; Signal Transduction; Stilbenes; Tumor Cells, Cultured | 2004 |
Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation; Humans; Selective Estrogen Receptor Modulators | 2004 |
Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Progesterone; Progestins; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses e
Topics: Breast Neoplasms; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; gamma-Linolenic Acid; Humans; Luciferases; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Calcitriol; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Genes, bcl-2; Humans; Predictive Value of Tests; Receptors, Calcitriol; Receptors, Estrogen; Tamoxifen; Vitamin D | 2004 |
Estradiol down-regulates CD36 expression in human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Northern; Breast Neoplasms; CD36 Antigens; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Neovascularization, Pathologic; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA; Thrombospondin 1; Time Factors | 2004 |
Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells.
Topics: Breast Neoplasms; Cell Proliferation; Cyclin A; DNA-Binding Proteins; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Mutation; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Smad2 Protein; Smad3 Protein; Smad4 Protein; Tamoxifen; Trans-Activators; Transforming Growth Factor beta; Tumor Cells, Cultured | 2004 |
Re-expression of estrogen receptor alpha using a tetracycline-regulated gene expression system induced estrogen-mediated growth inhibition of the MDA-MB-231 breast cancer cell line.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Chloramphenicol O-Acetyltransferase; Clone Cells; Doxycycline; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; S Phase; Tamoxifen; Transfection | 2004 |
Re: Playing the old piano: another tune for endocrine therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation.
Topics: Breast Neoplasms; Cell Proliferation; Cell Transformation, Neoplastic; Cycloheximide; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Time Factors; Tumor Cells, Cultured | 2004 |
Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
Topics: Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrrolidines; Raloxifene Hydrochloride; Response Elements; Tamoxifen; Thiophenes; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; G1 Phase; Genomic Instability; Humans; Middle Aged; Molecular Weight; Polyploidy; Protein Isoforms; Transfection; Tumor Suppressor Proteins | 2004 |
Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists.
Topics: Breast Neoplasms; Cell Line; Cloning, Molecular; Dexamethasone; Dihydrotestosterone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Estrogens, Non-Steroidal; Female; Fulvestrant; Genes, Reporter; Humans; Ligands; Light; Luciferases; Luminescent Measurements; Plasmids; Receptors, Estrogen; TATA Box; Transfection | 2004 |
17 beta -estradiol-mediated vessel assembly and stabilization in tumor angiogenesis requires TGF beta and EGFR crosstalk.
Topics: Adrenal Medulla; Animals; Aorta; Blotting, Western; Breast Neoplasms; Cattle; Cell Line; Cell Line, Tumor; Coculture Techniques; Collagen; Culture Media, Conditioned; Culture Media, Serum-Free; Drug Combinations; Endothelium, Vascular; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Humans; Laminin; Muscle, Smooth; Neovascularization, Pathologic; Proteoglycans; Receptor Cross-Talk; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta; Umbilical Veins | 2003 |
Distinct effects of the antiestrogen Faslodex on the stability of estrogen receptors-alpha and -beta in the breast cancer cell line MCF-7.
Topics: Acetylcysteine; Animals; Breast Neoplasms; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation; Genes, Reporter; Humans; Ligands; Point Mutation; Tamoxifen | 2004 |
interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Interferon Regulatory Factor-1; Phosphoproteins; Receptors, Estrogen | 2004 |
Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fluorescence Resonance Energy Transfer; Fulvestrant; Humans; Luciferases; Microscopy, Confocal; Models, Biological; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Phosphorylation; Protein Conformation; Protein Structure, Tertiary; Receptors, Estrogen; RNA Interference; Serine; Tamoxifen; Time Factors; Transcriptional Activation; Transfection | 2004 |
A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.
Topics: Breast Neoplasms; Cathepsin D; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 1; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Progesterone; Repressor Proteins; RNA, Messenger; Tamoxifen; Thiophenes; Transcription Factors | 2004 |
Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kina
Topics: Breast Neoplasms; Butadienes; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Fibroblast Growth Factor 1; Fulvestrant; Humans; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; Mitogen-Activated Protein Kinases; Neuregulin-1; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-raf; ras Proteins; Ribosomal Protein S6 Kinases, 90-kDa | 2004 |
Direct action of estradiol on gonadotropin-releasing hormone-1 neuronal activity via a transcription-dependent mechanism.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Calcium; Calcium Signaling; Estradiol; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fluorescent Dyes; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Mice; Nasal Mucosa; Neurons; Organ Culture Techniques; Organic Chemicals; Secretory Rate; Sodium Channel Blockers; Tetrodotoxin; Transcription, Genetic | 2004 |
Conference report--cancer research 2004--top of the class March 27-March 31, 2004; Orlando, Florida.
Topics: Androgen Antagonists; Animals; Breast Neoplasms; Cell Differentiation; Cell Proliferation; DNA Repair; Estradiol; Female; Fulvestrant; Genetic Therapy; Humans; Male; Neoplasms; Prostatic Neoplasms; Replication Protein A; Stem Cells | 2004 |
Extracellular calcium downregulates estrogen receptor alpha and increases its transcriptional activity through calcium-sensing receptor in breast cancer cells.
Topics: Breast Neoplasms; Calcimycin; Calcium; Cell Line, Tumor; Down-Regulation; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Immunoenzyme Techniques; Receptors, Calcium-Sensing; Transcription, Genetic | 2004 |
Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Coloring Agents; DNA Fragmentation; Drug Resistance, Neoplasm; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Fulvestrant; G1 Phase; Hormone Antagonists; Humans; Immunoblotting; Mifepristone; Phosphorylation; Receptors, Estrogen; Receptors, Progesterone; Resting Phase, Cell Cycle; Tamoxifen; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Hormonal regulation of the Grb14 signal modulator and its role in cell cycle progression of MCF-7 human breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Insulin; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proteins; Signal Transduction; Up-Regulation | 2005 |
Understanding the biologic mechanisms responsible for breast-cancer progression during tamoxifen or fulvestrant treatment.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Disease Progression; Estradiol; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Tamoxifen; Treatment Failure; Tumor Cells, Cultured | 2004 |
Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Leptin; Luciferases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Cell Surface; Receptors, Leptin; Recombinant Fusion Proteins; Response Elements; Signal Transduction; STAT3 Transcription Factor; Trans-Activators; Transcription, Genetic; Ubiquitin | 2004 |
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
Topics: Antimetabolites; Breast Neoplasms; Cell Division; Clodronic Acid; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors; Tumor Cells, Cultured | 2004 |
Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model.
Topics: Aromatase; Aromatase Inhibitors; Benzhydryl Compounds; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Coculture Techniques; Dexamethasone; Diethylstilbestrol; Drug Synergism; Estradiol; Fadrozole; Female; Fibroblasts; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mammary Glands, Human; Phenols; Prostaglandin-Endoperoxide Synthases; Proteins; RNA, Messenger; Transcription, Genetic; Trefoil Factor-1; Tumor Suppressor Proteins | 2005 |
Deregulation of cell proliferation by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells reflects both genotoxic and nongenotoxic events.
Topics: Benz(a)Anthracenes; Benzo(a)pyrene; Benzothiazoles; Breast Neoplasms; Bromodeoxyuridine; Carcinogens; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Replication; Dose-Response Relationship, Drug; Drug Interactions; Epigenesis, Genetic; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Thiazoles; Toluene; Tumor Suppressor Protein p53 | 2005 |
P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells.
Topics: Base Sequence; Breast Neoplasms; Cadherins; Cell Adhesion; DNA Primers; DNA, Complementary; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Humans; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2004 |
ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Fulvestrant; G1 Phase; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Promoter Regions, Genetic; RNA, Small Interfering; Sp1 Transcription Factor; Transcriptional Activation; Up-Regulation | 2005 |
Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Forecasting; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Women's Health | 2004 |
Bis(ethyl)norspermine potentiates the apoptotic activity of the pure antiestrogen ICI 182780 in breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Caspase 8; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Polyamines; Proto-Oncogene Proteins c-bcl-2; Spermine | 2005 |
The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; NF-kappa B; Sesquiterpenes | 2005 |
Estrogen receptor independent rapid non-genomic effects of environmental estrogens on [Ca2+]i in human breast cancer cells.
Topics: Breast Neoplasms; Calcium; Cations, Divalent; Cell Line, Tumor; Environmental Pollutants; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Humans; Receptors, Estrogen | 2005 |
AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Crk-Associated Substrate Protein; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Focal Adhesions; Fulvestrant; Genes, Dominant; Genetic Vectors; GTP Phosphohydrolases; Guanine Nucleotide Exchange Factors; Guanosine Diphosphate; Guanosine Triphosphate; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphorylation; Plasmids; Protein Binding; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; rac GTP-Binding Proteins; Receptors, Estrogen; Retinoblastoma-Like Protein p130; Serine; Signal Transduction; src Homology Domains; Transfection | 2005 |
Fulvestrant--ready to start its journey in the breast cancer adjuvant endocrine world?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Estradiol; Female; Fulvestrant; Humans | 2005 |
Basis of melengestrol acetate action as a progestin.
Topics: Animals; Binding, Competitive; Breast Neoplasms; Cattle; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Hormone Antagonists; Humans; Inhibitory Concentration 50; Melengestrol Acetate; Pregnenediones; Progesterone; Progestins; Promegestone; Receptors, Progesterone | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
Topics: Anilides; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Multivariate Analysis; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Tubulin | 2005 |
Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Nucleus; Cell Proliferation; Cytoplasm; DNA; Dose-Response Relationship, Drug; Estradiol; Estrogens; Fulvestrant; Humans; Immunohistochemistry; Kinetics; Microscopy, Fluorescence; Myristic Acid; Nuclear Localization Signals; Palmitic Acid; Phosphorylation; Plasmids; Promoter Regions, Genetic; Protein Binding; Protein Structure, Tertiary; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Serum Response Element; Signal Transduction; Time Factors; Transcription, Genetic; Transfection; Up-Regulation | 2005 |
Current and future perspectives on fulvestrant.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Triazoles | 2005 |
Clinical value of fulvestrant in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Selective Estrogen Receptor Modulators; United States | 2005 |
The history and mechanism of action of fulvestrant.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; History, 20th Century; History, 21st Century; Humans; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2005 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2005 |
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; GRB2 Adaptor Protein; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Models, Biological; Nitriles; Receptors, Estrogen; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Postmenopause; Retrospective Studies; Salvage Therapy; Tamoxifen; Treatment Outcome | 2005 |
Differential effects of estrogen on DNA synthesis in human periodontal ligament and breast cancer cells.
Topics: Adolescent; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Collagen; DNA; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Male; Periodontal Ligament; Proline; Radiopharmaceuticals; Receptors, Progesterone; Thymidine; Tritium | 2005 |
Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Receptor Cross-Talk; Receptor, ErbB-2; Serine; Signal Transduction; Tumor Cells, Cultured; Up-Regulation | 2005 |
Diffusion-time distribution analysis reveals characteristic ligand-dependent interaction patterns of nuclear receptors in living cells.
Topics: Bacterial Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Diffusion; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Ligands; Luminescent Proteins; Recombinant Fusion Proteins; Spectrometry, Fluorescence; Tamoxifen; Trans-Activators; Transfection; Tumor Cells, Cultured | 2005 |
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Palliative Care; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome | 2005 |
Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Palliative Care; Postmenopause; Treatment Outcome | 2005 |
Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Bongkrekic Acid; Breast Neoplasms; Caspase 9; Cell Line, Tumor; Cytochromes c; Drug Screening Assays, Antitumor; Enzyme Activation; Estradiol; Estrogens; Female; Fulvestrant; Humans; Membrane Potential, Mitochondrial; Mitochondria; Onium Compounds; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Tamoxifen; Toremifene | 2005 |
Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans | 2005 |
Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2004 |
Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance.
Topics: Antibodies; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Endothelial Cells; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression; Histone Acetyltransferases; Humans; Luciferases; Mammary Tumor Virus, Mouse; Mifepristone; Nuclear Receptor Coactivator 1; Phosphatidylinositol 3-Kinases; Progesterone; Promoter Regions, Genetic; Receptors, Progesterone; Recombinant Fusion Proteins; Response Elements; Signal Transduction; Transcription Factors; Transfection; Vascular Endothelial Growth Factor A | 2005 |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
Topics: Breast Neoplasms; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Mammary Glands, Human; Mutation; Oligonucleotide Array Sequence Analysis; Protein Binding; Raloxifene Hydrochloride; Receptor Cross-Talk; Response Elements; Signal Transduction; Tamoxifen; Transcription Factors | 2005 |
Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gefitinib; Humans; Mice; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prognosis; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Trastuzumab; Tumor Cells, Cultured; Tumor Escape; Xenograft Model Antitumor Assays | 2005 |
MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oncogene Proteins; Transfection | 2005 |
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Proliferation; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Humans; Insulin; Insulin Antagonists; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; Phosphoproteins; Receptor, IGF Type 1; Tamoxifen; Transcription, Genetic | 2005 |
Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells.
Topics: Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclins; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Mitogens; Phosphoproteins; RNA, Small Interfering; Transfection | 2005 |
Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Melatonin; Ovarian Neoplasms; Receptor, Melatonin, MT1; Signal Transduction; Tamoxifen; Up-Regulation | 2006 |
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
Topics: Annexin A5; Antineoplastic Agents, Hormonal; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Caspase 8; Caspases; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Estradiol; Estrogen Antagonists; Fas Ligand Protein; fas Receptor; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Membrane Glycoproteins; Microscopy, Electron; Mitochondria; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Transfection; Tumor Necrosis Factors; Tumor Suppressor Protein p53; Up-Regulation | 2005 |
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
Topics: Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Ibandronic Acid; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 2006 |
Inhibition of MCF-7 breast cancer cell proliferation by MCF-10A breast epithelial cells in coculture.
Topics: Breast; Breast Neoplasms; Cell Proliferation; Coculture Techniques; Collagen; Drug Combinations; Epithelial Cells; Estradiol; Fulvestrant; Genes, Tumor Suppressor; Growth Substances; Humans; Keratins; Laminin; Paracrine Communication; Proteoglycans; Serpins; Time Factors | 2006 |
Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Glutathione Transferase; Humans; Keratins; Nuclear Matrix-Associated Proteins; Proteasome Endopeptidase Complex; Tumor Cells, Cultured | 2006 |
Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 2006 |
Ethanol stimulates the secretion of matrix metalloproteinases 2 and 9 in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor Modulators; Ethanol; Fulvestrant; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction; Transcription, Genetic | 2006 |
Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Tamoxifen | 2006 |
Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.
Topics: Adolescent; Adult; Breast; Breast Neoplasms; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Mutation; Receptors, Progesterone; Risk Factors; Tamoxifen | 2006 |
Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells.
Topics: Beverages; Binding, Competitive; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estradiol; Fulvestrant; Humans; Phytotherapy; Plant Extracts; Receptors, Estrogen | 2006 |
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.
Topics: Acetyltransferases; Alleles; Breast Neoplasms; Cell Line, Tumor; Cloning, Molecular; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Receptor Coactivator 3; Oncogene Proteins; Peptides; Polymerase Chain Reaction; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Sequence Analysis, DNA; Tamoxifen; Thiophenes; Trans-Activators | 2006 |
Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells.
Topics: Androgens; Breast Neoplasms; Cell Line, Tumor; Cycloheximide; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation, Enzymologic; Glucuronosyltransferase; Humans; Oligonucleotide Array Sequence Analysis; Protein Synthesis Inhibitors; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Up-Regulation | 2006 |
Modulation by phenylacetate of early estrogen-mediated events in MCF-7 breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Fulvestrant; Genes, myc; Humans; Phenylacetates; Proto-Oncogene Proteins c-myc; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Transcriptional Activation; Transfection | 2007 |
Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Proteins; Oligonucleotide Array Sequence Analysis; Oligonucleotides, Antisense; Polyunsaturated Alkamides; Receptor, IGF Type 1; Tamoxifen | 2006 |
Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Fragmentation; Estradiol; Flow Cytometry; Fulvestrant; Humans; Hydroxyurea; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Microtubule-Associated Proteins; Microtubules; Neoplasm Proteins; Paclitaxel; Purines; RNA, Small Interfering; Roscovitine; Spindle Apparatus; Survivin; Thymidine; Transfection | 2007 |
Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitoxantrone; Neoplasm Proteins; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Quinazolines | 2006 |
Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Estradiol; Fulvestrant; Gamma Rays; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; Membrane Proteins; Mitochondrial Proteins; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Receptors, Estrogen; RNA, Messenger; Transcription, Genetic; Tumor Suppressor Protein p53 | 2006 |
Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chickens; COUP Transcription Factor II; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Receptors, Progesterone; Tamoxifen; Transcription, Genetic; Transfection | 2006 |
[Estrogenicity of adzuki bean Phaseolus angularis wight. and its effect on proesterone receptor level in human breast cancer MCF-7 cells].
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Phaseolus; Phytoestrogens; Plants, Medicinal; Receptors, Progesterone; RNA, Messenger; Seeds | 2006 |
[Estrogenic activity and its mechanism of ethanol extract from black soybean].
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Glycine max; Humans; Plants, Medicinal; Receptors, Progesterone; RNA, Messenger; Seeds; Trefoil Factor-1; Tumor Suppressor Proteins | 2006 |
Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Selective Estrogen Receptor Modulators | 2006 |
Evaluation of estrogenic/antiestrogenic activity of Onobrychis ebenoides extract - interaction with estrogen receptor subtypes ERalpha and ERbeta.
Topics: Breast Neoplasms; Calcification, Physiologic; Cell Survival; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fabaceae; Female; Fulvestrant; Genes, Reporter; HeLa Cells; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Luciferases; Osteoblasts; Phytoestrogens; Plant Extracts; Response Elements; Transfection | 2007 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Aromatase and breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
[Fulvestrant].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Ovariectomy; Randomized Controlled Trials as Topic; Tamoxifen | 2006 |
SVEP1 expression is regulated in estrogen-dependent manner.
Topics: Animals; Biomarkers, Tumor; Bone Marrow; Breast Neoplasms; Cell Adhesion Molecules; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Rats; RNA, Messenger; Stromal Cells | 2007 |
Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Fibroblasts; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Neoplasm Invasiveness; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-met; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Stromal Cells; Tumor Cells, Cultured; Up-Regulation; Wound Healing | 2006 |
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Transcription, Genetic; Trefoil Factor-1; Tumor Suppressor Proteins | 2006 |
The antiestrogen tamoxifen activates BK channels and stimulates proliferation of MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Large-Conductance Calcium-Activated Potassium Channels; Tamoxifen; Tetraethylammonium Compounds | 2007 |
Effect of antiestrogens on EGF-mediated movement of human breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cyclopropanes; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Tamoxifen | 2007 |
Molecular cloning and characterization of the human WISP-2/CCN5 gene promoter reveal its upregulation by oestrogens.
Topics: 5' Flanking Region; Base Sequence; Blotting, Western; Breast Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Cloning, Molecular; CREB-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Intercellular Signaling Peptides and Proteins; Molecular Sequence Data; Neoplasm Proteins; Promoter Regions, Genetic; Repressor Proteins; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Transcription Factors; Transcription, Genetic; Transfection | 2006 |
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Culture Media; DNA Methylation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Tamoxifen | 2006 |
Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen | 2007 |
Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Empathy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Program Evaluation; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome | 2007 |
Crosstalk between EGFR and extranuclear steroid receptors.
Topics: Androgen Receptor Antagonists; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Male; Phosphorylation; Prostatic Neoplasms; Receptor Cross-Talk; Receptors, Androgen; Receptors, Steroid; Signal Transduction; src-Family Kinases; Tyrosine; Up-Regulation | 2006 |
A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Topics: Binding, Competitive; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Ligands; Norpregnatrienes; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Steryl-Sulfatase; Tamoxifen; Tumor Cells, Cultured | 2007 |
DNA content and chromatin texture of human breast epithelial cells transformed with 17-beta-estradiol and the estrogen antagonist ICI 182,780 as assessed by image analysis.
Topics: Benzo(a)pyrene; Breast; Breast Neoplasms; Cell Line, Transformed; Cell Nucleus; Cell Transformation, Neoplastic; Chromatin; DNA, Neoplasm; Epithelial Cells; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Image Cytometry | 2007 |
Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
Topics: Breast Neoplasms; Carcinoma; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured; Up-Regulation | 2007 |
Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Microtubules; Mitosis; Paclitaxel; Prohibitins; Transfection | 2007 |
Estrogen-dependent regulation of Eg5 in breast cancer cells.
Topics: Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cysteine; Dose-Response Relationship, Drug; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens; Female; Flow Cytometry; Fulvestrant; Humans; Inhibitory Concentration 50; Kinesins; Mitosis; Pyrimidines; Receptors, Estrogen; Signal Transduction; Thiones; Up-Regulation | 2007 |
Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gelsolin; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Recombinant Fusion Proteins; Tamoxifen; Transfection; Transplantation, Heterologous | 2007 |
Mechanism involved in genistein activation of insulin-like growth factor 1 receptor expression in human breast cancer cells.
Topics: Analysis of Variance; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Genistein; Humans; Phytoestrogens; Receptor, IGF Type 1; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2007 |
Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Casein Kinase II; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-bcl-2; Tamoxifen; Time Factors; Transfection | 2007 |
Potentiation of ICI182,780 (Fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Nitriles; Prognosis; Proteasome Endopeptidase Complex; Receptors, Estrogen; Thiazoles | 2007 |
Effects of a phytoestrogen-containing soy extract on the growth-inhibitory activity of ICI 182 780 in an experimental model of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Glycine max; Humans; Kallikreins; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Organ Size; Phytoestrogens; Plant Extracts; RNA, Messenger; Thrombospondin 1; Uterus; Xenograft Model Antitumor Assays | 2007 |
Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Prospective Studies; Receptor, ErbB-2; Receptors, Progesterone; Treatment Outcome | 2007 |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2007 |
Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Pregnenediones; Progestins; Proto-Oncogene Proteins c-myc; Receptors, Progesterone; Transcription, Genetic | 2007 |
Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
Topics: Amino Acid Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cinnamates; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; HeLa Cells; Humans; Molecular Sequence Data; Protein Conformation; Stilbenes; Subcellular Fractions | 2007 |
The cooked meat derived genotoxic carcinogen 2-amino-3-methylimidazo[4,5-b]pyridine has potent hormone-like activity: mechanistic support for a role in breast cancer.
Topics: Animals; Breast Neoplasms; Carcinogens; Cell Growth Processes; Estradiol; Flavonoids; Fulvestrant; Imidazoles; Pituitary Gland; Prolactin; Rats | 2007 |
Ginsenoside Rg1 exerts estrogen-like activities via ligand-independent activation of ERalpha pathway.
Topics: Breast Neoplasms; Cells, Cultured; Drug Evaluation, Preclinical; Estradiol; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation; Genes, Reporter; Ginsenosides; Humans; Insulin-Like Growth Factor I; Ligands; Luciferases; Phosphorylation; Phytoestrogens; RNA, Messenger; Signal Transduction; Transfection | 2008 |
Ethanol-induced ligand-independent activation of ERalpha mediated by cyclic AMP/PKA signaling pathway: an in vitro study on MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Estradiol; Estrogen Receptor alpha; Ethanol; Fulvestrant; Humans; Ligands; Receptors, Progesterone; Signal Transduction; Trefoil Factor-1; Tumor Suppressor Proteins | 2007 |
Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Blotting, Southern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; DNA, Mitochondrial; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Ethidium; Female; Flow Cytometry; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2008 |
Estrogen receptors in BRCA1-mutant breast cancer: now you see them, now you don't.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, BRCA1; Humans; Jews; Mice; Mutation; RNA, Small Interfering | 2007 |
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Topics: Antineoplastic Agents, Hormonal; Blotting, Northern; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, BRCA1; Humans; Immunoblotting; Immunoprecipitation; Mutation; Research Design; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Transcription, Genetic | 2007 |
Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Butyrates; Cell Line, Tumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Polymerase Chain Reaction; RNA, Neoplasm; Vorinostat | 2007 |
Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mitogen-Activated Protein Kinases; Nitriles; Phenotype; Protein Kinase Inhibitors; Receptor, ErbB-2; RNA, Messenger; Tamoxifen | 2007 |
Cks1 regulates cdk1 expression: a novel role during mitotic entry in breast cancer cells.
Topics: Blotting, Northern; Breast; Breast Neoplasms; Carrier Proteins; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Division; Crk-Associated Substrate Protein; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Luciferases; Mitosis; Neuregulin-1; Phosphorylation; Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; S Phase; S-Phase Kinase-Associated Proteins | 2007 |
Estrogen induces estrogen-related receptor alpha gene expression and chromatin structural changes in estrogen receptor (ER)-positive and ER-negative breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromatin; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Micrococcal Nuclease; Models, Biological; Models, Genetic; Nucleosomes; Receptors, Estrogen; Signal Transduction | 2008 |
Soy isoflavones decrease the catechol-O-methyltransferase-mediated inactivation of 4-hydroxyestradiol in cultured MCF-7 cells.
Topics: Breast Neoplasms; Catechol O-Methyltransferase; Cell Line, Tumor; Cell Proliferation; Diet; Estradiol; Estrogens, Catechol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycine max; Humans; Models, Biological; Models, Chemical; Receptors, Estrogen | 2008 |
Understanding the data, meeting patients' needs.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Effects of thyroid hormones on human breast cancer cell proliferation.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression; Genes, Reporter; Humans; Luciferases; Thyroid Hormone Receptors beta; Triiodothyronine | 2008 |
Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line.
Topics: Base Sequence; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Neoplasms, Hormone-Dependent; Phenotype; Receptor, IGF Type 1; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction; Somatomedins | 2008 |
Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Receptors, Estrogen | 2008 |
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Culture Media, Conditioned; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Humans; Phosphorylation; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2009 |
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Estradiol; Female; Fulvestrant; Humans; Mice; Mice, Nude; Nitriles; Organ Size; Ovariectomy; Receptors, Growth Factor; Signal Transduction; Triazoles; Tumor Burden; Tumor Cells, Cultured; Uterus; Xenograft Model Antitumor Assays | 2008 |
Contribution of alpha2-adrenoceptors to the mitogenic effect of catecholestrogen in human breast cancer MCF-7 cells.
Topics: Adrenergic alpha-2 Receptor Antagonists; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogens, Catechol; Fulvestrant; Humans; Protein Binding; Receptors, Adrenergic, alpha-2; Receptors, Estrogen; Yohimbine | 2008 |
Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Adhesion; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Receptors, Estrogen; Transcription, Genetic; Tumor Cells, Cultured; Zinc Fingers | 2008 |
Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity.
Topics: Animals; Base Sequence; Binding Sites; Breast Neoplasms; Cell Division; Cell Line; Estradiol; Estradiol Congeners; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Luciferases; Megestrol; Molecular Sequence Data; Norpregnadienes; Oligodeoxyribonucleotides; Progesterone Congeners; Recombinant Proteins; Structure-Activity Relationship; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Vitellogenins; Xenopus | 1995 |
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Tamoxifen | 1995 |
The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor.
Topics: Binding Sites; Binding, Competitive; Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1995 |
Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media.
Topics: Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Cell Division; Cell Line; Culture Media, Conditioned; DNA, Bacterial; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Molecular Weight; Tamoxifen; Thymidine; Tumor Cells, Cultured | 1993 |
MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Death; Cell Division; Cell Survival; DNA Damage; DNA, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Etoposide; Fulvestrant; Humans; Mechlorethamine; Neoplasms, Hormone-Dependent; Tumor Cells, Cultured | 1995 |
Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1995 |
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Resistance; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Tamoxifen | 1995 |
New antiestrogen shows promise in ER-positive breast cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen | 1994 |
Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Division; Clone Cells; Culture Media, Serum-Free; Drug Resistance; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Pleural Effusion, Malignant; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1994 |
Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Calcitriol; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Time Factors; Tumor Cells, Cultured | 1994 |
Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Topics: Animals; Base Sequence; Breast Neoplasms; Cell Division; Chloramphenicol O-Acetyltransferase; Culture Media; Drug Resistance; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tamoxifen; Time Factors; Transfection; Tumor Cells, Cultured | 1994 |
Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.
Topics: Binding Sites; Breast Neoplasms; Cell Division; Drug Resistance; Estradiol; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1993 |
Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cathepsin D; Cell Division; Drug Resistance; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Proteins; Receptors, Estrogen; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1994 |
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Resistance; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Mice; Mice, Nude; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1993 |
Isolation of pMGT1: a gene that is repressed by oestrogen and increased by antioestrogens and antiprogestins.
Topics: Breast Neoplasms; DNA, Neoplasm; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mifepristone; Polyunsaturated Alkamides; Progestins; Tamoxifen; Tumor Cells, Cultured | 1993 |
Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Recombinant Proteins; RNA, Messenger; Tumor Cells, Cultured | 1996 |
Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells.
Topics: Base Sequence; Blotting, Western; Breast Neoplasms; Cell Division; Culture Media, Conditioned; DNA; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Insulin-Like Growth Factor I; Molecular Sequence Data; Polyunsaturated Alkamides; RNA, Messenger; Steroids; Tamoxifen; Tumor Cells, Cultured | 1995 |
Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors.
Topics: Breast Neoplasms; Cell Cycle; Cell Line; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Estradiol; Estradiol Congeners; Estrogen Antagonists; Female; Fulvestrant; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; RNA, Messenger; Simvastatin; Tamoxifen; Tumor Cells, Cultured | 1996 |
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Topics: Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Cyclins; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression; Humans; Oncogene Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Retinoblastoma Protein; Tumor Cells, Cultured | 1995 |
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Ductal, Breast; DNA, Neoplasm; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hydroxytestosterones; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Binding; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1996 |
Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin-resistant MCF-7 human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Antagonists; Female; Flow Cytometry; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Phenotype; Progesterone; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1996 |
Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells.
Topics: Breast Neoplasms; Cyclin B; Cyclin B1; Cyclin D1; Cyclin-Dependent Kinases; Cyclins; DNA; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Fulvestrant; G1 Phase; Humans; Oncogene Proteins; Phosphorylation; Retinoblastoma Protein; S Phase; Tumor Cells, Cultured | 1996 |
2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cattle; Cell Division; Estradiol; Estrogen Antagonists; Estrone; Female; Fulvestrant; HeLa Cells; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Organ Size; Receptors, Estrogen; Sulfur; Tamoxifen; Transcriptional Activation; Tumor Cells, Cultured; Uterus; Vitellogenins | 1996 |
Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer.
Topics: Breast Neoplasms; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Frozen Sections; Fulvestrant; Humans; Immunohistochemistry; Postmenopause; Receptors, Estrogen; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1996 |
Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity.
Topics: Animals; Breast Neoplasms; Cell Division; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Fulvestrant; Gelatinases; Humans; Mice; Mice, Nude; Phenotype; Protein Binding; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tamoxifen; Transcription Factor AP-1; Tumor Cells, Cultured | 1996 |
Inhibition of endothelial adhesion and invasion by breast carcinoma cells may contribute towards the anti-metastatic effects of tamoxifen.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Chemotherapy, Adjuvant; Collagen; Disease-Free Survival; Drug Combinations; Endothelium; Estradiol; Estrogen Antagonists; Extracellular Matrix; Female; Fulvestrant; Humans; Laminin; Proteoglycans; Tamoxifen; Tumor Cells, Cultured | 1996 |
Effect of growth factors on estrogen receptor mediated gene expression.
Topics: Breast Neoplasms; Carcinoma; Cell Division; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Reporter; Growth Substances; HeLa Cells; Humans; Insulin; Insulin-Like Growth Factor I; Luciferases; Receptors, Estrogen; Transfection; Tumor Cells, Cultured; Vitellogenins | 1996 |
Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Cycle; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Antagonists; Flow Cytometry; Fulvestrant; Humans; Phenotype; Ploidies; Receptors, Estrogen; Rhodamine 123; Rhodamines; Tamoxifen; Tumor Cells, Cultured | 1996 |
A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Breast Neoplasms; Carcinogens; Carcinoma; Cell Division; Culture Media, Conditioned; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 5; Mammary Neoplasms, Experimental; Oligonucleotides, Antisense; Rats; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1996 |
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proteins; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins | 1996 |
Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells.
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Receptors, Somatostatin; RNA, Messenger; Tamoxifen; Time Factors; Tumor Cells, Cultured | 1996 |
Human serum albumin shares the properties of estrocolyone-I, the inhibitor of the proliferation of estrogen-target cells.
Topics: Blood Proteins; Breast Neoplasms; Cell Cycle; Cell Division; Chromatography, Affinity; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factor 2; Fulvestrant; Humans; Kinetics; Metribolone; Peptide Fragments; Recombinant Proteins; Serum Albumin; Tumor Cells, Cultured | 1996 |
RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinogenicity Tests; Cell Cycle; Cell Division; Chick Embryo; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genes, ras; Heart; Humans; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Myocardium; Neoplasm Invasiveness; Tamoxifen; Tumor Cells, Cultured | 1996 |
Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genetic Vectors; Humans; Polyunsaturated Alkamides; Receptors, Estrogen; RNA Splicing; RNA, Messenger; RNA, Neoplasm; Tamoxifen; Transfection; Tumor Cells, Cultured | 1997 |
Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Topics: Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle; Cell Line; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; G1 Phase; Humans; Kinetics; Oncogene Proteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Retinoblastoma Protein; S Phase; Time Factors; Tumor Cells, Cultured | 1997 |
The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens.
Topics: Animals; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Enzymologic; Genes, Reporter; Genetic Vectors; Glutathione Transferase; Growth Hormone; Humans; Kinetics; Mice; Molecular Sequence Data; NAD(P)H Dehydrogenase (Quinone); Oligodeoxyribonucleotides; Promoter Regions, Genetic; Receptors, Estrogen; Recombinant Proteins; Tamoxifen; Transfection | 1997 |
Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182,780.
Topics: Acids; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cathepsin D; Culture Media, Serum-Free; Enzyme Activation; Enzyme Precursors; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Immunoblotting; Neoplasm Invasiveness; Tamoxifen; Tumor Cells, Cultured | 1997 |
Influence of antiestrogens on the migration of breast cancer cells using an in vitro wound model.
Topics: Breast Neoplasms; Cell Movement; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Neoplasm Invasiveness; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1997 |
Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Collagenases; Electrophoresis, Polyacrylamide Gel; Estradiol; Estrogen Antagonists; Fulvestrant; Gelatinases; Glycoproteins; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloendopeptidases; Neoplasm Invasiveness; Protease Inhibitors; Receptors, Estrogen; Tamoxifen; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 1997 |
Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.
Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1997 |
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genetic Markers; Humans; Mice; Mice, Nude; Phenotype; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1997 |
Effect of toxaphene on estrogen receptor functions in human breast cancer cells.
Topics: Breast Neoplasms; Chloramphenicol O-Acetyltransferase; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Polychlorinated Dibenzodioxins; Proteins; Receptors, Estrogen; RNA, Messenger; Toxaphene; Transcriptional Activation; Transfection; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1997 |
Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Kinetics; Recombinant Proteins; Tumor Cells, Cultured | 1997 |
Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Nucleus; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mice; Mice, Nude; Ovariectomy; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Transcription, Genetic; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured | 1998 |
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line; Chloramphenicol O-Acetyltransferase; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Humans; Letrozole; Luciferases; Mice; Mice, Nude; Nitriles; Ovariectomy; Polymerase Chain Reaction; Receptors, Progesterone; Recombinant Fusion Proteins; RNA, Messenger; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured | 1998 |
Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor.
Topics: Animals; Binding Sites; Breast Neoplasms; Cell Division; DNA Primers; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Glycine; Humans; Luciferases; Mice; Mice, Nude; Ovariectomy; Point Mutation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Valine | 1998 |
The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fibronectins; Fulvestrant; Humans; Neoplasm Invasiveness; Tamoxifen; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1998 |
Estrogen upregulation of BRCA1 expression with no effect on localization.
Topics: Antineoplastic Agents; BRCA1 Protein; Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Receptors, Estrogen; RNA, Messenger; Stimulation, Chemical; Tumor Cells, Cultured; Up-Regulation | 1998 |
The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Transforming Growth Factor alpha | 1998 |
Classification of breast cancer cells on the basis of a functional assay for estrogen receptor.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Survival; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Promoter Regions, Genetic; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Tamoxifen; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1998 |
Anti-estrogens induce apoptosis of multiple myeloma cells.
Topics: Apoptosis; Breast Neoplasms; Cell Division; Cell Survival; Coloring Agents; Estradiol; Estrogen Antagonists; Flow Cytometry; Fulvestrant; Hematopoietic Stem Cells; Humans; Immunoblotting; Multiple Myeloma; Propidium; Receptors, Estrogen; Tamoxifen; Toremifene; Tumor Cells, Cultured | 1998 |
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Models, Animal; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Mice; Mice, Nude; Ovariectomy; Tamoxifen; Toremifene | 1998 |
Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens.
Topics: Animals; Breast Neoplasms; Carrier Proteins; Cell Nucleus; Estradiol; Estrogen Antagonists; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Female; Fulvestrant; Genes, Tumor Suppressor; Growth Inhibitors; Half-Life; Humans; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Organ Culture Techniques; Pregnancy; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tamoxifen; Transcription, Genetic | 1997 |
Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Polyunsaturated Alkamides; Proto-Oncogene Proteins; S Phase; Tamoxifen; Tumor Cells, Cultured; Zinc Sulfate | 1997 |
Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780.
Topics: Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Growth Substances; Half-Life; Humans; Insulin-Like Growth Factor I; Iodine Radioisotopes; Receptor, IGF Type 1; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Up-Regulation | 1996 |
Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cholecalciferol; DNA Fragmentation; Estradiol; Estrogen Antagonists; Fulvestrant; Growth Substances; Humans; Receptors, Calcitriol; Receptors, Estrogen; Tumor Cells, Cultured | 1998 |
A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; DNA Primers; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured; Up-Regulation | 1998 |
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Division; Cells, Cultured; Choriocarcinoma; DNA Primers; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblasts; Fulvestrant; Humans; Letrozole; Microsomes; Nitriles; Placenta; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 1998 |
The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription.
Topics: Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; HeLa Cells; Humans; Progestins; Transcription, Genetic | 1999 |
Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells.
Topics: Breast Neoplasms; Chloramphenicol O-Acetyltransferase; Culture Media; Enzyme Induction; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genes, p53; Humans; Proto-Oncogene Proteins c-myc; Receptors, Estrogen; Transfection; Tumor Cells, Cultured | 1999 |
Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Protein Binding; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tumor Cells, Cultured | 1999 |
Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Cycle; Drug Synergism; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Female; Flow Cytometry; Fluorouracil; Fulvestrant; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Receptors, Estrogen; RNA, Neoplasm; Thymidylate Synthase | 1999 |
Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Binding, Competitive; Breast Neoplasms; Cell Count; Cell Division; DNA, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Mice; Rats; Rats, Wistar; Receptors, Estrogen; Tamoxifen; Thymidine; Tumor Cells, Cultured; Uterus | 1999 |
Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor Binding Proteins; Phosphoproteins; Receptor, Insulin; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 1999 |
Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium.
Topics: Breast Neoplasms; Calcimycin; Calcium; Calcium-Calmodulin-Dependent Protein Kinases; Cell Nucleus; Cytoplasm; Egtazic Acid; Enzyme Activation; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; HeLa Cells; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Recombinant Proteins; Tumor Cells, Cultured | 1999 |
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.
Topics: Animals; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; Intracellular Signaling Peptides and Proteins; Mammary Neoplasms, Experimental; Mice; Phosphoproteins; Phosphorylation; Receptor, Insulin; Receptors, Estrogen; Receptors, Somatomedin; Signal Transduction; Somatomedins; Survival Rate; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status.
Topics: Aryl Hydrocarbon Hydroxylases; Aryl Hydrocarbon Receptor Nuclear Translocator; Breast Neoplasms; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme System; DNA-Binding Proteins; Enzyme Induction; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Phenotype; Polychlorinated Dibenzodioxins; Receptors, Aryl Hydrocarbon; Receptors, Estrogen; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured | 1999 |
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Risk; Tamoxifen; Toremifene | 1999 |
Differences in morphology and cytoskeleton of MCF-7 and MX-1 cells after therapy with OH-tamoxifen and the pure estrogen antagonist ZM 182780. An immunofluorescence and scanning electron microscopic study.
Topics: Actins; Antineoplastic Agents; Breast Neoplasms; Cytoskeleton; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Immunohistochemistry; Keratins; Microscopy, Electron, Scanning; Receptors, Estrogen; Tamoxifen; Tubulin; Tumor Cells, Cultured; Vimentin | 1999 |
Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Iodine Radioisotopes; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 1999 |
Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Interleukin-1; Luciferases; Receptor Cross-Talk; Receptors, Estrogen; Recombinant Fusion Proteins; Response Elements; Transcriptional Activation; Tumor Cells, Cultured | 1999 |
Comparative analyses of mechanistic differences among antiestrogens.
Topics: Blood Proteins; Breast Neoplasms; Cell Division; Cinnamates; Drug Stability; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression; Humans; Protein Binding; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Stilbenes; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 1999 |
Rearrangement of the F-actin cytoskeleton in estradiol-treated MCF-7 breast carcinoma cells.
Topics: Actins; Breast Neoplasms; Cadherins; Cell Movement; Cytoskeleton; Estradiol; Estrogen Antagonists; Fluorescent Antibody Technique; Fulvestrant; Humans; Microscopy, Video; Neoplasm Invasiveness; Neoplasm Metastasis; Tumor Cells, Cultured | 1999 |
Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.
Topics: Blotting, Northern; Blotting, Western; Breast Neoplasms; DNA Primers; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Polyunsaturated Alkamides; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Tumor Cells, Cultured | 1999 |
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Interphase; Neoplasm Proteins; Receptor, ErbB-2; Receptors, Estrogen; S Phase; Tumor Cells, Cultured | 2000 |
How is tamoxifen's action subverted?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, BRCA1; Humans; Phosphoproteins; Proteins; Receptors, Estrogen; Retinoblastoma-Like Protein p130; Tamoxifen | 2000 |
The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; DNA Primers; Dose-Response Relationship, Drug; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Microscopy, Electron; Microscopy, Fluorescence; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 1999 |
EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway.
Topics: Breast Neoplasms; Cell Division; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Humans; Luciferases; Plasmids; Protein Structure, Tertiary; Receptors, Estrogen; Signal Transduction; Transfection; Tumor Cells, Cultured | 2000 |
Differential cross-talk of estrogen and growth factor receptors in two human mammary tumor cell lines.
Topics: Breast Neoplasms; Cell Division; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Insulin-Like Growth Factor I; Neuregulin-1; Receptors, Estrogen; Signal Transduction; Tamoxifen; Tumor Cells, Cultured | 1999 |
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.
Topics: Adenocarcinoma; Androstadienes; Breast Neoplasms; Butadienes; Chromones; Culture Media, Serum-Free; Cyclic AMP-Dependent Protein Kinases; Cyclin D1; Depression, Chemical; DNA Replication; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Flavonoids; Fulvestrant; Humans; Isoquinolines; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mitosis; Morpholines; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Retinoblastoma Protein; Sulfonamides; Wortmannin | 2000 |
Aromatase inhibitors and their antitumor effects in model systems.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Mice; Mice, Inbred BALB C; Models, Biological; Neoplasms, Hormone-Dependent; Tamoxifen; Transfection | 1999 |
Response of estrogen receptor containing tumour cells to pure antiestrogens and the calmodulin inhibitor, calmidzolium chloride.
Topics: Breast Neoplasms; Calmodulin; Cell Death; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Pituitary Neoplasms; Receptors, Estrogen; Tumor Cells, Cultured | 2000 |
Estradiol induces functional inactivation of p53 by intracellular redistribution.
Topics: Blotting, Western; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Electrophoresis, Polyacrylamide Gel; Estradiol; Estrogen Antagonists; Female; Fulvestrant; G1 Phase; Humans; Immunohistochemistry; S Phase; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Activity of benzo[a]pyrene and its hydroxylated metabolites in an estrogen receptor-alpha reporter gene assay.
Topics: Benzo(a)pyrene; Benzoflavones; beta-Galactosidase; Breast Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression; Genes, Reporter; Genetic Techniques; Humans; Hydroxylation; Luciferases; Receptors, Estrogen; Transfection; Tumor Cells, Cultured | 2000 |
Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mifepristone; Progestins; Prostate-Specific Antigen; Proteins; Receptors, Estrogen; Receptors, Progesterone; Tissue Kallikreins; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |
The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cyclin-Dependent Kinases; Cyclins; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Retinoblastoma Protein; Tumor Cells, Cultured | 2000 |
WISP-2 as a novel estrogen-responsive gene in human breast cancer cells.
Topics: Air Pollutants, Occupational; Benzhydryl Compounds; Breast Neoplasms; CCN Intercellular Signaling Proteins; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Keratins; Neoplasm Proteins; Phenols; Repressor Proteins; RNA, Messenger; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2000 |
Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma in Situ; Cell Division; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Transplantation; Receptors, Estrogen; Transplantation, Heterologous | 2000 |
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
Topics: Animals; Blood-Brain Barrier; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Preoperative Care; Rats; Receptors, Estrogen | 2000 |
Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Estrogens; Flow Cytometry; Fulvestrant; Humans; Luciferases; Receptors, Estrogen; Signal Transduction; Transfection; Tumor Cells, Cultured; Up-Regulation | 2000 |
A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence.
Topics: Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA-Binding Proteins; E2F4 Transcription Factor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Kinetics; Models, Biological; Oligodeoxyribonucleotides, Antisense; Phosphoproteins; Protein Serine-Threonine Kinases; Proteins; Resting Phase, Cell Cycle; Retinoblastoma-Like Protein p130; Transcription Factors; Tumor Cells, Cultured | 2000 |
Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Basement Membrane; Breast Neoplasms; Cell Adhesion; Collagen; Drug Combinations; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Laminin; Microscopy, Electron, Scanning; Microvilli; Neoplasm Invasiveness; Neoplasm Metastasis; Proteoglycans; Pseudopodia; Tamoxifen; Tumor Cells, Cultured | 1999 |
Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain.
Topics: Adenocarcinoma; Antigens, Polyomavirus Transforming; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; G1 Phase; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Structure, Tertiary; Recombinant Fusion Proteins; Retinoblastoma Protein; Tamoxifen; Transfection; Tumor Cells, Cultured | 2000 |
Measurement of markers for breast cancer in a model system using laser scanning cytometry.
Topics: Apoptosis; Breast Neoplasms; Carcinoma; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Immunohistochemistry; Ki-67 Antigen; Microscopy, Confocal; Microscopy, Fluorescence; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured | 2000 |
Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
Topics: Breast Neoplasms; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Estradiol; Fulvestrant; Heparin; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Pertussis Toxin; Protein-Tyrosine Kinases; Receptors, Cell Surface; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Virulence Factors, Bordetella | 2000 |
Faslodex (ICI 182780). an oestrogen receptor downregulator.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase II as Topic; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Receptors, Estrogen | 2000 |
Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Flavonoids; Fulvestrant; Humans; MAP Kinase Signaling System; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Thymidine; Transcription, Genetic; Tumor Cells, Cultured; Up-Regulation | 2000 |
Increased expression of cytochrome p450 1A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines.
Topics: Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Blotting, Northern; Blotting, Southern; Breast Neoplasms; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Neoplasm Proteins; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 2000 |
Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Chorionic Gonadotropin, beta Subunit, Human; Dehydroepiandrosterone; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Nitriles; Triazoles; Tumor Cells, Cultured | 2000 |
Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.
Topics: Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Proteins; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger; Tamoxifen; TNF Receptor-Associated Factor 1; Tumor Cells, Cultured | 2000 |
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Stilbenes; Tamoxifen; Time Factors; Toremifene; Tumor Cells, Cultured | 2000 |
TCDD elevates erbB2 expression and signaling in T47D cells by reversing serum potentiation of estrogen receptor activity, independent of estrogen levels and enhanced ER down-regulation.
Topics: Breast Neoplasms; Cell Division; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Intracellular Membranes; Neuregulin-1; Polychlorinated Dibenzodioxins; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Estrogen; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2000 |
Regulation of the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Deoxyribonuclease I; DNA; DNA Footprinting; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Proteins; Response Elements; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |
Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol.
Topics: Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Chromatography, Thin Layer; Dehydroepiandrosterone; Dexamethasone; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunoassay; Mitogens; Tamoxifen; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Hormonal; Blotting, Northern; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Movement; Cells, Cultured; Cysteine-Rich Protein 61; Disease Progression; DNA, Complementary; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Library; Growth Substances; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Middle Aged; Multivariate Analysis; Neoplasm Transplantation; Promoter Regions, Genetic; Protein Binding; Receptors, Estrogen; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |
Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Nerve Growth Factor; PC12 Cells; Phosphorylation; Rats; Receptor, trkA; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 2001 |
Identification and implantation stage-specific expression of an interferon-alpha-regulated gene in human and rat endometrium.
Topics: Adult; Amino Acid Sequence; Animals; Blotting, Northern; Breast Neoplasms; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; DNA, Complementary; Drug Synergism; Embryo Implantation; Endometrium; Epithelium; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Humans; Interferon-alpha; Menstrual Cycle; Microtubule-Associated Proteins; Molecular Sequence Data; Ovariectomy; Pregnancy; Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sequence Homology; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2001 |
Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer.
Topics: Adenocarcinoma; Antibodies; Breast Neoplasms; Cell Division; Cysteine-Rich Protein 61; Dactinomycin; DNA, Neoplasm; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Growth Substances; Humans; Immediate-Early Proteins; In Situ Hybridization; Intercellular Signaling Peptides and Proteins; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcriptional Activation; Tumor Cells, Cultured | 2001 |
Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors alpha and beta.
Topics: Breast Neoplasms; Choriocarcinoma; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Genes, Reporter; Humans; Leptin; Promoter Regions, Genetic; Receptors, Estrogen; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2001 |
Estradiol-regulated expression of the immunophilins cyclophilin 40 and FKBP52 in MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Carrier Proteins; Cycloheximide; Cyclophilins; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression; Humans; Peptidyl-Prolyl Isomerase F; Peptidylprolyl Isomerase; Protein Synthesis Inhibitors; RNA Stability; RNA, Messenger; Tacrolimus Binding Proteins; Tumor Cells, Cultured | 2001 |
Differential regulation of retinoblastoma protein by hormonal and antihormonal agents in T47D breast cancer cells.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Estrogens; Fulvestrant; Gonanes; Humans; Mifepristone; Phosphorylation; Progesterone; Promegestone; Receptors, Estrogen; Receptors, Progesterone; Retinoblastoma Protein; Tumor Cells, Cultured | 2001 |
Cell-transforming activity and estrogenicity of bisphenol-A and 4 of its analogs in mammalian cells.
Topics: Animals; Benzhydryl Compounds; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Female; Fetus; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Phenols; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Structure-Activity Relationship; Toremifene; Tumor Cells, Cultured | 2001 |
Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Endometrium; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tumor Cells, Cultured | 2001 |
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
Topics: Antineoplastic Agents; Breast Neoplasms; Cytological Techniques; Drug Resistance; Enzyme Inhibitors; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2001 |
S-adenosylmethionine decarboxylase overexpression reduces invasiveness and tumorigenicity in nude mice of MCF-7 breast cancer cells.
Topics: Adenosylmethionine Decarboxylase; Agar; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Collagen; DNA-Binding Proteins; Drug Combinations; Epidermal Growth Factor; Estradiol; Female; Fulvestrant; Humans; Laminin; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Proteoglycans; Sensitivity and Specificity; STAT3 Transcription Factor; Tamoxifen; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.
Topics: Blotting, Northern; Blotting, Western; Breast Neoplasms; DNA Methylation; Enzyme Activation; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-raf; Receptor, ErbB-2; Receptors, Estrogen; Ribonucleases; Transfection; Tumor Cells, Cultured | 2001 |
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Topics: Acetylation; Azacitidine; Breast Neoplasms; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Receptors, Estrogen; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Protein Kinase C; Protein Kinase C-alpha; Receptors, Estrogen; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Hypoxia reduces hormone responsiveness of human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Down-Regulation; Endothelial Growth Factors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation, Neoplastic; Hormones; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Lymphokines; Oxygen; Progestins; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Cooperative coactivation of estrogen receptor alpha in ZR-75 human breast cancer cells by SNURF and TATA-binding protein.
Topics: Blotting, Western; Breast Neoplasms; Chromatin; Cloning, Molecular; DNA-Binding Proteins; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Fulvestrant; Gene Deletion; Ligands; Luciferases; Models, Biological; Mutation; Nuclear Proteins; Nuclear Receptor Coactivator 2; Oligonucleotides; Peptides; Precipitin Tests; Protein Binding; Protein Structure, Secondary; Receptors, Estrogen; Response Elements; TATA-Box Binding Protein; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured; Two-Hybrid System Techniques; Zinc Fingers | 2002 |
Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2001 |
Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, bcl-2; Humans; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Paclitaxel; Signal Transduction; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Cycle Proteins; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Humans; Precipitin Tests; Protein Binding; Proto-Oncogene Proteins; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
Topics: Adenylyl Cyclases; Breast Neoplasms; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Indoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-raf; Pyrroles; Receptors, Cell Surface; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Tumor Cells, Cultured | 2002 |
Expression and regulation of Cyr61 in human breast cancer cell lines.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Breast Neoplasms; Calcitriol; Cysteine-Rich Protein 61; Drug Resistance; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Immediate-Early; Growth Substances; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Protein Structure, Tertiary; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Selective Estrogen Receptor Modulators; Tamoxifen; Tetradecanoylphorbol Acetate; Transcriptional Activation; Transfection; Tretinoin; Tumor Cells, Cultured | 2002 |
Oestrogenic activity of parabens in MCF7 human breast cancer cells.
Topics: Animals; Binding Sites; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Food Preservatives; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Ligands; Models, Molecular; Molecular Structure; Parabens; Protein Binding; Proteins; Receptors, Estrogen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7.
Topics: Apoptosis; Benzhydryl Compounds; Breast Neoplasms; Cell Division; Coumestrol; DDT; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens, Non-Steroidal; Female; Fulvestrant; Humans; Molecular Structure; Phenols; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Surface-Active Agents; Tumor Cells, Cultured | 2002 |
Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Oligonucleotide Array Sequence Analysis; Proteins; Receptors, Estrogen; RNA, Messenger; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Fulvestrant: clinical application of an estrogen receptor downregulator.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Goserelin; Humans; Tamoxifen | 2002 |
Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade.
Topics: Anisomycin; Anti-Bacterial Agents; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genes, ras; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-raf; Receptors, Estrogen; Recombinant Proteins; Tamoxifen; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 2002 |
C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Doxycycline; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression; Genes, myc; Humans; Luciferases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc; Receptors, Estrogen; RNA, Messenger; Transfection; Tumor Cells, Cultured | 2002 |
Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells.
Topics: Breast Neoplasms; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Introns; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Topics: Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Oligonucleotides, Antisense; Protein Serine-Threonine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myc; RNA, Messenger; Tumor Suppressor Proteins; Up-Regulation | 2002 |
Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
Topics: Animals; Breast Neoplasms; Cyclic AMP Response Element-Binding Protein; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-1; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; NF-kappa B; Nuclear Proteins; Nucleophosmin; Oligonucleotide Array Sequence Analysis; Phosphoproteins; Signal Transduction; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2002 |
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Endocrine Glands; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Trastuzumab; Tumor Cells, Cultured | 2002 |
2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta.
Topics: 2-Methoxyestradiol; Apoptosis; Breast Neoplasms; Cell Division; Cytochrome P-450 Enzyme Inhibitors; Endothelium, Vascular; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Flavonoids; Fulvestrant; Humans; Receptors, Estrogen; Tumor Cells, Cultured | 2002 |
A potent specific pure antiestrogen with clinical potential.
Topics: Animals; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Macaca nemestrina; Mice; Mice, Nude; Neoplasm Transplantation; Ovariectomy; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterus | 1991 |